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This thesis highlights the use of transition metal catalysts in the synthesis of highly 
functionalised nitrogen heterocycles using ene-ynamides as starting materials. 
Relying on the initial discovery of copper-catalysed cascade reaction, a one pot carbon 
nitrogen bond formation and rearrangement cascade sequence has been developed to 
synthesise functionalised oxyisoquinolines with the use of an environmentally benign, 
inexpensive copper catalyst. The reaction proceeds through ynamide formation, followed by 
an initial aza-Claisen rearrangement, subsequent [1,5]-hydride transfer and 6π 
electrocyclisation. Exploration of the substrate scope and its limitations have allowed 
increased access to novel functionalised fused pyridine derivatives. 
Finally, generation of five membered nitrogen based heterocycles with dienamide moieties 
through gold catalysed cycloisomerisation of 1,6-ene-ynamides is described. Polycyclisation 
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Transition metal catalysis has been a driving force among the organic synthetic community 
leading to highly functionalised and novel transformations that could not be achieved by 
other synthetic routes.1-3  Among the transition metal series, the use of copper as a catalyst 
in achieving these transformations has been attracting wide attention over the last decade. 
Research activities in this area have led to the emergence of molecules ranging from the 
very simple ones to functionalised, complex and biologically relevant products.4, 5  The 
potential on the use of copper as catalysts in achieving transformations lies on the factors of 
cost, availability and toxicity.6 
Copper-catalysed cyclisation reactions have led to a wide range of molecules with different 
biological activities and alkynes have emerged as important building blocks in such 
synthesis.7 The carbon-carbon triple bond of alkynes makes them versatile and act as a 
synthons for different array of synthetic routes. In 2007, Yan and its co-workers reported 
the copper-catalysed cyclisation of propargylic acetate (Scheme 1).8 
 
Scheme 1: Cu-catalysed cycloisomerisation of propargylic acetate 
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In the presence of copper(I)iodide, propargylic acetates bearing pyridine ring undergo 
cyclisation to yield functionalised indolizines. According to the proposed mechanism 
(Scheme 2), activation and coordination of the triple bond by the copper catalyst produces 
an allene 3 followed by nucleophilic attack of the lone pair of pyridyl nitrogen to yield 4. 
Subsequent deprotonation and demetalation affords the desired product 2 in high yields. 
 
Scheme 2: Proposed mechanism for the formation of indolizine 
2. Synthesis of ynamides 
Ynamides are electron-rich π systems possessing an electron-withdrawing group on a 
nitrogen atom. The electronic bias created by the nitrogen atom is responsible for the highly 
regioselective transformations within the molecule (Scheme 3). They are used as versatile 
motifs in increasing number of novel transformations.9-11 
 
Scheme 3: Reactivity of ynamides 
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Ynamides are synthesised mainly through copper-mediated cross-coupling reactions though 
they vary in scope and reaction conditions. Each of the methods has its own limitations but 
this section tends to highlight the methods used in this work and those that are mainly used 
in the group. Through copper catalysed amidation reactions, ynamides with diverse 
functionalities can be assembled (Scheme 4).12-15 
 
Scheme 4: Copper catalysed ynamide formation 
One of the major limitations of the above methods is the failure to access ynamides with C-
terminus functionalities such as hydrogen and esters. Recently, the research group of 
Anderson provided a solution by the use of trichloroethylene to access 1,2-
dichloroenamides 12. Subsequent treatment of dichloroenamides with butylithium and 
trapping with an electrophile forms ynamides with functionalities like esters at the C-




Scheme 5: Ynamide formation via 1,2-dichloroenamides 
3. Synthesis and reactions of ketenimines from ynamides. 
3.1 Thermal methods 
Ynamides can serve as starting materials for the synthesis of highly reactive ketenimines 
which can subsequently undergo numerous transformations (Scheme 6).16 
 
Scheme 6: ketenimine synthesis from ynamides 
Ketenimines belong to the sub-class of unsaturated nitrogen-containing compounds which 
can be employed as building blocks to introduce an N, C, C triatomic moiety.16 They are 
characterized by the presence of an sp-hybridized carbon or a carbon backbone with a 
strong polarization.  
The research group of Wudl reported the first synthesis of ketenimine from ynamide via a 





Scheme 7: Use of sulfonylynamides to generate ketenimines via thermal methods 
 
At 120 °C, ester ynamide 13 was converted to ketenimine 14 which subsequently led to the 
formation of a tertiary nitrile 15 as a result of nitrogen to carbon migration. Further 
hydrolysis of 13 afforded amide 16. 
Similarly, Hsung and his research group explored the use of N-allylsulfonylynamide as 
starting materials for the generation of ketenimines (Scheme 8).18 Ketenimine 18 was 
generated from ynamide 17 through an aza-Claisen rearrangement. Upon further heating of 
18, 1,3-sulfonyl shift gave the tertiary nitrile 19 in relatively good yield. 
When the N-allylsulfonylynamide was substituted by a triisopropylsily (TIPS) group 20, the 
corresponding ketenimine 21 was isolated which can further be trapped with pyrrolidine 
through nucleophilic addition to give amidine 22 in excellent yield. Extended heating caused 




Scheme 8: Ketenimine generation through aza-Claisen rearrangement 
In a similar fashion, Hsung and his group further explored the synthesis of amidine by simple 
modification of ynamides (scheme 9).19 
 
Schemem 9: Imidates synthesis via aza-Claisen/[3,3] sigmatropic rearrangement 
With the use of carboxy-substituted ynamides 25 and 26, imidates 28 and 29 were obtained 
through a tandem aza-Claisen and [3,3]-sigmatropic rearrangements. 
In order to prevent the 1,3-sulfonyl shift, Hsung and his members employed the use of N-
phosphorylynamide in the generation of ketenimines (scheme 10).20 Ketenimine 31 was 
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generated from ynamide 30 bearing a cyclic phosphoramidate moiety which further reacted 
with an imine in a [2+2] cycloaddition manner to yield azetidimine 32. 
 
Scheme 10: Azetidinimine synthesis using N-phosphorylynamide 
In the absence of an imine, N-phosphorylynamide 30 underwent a carbocyclization process 
to yield a zwitterions 33 which afforded a cyclopentenimine 34 in moderate yield through a 
Wagner-Meerwein 1,2-H shift (scheme 11).21 
 
Scheme 11: Cyclopentenimine generation via carbocyclization/1,2-H shift 
3.2 Base-mediated methodologies. 
Evano and his group explored the syntheses of ketenimines using ynimines as starting 
materials (scheme 12).22 Ynimines represent class of ynamides in which imino substituents 
are responsible for their stabilization. Treatment of silyl-substitued ynimine 35 with an 
organolithium reagent generated ketenimine lithium anion 26. Trapping of 36 with an alkyl 
halide afforded ketenimines 37 from good to excellent yields. It was noticed that the silyl 




Scheme 12: Isolation of sily-ketenimines 
The research group of Cao generated ketenimines by simple removal of the electron-
withdrawing group on the ynamide using anionic conditions (scheme 13).23 
 
Scheme 13: Desulfonylation followed by nucleophilic reaction 
Deprotection of bis-phenylsulfonyl ynamide 38 using amine gave 39. Nucleophilic reaction 
of 39 with a second equivalent of amine yielded amidines 40. Steric hindrance on the amine 
component posed some challenges on the overall reaction progress. 
Dodd and Cariou got access to azetidinimines through ketenimines using [2+2] cycloaddition 
reaction (scheme 14).24 Treatment of N-tert-butylcarbamate ynamide 41 with lithium tert-
butoxide gave ketenimine 42. Reaction of 42 with an imine under microwave heating 
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produced azetidinimines 43. Biaryl azetidinimines 45 were obtained by further 
functionalization of 44 using known cross-coupling reactions. 
 
Scheme 14: Azetidinimines synthesis 
3.3 Transition metal-catalysed method 
Apart from the investigation of thermal aza-Claisen rearrangement of N-ally ynamides, the 
research group of Hsung extended their studies with the use of transition metals (scheme 
15).25 Activation of N-allyl ynamide 46 with Pd(PPh3)4 gave ynamide-π-allyl complex 47 
through oxidative addition. Complex 47 is in equilibrium with ketenimine complex 48. 
Trapping of ketenimine complex 48 with a primary/secondary amine gave complex 49. 
Tautomerization of 49 gave a π-allyl complex 50 and reductive elimination of 50 afforded 
















The synthesis of nitrogen heterocycles is vital for both organic synthesis and medicinal 
chemistry. Isoquinolines and their reduced derivatives are present in numerous naturally 
occurring alkaloids,26-30 commonly found in natural products. Such alkaloids have showed 
antitumor,31 antimicrobial32 and other biological activities.33-35 Heterocyles containing 
isoquinoline motifs can also be utilised in pharmaceutical27, 36 and material sciences.37 In 
addition, they are widely employed as chiral ligands for transition metal catalysts38-41 and 
some of their iridium complexes find application in organic light emitting diodes.42-45 
The traditional or classic methods for the construction of these heterocyclic scaffolds 
include Pictet-Spengler cyclization,46-48 Bischler-Napieralski synthesis49, 50and Pomeranz-
Fritsch synthesis 51, 52 (Scheme 16). 
 
 
Scheme 16: Access to isoquinoline skeleton 
These classic methods used to access these heterocycles have some fundamental problems 
that make them less attractive. They usually require strong acids53-55 or tedious reaction 
procedures, making it difficult to access substrates with different functional and protecting 
groups. To overcome these limitations, a general, flexible and convergent approach to these 
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isoquinoline derivatives is highly needed. Over the last two decades, protocols involving 
metals which serve as an alternative to the traditional methods, have been developed. New 
activation modes have been proposed leading to enhanced efficiency, atom economy and 
mild reaction conditions. The metal catalysed methodologies will be discussed in the 
subsequent sections.  
 
2. Metal-catalysed formation of isoquinoline and its derivatives 
2.1 Silver-catalysed synthesis of isoquinolines 
In 2009, Liang and co-workers reported the cyclization of 2-alkynyl benzyl azides 57 to 
access isoquinoline derivatives via silver catalysis (Scheme 17).56 
 
Scheme 17: Silver catalysed cyclisation of azides 
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They proposed that the coordination of Ag catalyst to the alkyne 60 generates 61. 
Regioselective nucleophilic attack of the nitrogen atom onto the electron deficient triple 
bonds gave 61 via 6-endo-dig cyclization, followed by the loss of nitrogen and proton to 
form 62. Treatment of 62 with TFA gave the isoquinoline salt 64. The reaction of the 
isoquinoline salt with sodium bicarbonate gave the corresponding functionalised 
isoquinoline 64. They equally observed that an increase in temperature to about 90 °C 
produces the Huisgen 1,3-dipolar cycloaddition product and lower yields of isoquinoline. 
The research group of Wu developed a methodology for the synthesis of 
dihydroisoquinolines using a dual activation mode of catalysts (Scheme 18).57 They 
combined silver triflate and proline in the multicomponent reaction of 2-






Scheme 18 Lewis acid and organocatalyst-cocatalysed reaction 
The condensation of ketone 67 with proline 69 produces enamine 70 which attacks the π 
activated system of 71 through its imine in a cascade fashion. Anilines 66 with both 
electron-donating and electron withdrawing groups were well tolerated. Their findings 
highlighted an important and efficient strategy of lewis acid and organocatalyst combination 
in synthetic organic chemistry. 
Similarly, Zhou and co-workers developed a three component, silver catalysed synthesis of 
diazo-containing dihydroisoquinolines through a cascade imine-yne cyclization of 2-
alkynylbenzaldehydes 72, amines 73 and diazo compounds 74 (Scheme 19)58 The proposed 
mechanism invokes the formation of imine 76 by the condensation of the aldehyde 72 and 
amine 73, followed by an intramolecular imine-yne cyclisation to produce intermediate 77. 
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Subsequent nucleophilic attack of the diazo compound via an intermolecular version forms 
78. Loss of proton and protonation produces the desired compound 75. 
 
 
Scheme 19: Silver catalysed multicomponent reaction 
The substrate scope was not broad. Substitution at the aromatic region was very limited and 
the amine used was limited to aniline. 
Yamamoto and co-workers reported the synthesis of 1,2-dihydroisoquinolines by direct 
addition of pronucleophiles  80 to imines 79 using silver triflate as a catalyst (Scheme 20).59 
The reaction is proposed to proceed via the coordination of silver to the triple bond which 
triggers the attack of the nitrogen onto the triple bond to give the isoquinolinium species 






Scheme 20: Silver-catalysed addition of pronucleophiles to generate 1,2-
dihydroisoquinolines 
The formation of the reactive isoquinolinium species was assumed to be the key step since 
the amines were not activated by any electron-withdrawing group. The substrate scope was 




2.2 Palladium-catalysed synthesis of isoquinoline 
The use of palladium catalysis towards the synthesis of isoquinoline derivatives has been 
greatly explored by Larock and his co-workers.60-62 In 1988, they carried out the palladium 
catalysed synthesis of isoquinolines via annulation process (Scheme 21)63 In this protocol, 
tert-butylimine of o-iodobenzaldehyde 88 was combined with internal alkynes 89, in the 




Scheme 21: Palladium catalysed iminoannulation of alkynes 
The methodology was extended to vinylic imines 91 and 94 which gave the desired products 
as tetrahydroisoquinoline and pyridine derivatives 93 and 96 respectively. The annulation 
chemistry failed when alkyl-substituted alkynes for example 4-octyne and 3-hexyne were 
incorporated. This was attributed to numerous alkyne insertion products which were not 
isolated. The proposed mechanism60 was in tandem to the various work they have done on 
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annulation chemistry. Reduction of palladium (II) to palladium (0) leads to oxidative 
insertion to give an organopalladium intermediate. Coordination to the alkyne moiety 
followed by insertion leads to vinylic palladium species. Such species reacts with the imine 
to generate a seven membered ring palladacyclic salt. Reductive elimination leads to 
demetalation and generation of tert-butylisoquinolinium salt. Subsequent fragmentation 
delivers the annulated product. 
Furthermore, Larock and co-workers reported the synthesis of isoquinolines via cyclisation 
of terminal alkynes 98 using palladium and copper catalysis (Scheme 22)64 
 
 
Scheme 22: Synthesis of isoquinolines via Pd and Cu catalysis 
3-Substitued isoquinolines 99 were accesed via the coupling/cyclisation of tert-butylimine of 
o-iodobenzaldehyde 97 with terminal alkyne 98 .The coupling was effected by the palladium 
catalyst while the subsequent cyclisation of the iminoalkyne was brought about by copper. 
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Good to excellent yields of the desired products were obtained. The substrate scope was 
extended to pyridine derivative 100 which generated a product with two heterocyclic rings 
fused together 102. The synthetic utility of the coupling/cyclisation cascade was 
demonstrated in the synthesis of the naturally occurring alkaloids, decumbens B 105 in 
relatively good yield. 
2.3 Rhodium-catalysed synthesis of isoquinolines 
Limited work has been done on the synthesis of isoquinolines using rhodium as a catalyst. 
Recently, Li and his group reported the synthesis of functionalised 4-Bromo-1,2-





Scheme 23: Rhodium-catalysed formation of dihydroisoquinolines 
The formation of α-imino rhodium carbene 109 from the sulfonyl triazole 108 triggers the 
nucleophilic attack intramolecularly to give the bromonium ylide 110. Formation of the ylide 
is the key step. Demetalation gives 111 which is in equilibrium with 112. Subsequent 6π 
electrocyclisation furnishes the desired product 113. The substrate scope was quite broad as 
isoquinolines with different electronic demands involving electron donating and electron 
withdrawing groups were accommodated. Further functionalisation were achieved through 
the vinyl bromide moiety present in the products. Classical transition metals catalysed 
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coupling reactions like Heck, Sonogashira and Suzuki reactions were performed and their 
corresponding products were obtained in good to excellent yields. 
2.4 Copper-catalysed formation of isoquinolines 
Wang and co-workers reported that 1,2-dihydroisoquinolines can be synthesised from o-





Scheme 24: 1,2-dihydroisoquinolines synthesis via Cu catalysis 
Reaction of 119 with sulfonyl azide through copper-catalysed alkyne-azide cycloaddition and 
Dimroth rearrangement gives ketenimine 120. Depending on the groups present in the 
ketenimine, 120 can undergo 1,5-OR or 1,5-H shift to generate 121 or 123 respectively. 6π 
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electrocyclic ring closure of 121 and 123 generates 122 and 124 respectively. Both electron 
donating and electron withdrawing groups were tolerated in their products. The 
methodology was also extended in the synthesis of different isoquinolium salts. 
Ma and co-workers discovered access to substituted isoquinolines 127 via copper catalysed 
cascade of o-halobenzylamines 125 and β-keto esters 126 (Scheme 25).67 Coupling of the 
halobenzylamines 125 with β-keto esters 126 generates 128. Subsequent condensation and 
cyclization yields 130, which after dehydrogenation under the presence of air affords the 
desired product 127. β-keto esters with bulky groups gave low yields of the substituted 
isoquinolines due to steric hindrance. 
 
 
Scheme 25: Cu-mediated formation of isoquinolines from keto esters and 
halobenzylamines 
Ohno and co-workers highlighted the synthesis of isoquinoline-fused polycycles in an atom 
economical manner via copper catalysis (Scheme 26).68 Their strategy employed the 
34 
 
assembly of four components 131, 132, 133 and 134 through the coupling reaction of 
Mannich and imine formation to generate 136. Subsequent cascade cyclisation and 
oxidation generate the desired fused polycycle 135. Various substitution on 2-
ethynylbenzaldehyde 131, amine 133 and nucleophile 134 were accommodated in the 
synthesis. The formation of one carbon-carbon and four carbon-nitrogen bonds contributed 
to the importance of atom economy concept in organic chemistry. 
 
 
Scheme 26: Access to isoquinoline fused polycycles via Cu catalysis 
Furthermore, the research group of Ray reported the copper mediated synthsesis of 3-
substituted isoquinolines 139 via cascade cross coupling and cyclisation (Scheme 27).69 From 
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the proposed mechanism, three basic steps namely imine formation, Sonogashira cross 
coupling and 6-endo-dig-cyclisation were responsible for the formation of the product 141. 
Electron rich and electron deficient groups were tolerated in the aromatic region of the 
bromobenzaldehyde. However, the terminal alkyne was limited to phenylacetlylene mainly. 
 
Scheme 27: Cu-catalysed isoquinoline formation 
2.5 Nickel-mediated synthesis of isoquinolines 
Cheng and co-workers provided a novel route to isoquinolines via annulation of 2-
iodobenzaldimines 142 with alkynes 143 using nickel as catalyst (Scheme 28).70. A plausible 
mechanism was proposed commencing with the reduction of Ni(II) to Ni(0). Generation of 
the nickelacycle 145 was as a result of the oxidative insertion of 142 to Ni(0). Subsequent 
coordinative insertion of 145 onto 143 generates either 146 or 147, which undergoes 
demetalation to give cation 148. The nucleophilic attack of iodide ion generated leads to the 
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cleavage of the tert-butyl group on 148 to give the final product 144. The two regioisomers 
observed in some of the isoquinolines made accounts for the dual insertion pathways 
proposed in the mechanism. The substrate scope was quite broad and alkynes ranging from 
terminal, internal and dialkyl substituted ones were all tolerated compared with their 




Scheme 28: Ni-mediated isoquinoline synthesis 
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2.6 Gold-catalysed formation of isoquinolines. 
In 2005, Youn reported the metal catalysed version of Pictect-Spengler reaction using 
AuCl3/AgOTf (Scheme 29).
48 The conditions were mild as some of the acylated derivatives of 
the tetrahydroisoquinoline 150 were achieved at room temperature. The imines 
investigated ranged from electron rich, electron deficient, aliphatic as well as 
heteroaromatics. According to the proposed mechanism, coordination of the gold complex 
to the imine leads to its activation in an electrophilic pathway. 
 
 
Scheme 29: Au-catalysed version of Pictet-Spengler reaction 
3 Results and Discussion  
3.1 Reaction design 
Investigation into a 1,5-hydride/cascade cyclisation of N-allyl ynamides was underway in our 
group which led to the assembly of highly functionalised and complex nitrogen heterocycles. 
In the course of these investigations, a new reaction was discovered for the synthesis of 





Scheme 30: Cu-catalysed isoquinoline formation 
Depending on the conditions of the reaction, oxyisoquinoline 152 or isoquinoline 153 are 
formed in high yields. According to the proposed mechanism, benzyhdric ether containing 
ynamide 151 undergoes aza-Claisen rearrangement to generate ketenimine 154. [1,5]-
Hydride transfer and subsequent 6π electrocyclisation produce oxyisoquinoline 156. Further 
elimination and desulfonylation affords the isoquinoline 153 in excellent yields. 
This was subsequently extended to N-allyl ynamides bearing an acetal group. It was 
discovered that when 158 was treated with copper(I)iodide and without a base, dialkoxy 
1,2-dihydroisoquinoline 159 was formed in very good yield (Scheme 31). 
Scheme 31: Synthesis of dihydroisoquinoline via copper catalysis 
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Further revelation indicated that mesyl ynamides gave a cleaner reaction and increased 
yield than tosyl equivalents. The reaction can also proceed without the catalyst in low yield 
(22%), suggesting the thermal nature of the reaction. In the absence of copper catalyst, 
pronounced degradation was observed.  
The utility of this reaction in accessing a functionalised oxyisoquinoline core led to further 
investigaton of the substrate scope (Figure 1). Various groups on the N-substituent of the 
ynamide, variations on the hydride donor-acceptor linker, substitution on the acetal region 




Figure 1: Substrate scope of dihydroisoquinoline synthesis 
These parameters were chosen for us to have a better understanding of the nature of this 
newly discovered reaction and hopefully more insights will be achieved on the reaction 
mechanism. Addition of various groups on the N-substituent of ynamdes may give us some 
information on the aza-Claisen rearrangement assuming we get regio-isomers. In addition, 
introducing various groups on the ally region can provide useful handle for further 
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functionalisation. In the course of the investigation, we planned to modify the donor-
acceptor linker by the incorporation of both electron donating and electron withdrawing 
groups. Such groups may potentially play a role on the rate of the reaction leading to 
increased or low yields of dihydroisoquinolines. 
As the reaction was proposed to proceed through [1,5]-hydride transfer, various 
substituents on the acetal region may affect the rate of such shift. Apart from the common 
mesyl and tosyl groups on the nitrogen, other stabilising or protecting groups will be 
investigated. Whilst the formation of the desired 1,2-dihydroisoquinolines and ynamide 
formation are catalysed by copper catalysts, though from different sources, we planned to 
investigate and possibly develop the synthesis of these dihydroisoquinolines using a one-pot 
strategy. The advantages of one-pot methodology can be seen from the perspective of cost, 
minimal handling and time. With these hypothesis and questions in mind, we began the 
investigation exploring the reactivity of ynamides with various groups on the allyl region.  
3.2 Variation on the N-substituent of ynamide 
In order to investigate the effects of substituted allyl groups, an ynamide bearing the prenyl 
group was prepared by five step route (Scheme 32) 
From the commercially available 2-bromobenzaldehde 160, Sonogashira coupling with 
trimethylsilylacetylene gave the silylated alkyne 161 in an excellent yield. Cleavage of the 
trimethylsilyl group using potassium carbonate and methanol gave the terminal alkyne 162. 
Acid catalysed acetalisation with ethylene glycol gave the acetal derivative 163 in high 
yields. Bromination of 163 to furnish the alkynyl bromide 164 was achieved using N-
bromosuccinamide. Flash column chromatography purification of 164 was done with 
triethylamine deactivated silica as it was observed that non-deactivated column may lead to 
41 
 
opening of the acetal ring. The copper catalysed coupling of the bromoalkyne 164 wth 
prenyl sulfonamide 165 produced the ynamide 166 in low yield. Substantial amounts of 
formation of the ynamide was developed by Hsung and co-workers.15 
 
 
Scheme 32: Initial ynamide preparation in a five step route 
When the prenyl substituted ynamide 166 was subjected to the optimised condition for the 
formation of heterocycle, it reacted cleanly, affording the quaternary carbon 
dihydroisoquinoline containing product 167 in high yield (Scheme 33) 
 
Scheme 33: Copper-catalysed synthesis of oxyisoquinoline 
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We turned our attention to the synthesis of ynamide bearing the cinnamyl group 170. 
Surprisingly, applying the copper catalysed coupling conditions developed by Hsung led to 
the direct formation of the oxyisoquinoline 169 isolated in very high yield (84%) from 
cinnamyl sulfonamide 168 and alkynyl bromide 164 without the ynamide 170 being isolated 
(Scheme 34). The cyclic heterocycle-dihydroisoquinoline 169 was isolated as a single 
regioisomer. In this new discovery, we were glad that oxyisoquinoline synthesised was not 
affected by the additives inherent in the reaction as no degradation or any other spot were 
seen on the TLC. 
 
 
Scheme 34: One pot ynamide formation rearrangement cascade 
The formation of a single isomer of 169 with complete allylic inversion validates the 
concerted aza-Claisen rearrangement as proposed in the mechanism. Without the 
formation of branched or linear isomers, the cationic step-wise process is ruled out. 
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With clean conversion in this case, we investigated the viability of applying the one pot 
reaction conditions more widely, with the advantages of minimal handling, cost and saving 
time. Through treating bromoalkyne 164, with various allylsulfonamide derivatives 165, 171-
175 under Hsung’s conditions, we explored the simple modification of increasing the 
reaction temperature on complete consumption of the limiting reagent or apparently no 
further reaction (Scheme 35). All the different allylsulfonamide derivatives 165, 171-175 
explored gave their corresponding oxyisoquinolines 167, 176-180 from good to excellent 
yields, with their corresponding ynamides not isolated. Generally, monitoring of the 
ynamide formation with thin layer chromatography (TLC) analysis showed the reaction to be 
quite slow, and longer times were required for completion. Whilst the prenyl ynamide 166 
was earlier isolated through a two-step process, its one pot reaction proceeded cleanly to 
afford the quaternary containing cyclic product 167 in good yield. The excellent yield of 176 
proved the viability of the one-pot two step strategy. Oxyisoquinoline 177 was formed in 
high yield and isolated as mixture of E/Z isomers in the ratio 0.4:1 without raising the 





Scheme 35: One pot formation of dihydroisoquinoline with substituted allyl groups 
The complexity of the 1H-NMR spectroscopy arising from many overlapping resonances 
made it difficult to identify the isomers. Equally, their separations during flash column 
chromatography were unsuccessful. Although the yield of 179 was lower, the additional 
functionality of the protected alcohol makes it attractive. The low yield can be explained by 
an indication of some deprotected silyl product in the reaction mixture. However, such 
product was never isolated. The vinyl bromide moiety present in 178 can serve as a useful 




3.3 Reaction mechanism 
The reaction mechanism for the formation of the dihydroisoquinoline (Scheme 36) is 
proposed to proceed via the aza-Claisen rearrangement of ynamide 181 to yield the 
ketenimine 182. Subsequent [1,5] hydride transfer will give the imine intermediate 183, 
with corresponding destruction of the benzene aromaticity. A 6π electrocyclisation gives the 
cyclic product 180 with restoration of the aromaticity. At this stage, we don’t know the 
exact role of copper, however we believe that the copper catalyst could potentially play a 
role during each stage of this thermally viable cascade. 
 
 
Scheme 36: Proposed mechanism for the formation of dihydroisoquinoline 
The mechanism is supported by the works of the research groups of Alajarin72, 73and Wang66 
in the synthesis of quinolone and dihydroisoquinolines respectively. Alajarin and co-workers 
discovered the synthesis of 4-quinolone 185 via tandem [1,5]-hydride transfer/6π 
electrocyclisation of acetalic ketenimines (Scheme 27)73. [1,5]-Hydride transfer of 
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ketenimine 184 generates 186 which undergoes 6π electrocyclic ring closure to give 185. 
The formation of 186 via [1,5]-hydride migration was attributed to the “hydricity” of the 
acetalic hydrogen and high electrophilicity of the central carbon of the ketenimine making it 
susceptible to hydride shift/attack. “Hydricity” literally means hydride transfer ability. They 
opined that the “hydricity” of 1,3-dioxolanes is as a result of the interaction of the lone pair 
electrons present on the oxygen atoms. Such interaction weakens and polarises the carbon-
hydrogen bond of 1,3-dioxolanes, conferring negative charge on the hydrogen atom. 
 
 
Scheme 37: 4-Quinoline synthesis 
3.4 Variations on the ynamide acetal 
3.4.1 Dioxane derivatives 
Our next objective was to vary the ring size of the acetal function and monitor change in 
behaviour in the one-pot rearrangement cascade. Treatment of the Sonogashira protected 
alkyne 161 with 1,3-propanediol under acidic condition gave the six membered acetal 187 
which was used without purification (Scheme 38). Deprotection 188 and subsequent 
bromination formed the bromoalkyne 189 in an excellent yield, which was used 
47 
 
immediately in the next step. When the bromoalkyne 189 was subjected to the one pot two 
step cyclisation conditions with N-mesylcinnamyl amine 168, the oxyisoquinoline 190 was 
obtained in high yield. From this result, it can be seen that the yield of 190 is lower when 
compared with its corresponding cyclic product 169 bearing the five membered acetal 
group (1,3-dioxolane). The reaction time for the formation of 190 is also longer. This is in 
complete agreement with the findings of Alajarin and co-workers. 72 Through computational 
studies, they found out that the activating order for “hydricity” of acetalic hydrogens is 
observed to occur in this range: 1.3-dioxolane > 1,3-dithiolane > 1,3-dioxane > 1,3-dithiane. 
 
 
Scheme 38: The synthesis of dihydroisoquinoline with 1,3-dioxane group 
Further reactivity was explored with crotyl sulfonamide 191 (Scheme 39). Bromoalkyne 189 




Scheme 39: Substrate scope of heterocycle with 1,3-dioxane function 
The reaction of 189 with N-mesylallyl amine 175 under copper catalysis was problematic as 
substantial degradation was seen inside the reaction mixture. At the end of the reaction, 
TLC analysis indicated the presence of ynamide and other spots. Efforts to isolate the 
remaining ynamide proved unsuccessful. The desired cyclic product 193a came off in a very 
low yield alongside another product 193b. The product 193b was as a result of 
neighbouring-group assisted breaking on the ring and subsequent demesylation. It was 
difficult to determine whether 193b was formed during the course of the reaction or during 
purification by flash column chromatography. We opined that lower hydricity of acetalic 
hydrogen in 1,3-dioxanes may contribute to the opening of the ring. 
3.4.2 Dithiolane fragment 
Apart from using 1,3-dioxane as a source of hydride donor, we investigated the use of 1,3-





Scheme 40: Synthesis of dithiolane derived alkynyl bromide 
Deprotection of 161 and subsequent treatment of 162 with 1,2-ethanedithiol gave the 
dithiolane 194 in low yield. Bromination of terminal alkyne 194 failed. It was observed that 
the reaction mixture turned into a black solution after twenty minutes. 1H-NMR spectrum of 
the reaction mixture was very complex and such that no useful interpretation could be 
made. The investigation was discontinued after several failed attempt to generate 
bromoalkyne 195. 
3.4.3 Alkyl substituent 
Moving from dithiolane synthesis, we decided to explore the possibility of using an alkyl 
group as a hydride source in the one-pot two step strategy. This was investigated to 
determine the extent in which alkyl group can be used to facilitate hydride shifts. To achieve 
this, the synthesis of a methyl derived alkynyl bromide 199 was made in three steps 
(Scheme 41). Sonogashira coupling of commercially available 2-bromotoluene 196, 






Scheme 41: Formation of methyl derived bromoalkynes 
When the methyl derived bromoalkyne 199 was reacted with N-mesylallyl amine 175 under 
copper catalysis, the expected dihydroisoquinoline 200 was not formed (Scheme 42) 
 
Scheme 42: Methyl derived bromoalkynes under copper catalysis 
From TLC analysis, complete consumption of sulfonamide was seen at 24 hours. Subsequent 
increase in temperature led to degradation. Purification and isolation of the cyclic product 
using flash column chromatography was unsuccessful. Complex mixtures were seen as 
observed by 1H-NMR spectroscopy. This observation can be explained by the lack of 
“hydricity” of methyl groups when compared to dioxolanes or dithiolanes. This is supported 
by the work of Alajarin and co-workers73. Complex mixtures and degradation were also seen 
when 199 was reacted with bromo substituted allyl sufonamide 173. 
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3.4.4 Pinacol derivative. 
To test the influence of substituted dioxolane unit on the ynamide aza-Claisen-initiated 




Scheme 43: Preparation and cyclisation of isoquinoline with pinacol unit 
Using the developed reaction sequence, treatment of the silylated alkyne 161 with pinacol 
202 led to the formation of substituted product 203. Cleavage of the trimethylsilyl group 
and bromination gave 205 in quantitative yield. The reaction of the pinacol containing 
bromoalkyne 205 proceeded cleanly with N-mesylcinnamyl amine 168 in the one-pot 
strategy to give the dihydroisoquinoline 206 in high yield. This promising result motivated us 
to expand the scope of the reaction with different sulfonamides so as to access cyclic 
products with different molecular architectures/scaffolds (Scheme 44). Clean and rapid 
52 
 
reactivity was observed with N-mesylcrotyl amine 191, affording the cyclic product 207 in 
high yield. In addition, 208 was formed under the same reaction conditions of ynamide 
formation without further increase in temperature. Interestingly, 208 was isolated as 
mixture of E/Z isomers in 0.4:1 ratio. Efforts to isolate the isomers were unsuccessful. 
 
 
Scheme 44: Reaction scope of pinacol derived isoquinoline 
 
3.4.5 Use of chiral dioxolane 
Following the results obtained with the use of dioxolanes in the copper catalysis, we then 
investigated the use of chiral dioxolanes with the intention of incorporating stereocontrol 





Scheme 45: Chiral diols as “chiral inducers” 
This approach can bring some advantages. Firstly, the enesulfonamide moiety in the 
resulting oxyisoquinoline provides a useful group for the elaboration of the heterocyclic 
core in a manner generating stereogenic centres, the asymmetry of which may be 
controlled by a chiral dioxolane. We also hypothesized that the considerable congestion 
around the ynamide, coupled to a well-defined transition state for the Claisen 
rearrangement, might result in transfer of remote stereochemical information from the 
stereogenic centres on the dioxalane to the newly forming stereogenic centres when 1,2-
disubstituted alkenes are used in the cascade. Furthermore, the use of C2-symmetric, 
optically active 1,2-diols will increase the extent of diastereoselection in the formation of 
the new stereogenic centre, thereby reducing the complexity of diastereodifferentiating 
events. Induction of high degrees of diastereoselection have been achieved with the use of 
C2-symmetric, optically active 1,2-diols.
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With the terminal alkyne 162 obtained from the corresponding Sonogashira coupling and 
deprotection (Scheme 46), acetalisation with (S,S)-(-)-hydrobenzoin 209 gave the chiral 
acetal 210. Bromination of 210 furnished the bromoalkyne 211 in good yield. The 
purification of the bromoalkyne was a bit difficult as small impurities could not be removed 





Scheme 46: Formation of chiral oxyisoquinoline 
The one pot cascade of bromoalkyne 211 with N-mesylcinnamyl amine 168 led to the 
optically active oxyisoquinoline 212 in high yield and as a 1:1 mixture of diastereoisomers, 
which could not be separated by flash column chromatography or recrystallization. No level 
of stereocontrol found in the synthesis of oxyisoquinoline 212 led us to investigate the 
effect of having a tosyl group on the nitrogen atom of the ynamide that is generated in the 
reaction mixture (Scheme 47). We opined that introducing a bulky group like tosyl group 
could potentially induce some levels of stereocontrol. 
 
 
Scheme 47: Synthesis of chiral tosylated oxyquinoline 
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The level of diastereoselection did not improve when N-tosylcinnamyl amine 213 was used, 
as it still gave 1:1 mixture of 214. The isomers were non-isolable/separable with flash 
column chromatography or recrystallization.  
The use of (R,R)-butane-2,3-diol as a chiral inducer was also investigated (Scheme 48). 
Following the usual sequence of reaction, treatment of 162 with (2R,3R)-butane-2,3-diol 215 
using Dean-Stark trap gave the chiral acetal 216. Bromination of 216 occured in excellent 
yield. The one-pot ynamide formation rearrangement cascade of 217 with N-tosylcinnamyl 
amine 213 generated the desired chiral spiroisoquinoline 218 in 1:1 mixture of 
diastereoisomers and in high yield. The isomers could not be separated using flash column 
chromatography or recrystallisation  
 
 
Scheme 48: Preparation and stereoinduction of 218 
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Although there is no degree of stereoinduction in these cases, the ability to generate these 
chiral compounds opens a different avenue for further investigation. Changes in the 
reaction conditions might lead to high degree of selectivity. 
To access a library of chiral oxyisoquinolines derived from chiral diols, we applied the one 
pot cyclisation cascade by varying the sulfonamides (Scheme 49). The versatility and 
convergence of our methodology was shown in these syntheses as they were formed in 
good yields with no trace of degradation. 
The vinyl bromide moiety present in 223 is interesting as it opens a new route for further 
functionalisation. Substitution of the methyl group on the allyl region of 222 did not affect 





Scheme 49: Examples of spiroisoquinoline derived from chiral 1,2-diols 
Chiral oxyisoquinoline 224 was afforded in high yield with methaallyl sulfonamide. Reactivity 
was observed with both tosyl and mesyl protecting groups on the nitrogen, 225 and 226 
respectively. Generally, mesyl groups reacted faster with higher yields when compared to 
the tosyl protected equivalents. 
Furthermore, we investigated how the use of (+)-diethyl L-tartrate 227 as a chiral auxiliary, 
would affect the reaction. Initially we started with the synthesis of the chiral diol derived 
alkynyl bromide 232 (Scheme 50). Starting from 2-bromobenzaldehyde 160, treatment with 
(+)-diethyl L-tartrate 227 under acidic conditions gave the chiral acetal 229 in low yield. 
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Efforts to improve the yield by increasing the catalytic loading and longer reaction time 
were not successful. Sonogashira coupling with trimethyl acetylene gave 229 in high yield. 
This yield required increase in temperature (50 to 70 °C) and longer reaction time (72 h). 
Deprotection of 229 with potassium carbonate and methanol caused the cleavage of the 
trimethylsilyl group as well as transesterification of the ester group to generate 230. 
The transesterification problem was solved by the replacement of methanol with ethanol, 
although 231 was formed in low yield after extending the reaction time to 24 h. Subsequent 




Scheme 50: Synthesis of chiral derived alkynyl bromide 232 
The reaction of chiral diol derived alkynyl bromide 232 with allyl sulfonamide 175 failed to 
deliver the desired product (Scheme 51). The formation of its ynamide was however seen on 
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TLC analysis. Complex mixtures were seen as observed by the 1H-NMR spectrum of the 
reaction mixture. Flash column chromatography of the reaction mixture did not work. 
 
 
Scheme 51: Formation of spiroisoquinoline 233 
The inability to make the spiroisoquinoline 233 inspired us to synthesize its corresponding 
ynamide and subject it to the optimised conditions (Scheme 52) developed by a member of 
our group-Holly Adcock to achieve a clearer picture of the reactivity of the substrate. 
Copper-catalysed coupling of 220 and 232 generated the ynamide 234 in moderate yield. 
When the ynamide 234 was subjected to the optimised conditions, the desired 
oxyisoquinoline 235 was not formed. The ynamide 234 was completely unreacted as it was 
recovered back from flash column chromatography. Extending the reaction time to more 
than 24 h did not improve the reaction. One possible explanation to this effect is that the 
electron withdrawing ability of the ester group attached to the acetal can cause 
deactivation, thereby reducing the relative capabilities of the acetal to act as a hydride 





Scheme 52: Formation of ynamide 234 and its copper catalysis 
The lack of reactivity in terms of diastereoinduction discouraged us from investigating other 
substrates containing chiral dioxolanes with ester groups. 
3.4.6 Alteration of the protecting group  
Mesyl and tosyl nitrogen protecting groups were all tolerated in our synthesis. For further 
elaboration, we attempted the synthesis of dihydroisoquinoline with different protecting 
groups (Scheme 53). Pleasingly, oxyisoquinoline 237 containing a nosyl group was formed in 
very high yield. Deprotection of the nosyl group may potentially open a new route for 
further functionalisation. No reactivity was observed with the reaction of bromoalkyne 164 
and diethyl allylphosphoramide 238. The starting materials were simply recovered. The 
formation of 241 containing triisopropylphenyl group is encouraging as it serves as an 
alternative to the tosyl group. Its low yield may be due to steric hindrance as some of N-






Scheme 53 Oxyisoquinolines with different protecting groups 
3.4.7 Modification of the connector tether. 
The modification of the benzene ring acting as the hydride donor-acceptor linker or 
connector tether was then explored in our synthsesis to achieve alternative functionalised 
cyclic products. A chloro group was incorporated into the meta-position relative to the 
hydride donor and para relative to the hydride acceptor (Scheme 54). Sonogashira coupling 
of commercially available 2-bromo-5-chlorobenzaldehyde 242 with trimethylsilyl acetylene 
gave the protected alkyne 243. Deprotection and subsequent acetal formation with 
ethylene glycol under acidic conditions, using a Dean-Stark trap furnished 245. Bromination 
of acetal 245 using N-bromosuccinamide gave the bromoalkyne 246, containing chloro 





Scheme 54: Towards the synthesis of para chloro substituted bromoalkyne 
The synthesised bromoalkyne was tried in the one-pot ynamide formation rearrangement 
with two different sulfonamides (Scheme 55). Clean reactivity was observed with the use of 
allylmesyl sulfnamide 175, giving the desired product 247 in a very high yield. The reaction 
with the bromo-substitued sulfonamide 173 was not straight forward. Multiple spots were 
seen from the TLC analysis. After flash column chromatography, the desired product 248 
was observed from 1H-NMR spectroscopy but contaminated with solvents. However, efforts 
to get the complete data proved abortive as the product underwent degradation during the 





Scheme 55: Chloro-substituted oxyisoquinolines 
The incorporation of a fluoro substituent in a meta position relative to the acetal was also 
explored. The same reaction sequence was followed commencing from the commercially 
available 2-bromo-5-fluorobenzaldehyde (Scheme 56) 
 
Scheme 56: Installing a fluoro substituent in the meta relative to the hydride donor 
The one-pot cyclisation cascade was successful with the use of sulfonamides 171 and 173 





Scheme 57: Fluoro-substituted oxyisoquinolines 
This highlights the compatibility of our methodology in a convergent manner. 
Spiroisoquinoline 255 was formed in a high yield with no trace of degradation. 
 We also turned our attention to investigate the presence of a fluoro substituent on the 
connector tether in an ortho position relative to the hydride donor (acetal). We followed 
this strategy to see if there will be change in reactivity. Similarly, the same reaction 





Scheme 58: Oxyisoquinoline 261 with fluoro group in ortho relative to the acetal 
The syntheses of the starting materials were more robust when compared with 2-bromo-5-
bromobenzaldehyde. The one pot process gave the desired cyclic product 261 in high yield. 
The nosyl nitrogen protecting group was well tolerated in the synthesis. 
The scalability of the one-pot ynamide cyclisation cascade was demonstrated by the 
reaction of the alkynyl bromide 260 with N-tosylcinnamyl amine 213 (Scheme 59). 






Scheme 59: Gram scale synthesis of 262 
For further comparison, we explored the effect of an electron donating group (EDG) on the 
aromatic hydride donor-acceptor linker. The preparation of the alkynyl bromide with a 
methoxy group was achieved following the usual protocol (Scheme 60). Bromination of 3-
methoxybenzaldehyde 263 generated 2-bromo-5-methoxybenzaldehyde 264 in quantitative 
yield. Subsequent Sonogashira coupling 265, deprotection 266, acetal formation 267 and 
bromination gave 268 in very high yield. 
 
Scheme 60: Preparation of alkynyl bromide with an EWG 
The one-pot cyclisation cascade involving substrate with an electron donating group 
furnished the oxyisoquinolines in moderate yields (Scheme 61). The electron rich, methoxy 
67 
 
group which is in para position relative to the hydride acceptor can reduce the 
electrophilicity of the ketenimine generated through mesomerism. In addition, its meta 
position relative to the hydride donor can equally decrease the “hydricity” of the acetal via 
inductive effect.75 It is likely that these two synergistic effects can contribute to the 
moderate yields of isoquinolines 269 and 270. Similarly, the desired product 270 was 
isolated as a mixture of E/Z isomers in the ratio 0.5:1. The complexity of the 1H-NMR 
spectroscopy prevented us from identifying the isomers. 
 
 
Scheme 61: Effect of EDG on the aromatic connector tether 
3.4.8 Modification at the benzylic position 
The use of benzylic ethers as a hydride donor was explored (Scheme 62). We were 
particularly interested to observe if the benzhydric ether containing ynamide will react 
under the developed one-pot cascade cyclisation as previous investigation in the group 




Scheme 62: Systems with benzylic ethers under cyclisation 
Terminal alkyne 271 was available in the group made by Holly Adcock. Bromination of 271 
was achieved in a very high yield. One pot process of 272 with bromoallyl sulfonamide 171 
gave dihydroisoquinoline 273 in moderate yield. In addition, we did not observe the 
formation of isoquinoline as a result of neighbouring-group elimination and desulfonylation 
as indicated by Holly Adcock when she tried such systems under copper catalysis.71 Full 
conversion was not achieved as the starting materials were not all consumed. Complex 
reaction mixtures were obtained from the formation of 274. TLC analysis indicated three 
spots but their purification and isolation was not fruitful  
3.4.9 Heteroaromatic linkages 
In the proposed mechanism, the [1,5] hydride transfer is accompanied with a corresponding 
disruption of aromaticity in the benzene ring. We became interested in looking at the 
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possibility of incorporating other aromatic systems apart from benzene in the cascade 
reaction. We reasoned that the degree of aromaticity of such systems may affect the 
outcome of the reaction and potentially provide access to desirable substrates containing 
hetero-aromatic motifs. To achieve this, alkynyl bromide with pyridine ring was was 
synthesised (Scheme 63) in order to subject it to copper catalysis. 
 
 
Scheme 63: Towards the synthesis of pyridine derived alkynyl bromide 
Formylation of the 3-position of freshly distilled 2-bromopyridine with lithium 
diisopropylamide gave 276 in moderate yield. The purity of 2-bromopyridine is vital as slight 
impurities from the commercially available reagent can shut down the reaction completely. 
Sonogashira coupling of 276 gave the silyated alkyne 277 in high yield. Acetalisation with 
ethylene glycol gave the acetal 278 in poor yield. Increased reaction yield of 278 was not 
achieved as degradation occurred upon longer reaction time. Deprotection 279 and 
subsequent bromination furnished the pyridine derived alkynyl bromide 280. However, 
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upon removal of solvent using rotary evaporator, the clear solution turned into a black and 
sticky solution. The 1H-NMR spectrum of the black solution was clean and clearly showed 
the correct signals of the alkynyl bromide product with no seen impurities. It was used 
immediately in the one pot cyclisation cascade (Scheme 64). 
 
 
Scheme 64: Pyridine ring system under copper catalysis  
The pyridine derived alkynyl bromide 280 underwent the desired reaction with allylmesyl 
amine 175 to form the spiroisoquinoline 281 in moderate yield. This methodology has 
proved the ability to access diverse heteroaromatic compounds fused together. Not all the 
sulfonamide was consumed in the reaction and the alkynyl bromide 280 was not very 
soluble in toluene. This may account for the moderate yield of the cyclic product 281. 
Following up on the studies on pyridine based cyclic product, the synthesis of thiophene-





Scheme 65: Formation of thiophene derived alkynyl bromide 
The catalysis profile of the copper catalysis of 287 with different sulfonamides is shown in 
(Scheme 66). Complex mixtures and degradation were seen in the formation of 288 and 





Scheme 66: Thiophene based system under copper catalysis 
However, the cyclic product is not very pure as some impurities which cannot be removed 
by flash column chromatography exist.  
3.4.10 Reactivity of other ynamides. 
Some interesting ynamides were made for their reactivity in gold-catalysed reactions. We 
decided to subject some of them under the optimised conditions developed by Holly Adcock 
and observe their reactivity towards copper catalysis. Pinacol acetal derived ynamide 291 
was synthesised and subjected to the optimised condition of copper catalysed cyclisation 
reaction (Scheme 67). Interestingly two spots were seen on TLC and the purification and 
isolation of the reaction mixture revealed the formation of 292a and 292b in moderate 
yields. Cyclic product 292a was the desired product of copper catalysed cyclisation cascade, 
but in its deprotected form as the pinacol acetal was cleaved under the reaction conditions. 
The substituted benzaldehyde product 292b arose from the direct addition of water across 
the triple bond and cleavage of pinacol acetal. The source of water that is responsible for 
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this side product is likely to come from the solvent or an air ingress into the reaction 
mixture. The reaction was quite fast as it took only two hours to go to completion. 
 
 
Scheme 67: Synthesis and copper catalysis of pinacol acetal derived ynamide 291 
Ynamide 293 containing an acetal made from propylene glycol was donated by Holly Adcock 
and was investigated. (Scheme 68). Clean reactivity was seen with the formation of 
spiroisoquinoline in moderate yield. The moderate yield could not be accounted for as no 
side products were seen in the reaction mixture. 
 
Scheme 68: Cyclisation cascade of ynamide 293 
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Exploration into the use of benzydric ether-containing ynamides followed next. 
Naphthalene-containing ynamide 299 was prepared in six steps (Scheme 69). Sonogashira 
coupling of 2-bromobenzaldehyde 160 with trimethylsilylacetylene gave the protected 
alkyne 161. Treatment of protected alkyne 161 with freshly prepared Grignard reagent 295 
generated the secondary alcohol 296 in high yield. Methylation and deprotection of 
secondary alcohol 296, all in one pot led to the formation of terminal alkyne 297. 
Bromination of 297 gave the alkynyl bromide 298 which was used immediately in the next 
step. Copper catalysed coupling of bromoalkyne 298 with allyl sulfonamide 175 furnished 
the ynamide 299 in good yield. 
 
Scheme 69: Preparation of naphthalene containing ynamide 
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Under copper catalysis, ynamide 299 was not compatible with the one pot cascade reaction 
(Scheme 70). Whilst ynamide 299 was consumed in the reaction, a complex mixture was 
generated prior to purification. 
 
Scheme 70: Naphthalene containing ynamide under copper catalysis 
Isolation by flash column chromatography failed due to the complexity of the mixture. 
Change in solvent to m-xylene and increased reaction temperature did not improve the 
reaction. 
A different benzydric ether ynamide 305 was made via the same reaction sequence as the 




Scheme 71: Formation of benzydric ether ynamide 305 
Disappointedly, the copper catalysed rearrangement cascade of ynamide 305 failed 
(Scheme 72). Complex mixtures and degradation were observed. The unsuccessful results 





Scheme 72: Ynamide 305 under copper catalysis 
4. Conclusion 
A one pot carbon-nitrogen bond formation and rearrangement cascade sequence has been 
developed in which ynamide formation is followed by [1,5]-hydride transfer/cascade 
cyclisation to synthesize oxyisoquinolines with the use of an environmentally benign, 
inexpensive copper catalyst. Exploration of the substrate scope and limitations have allowed 
access to highly functionalised fused heterocycles. The introduction of various groups in the 
novel isoquinolines can serve as synthetic handles for further cross-coupling reactions. In 
the developed one pot process, an initial aza-Claisen rearrangement, subsequent [1,5]-
hydride transfer and 6π electrocyclisation has generated diverse fused pyridine derivatives 





Chapter 3  





As seen in the previous chapter, the use of ynamides as starting materials to access 
functionalised heterocycles under transition metal catalysis is of much interest in our group. 
Apart from copper, the use of gold catalysts to achieve novel transformations has also been 
at the centre of our research and modification of ynamides can provide alternative 
pathways for new reactions. In line with this perspective, numerous studies on the 
transition metal-catalysed reactions have been explored76-78. In the midst of these reactions, 
transition metal catalysed cycloisomerisation of enynes has been widely explored because 
of the accessibility of substrates with different functionalities and diversities, derived from 
simple starting materials3, 79-83. Among the enynes,1,6-enynes have proved to be versatile 
substrates for cycloisomerisations due to their ease of preparation and change in 
functionality (Scheme 73)3, 84, 85 
Generally, electrophilic activation of the alkyne component by a π Lewis acid brings about 
the nucleophilic attack of the alkene fragment, which triggers the entire skeletal 
transformation. Studies have indicated that the various pathways are also dependent on the 
nature of substrates and catalyst used3, 86. The numerous pathways of cycloisomerisation of 
1,6-enynes can generate six membered alkenes, five membered heterocycles with a diene 
moiety,cyclobutenes and other tricyclic products, all with different functionalities. Following 
the importance of cycloisomerisation to generate different interesting products, the 





Scheme 73: Reaction pathways of 1,6-enyne cycloisomerisation 
2. Transition metal catalysed cycloisomerisation of 1,6-enynes 
2.1 Platinum catalysed cycloisomerisations. 
Malacria and co-workers reported the Pt(II)-catalysed cycloisomerisation of 1,6-ene-
tosylynamides affording a five-membered nitrogen heterocycle containing 1,3-diene moiety 
308 (Scheme 74)87. According to the proposed mechanism, the electrophilic activation of 
the triple bond in 309 by the platinum catalyst followed by the nucleophilic attack of double 
bond of alkene generates the platinum cyclopropyl carbene intermediate 310a or 
keteniminium species 310b. Ring opening of cyclopropylplatina carbene 310a generates the 
zwitterion 311 and subsequent demetalation forms cyclobutenamide 312. The nitrogen 
heteroatom provides some sort of stabilisation to zwitterion 311. Finally, electrocyclic ring 
opening of 312 furnishes the desired product 313. This mechanism is supported by the 
theoretical DFT calculations carried out by the research groups of Soriano88 and 
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Echavarren89. It is equally important to note that this mechanism holds true for other 
transition metal complexes or salts including gold,palladium and ruthenium88. From a 
different pathway, the generation of keteniminium species as supported by Hsung and co-
workers90 can form the cyclobutyl cation 311 via [2 + 2] cycloaddition. Subsequent steps can 
equally lead to the formation of the cyclic product 313 
 
 
Scheme 74: Platinum-catalysed cycloisomerisation of ene-ynamide 307 
Extending the reaction sequence to 1,7-ene-ynamides gave cyclobutanones due to 
hydrolysis of enamines91. The substrate scope was limited to ene-ynamides with a terminal 
alkyne moiety. 
In a similar version, Murai and co-workers investigated the cycloisomerisation of 1,6-enynes 
under platinum catalysis (Scheme 75)92. Substrate scope ranged from mono-substituted 
alkenes to di and tri-derivatives. They found out that the use of platinum complexes with 
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different coordinating ligands inhibited the reaction, proving that the presence of halide 
ions was necessary for the reaction to proceed. 
 
 
Scheme 75: Cycloisomerisation of 314 under platinum catalysis 
Furstner and co-workers explored the use of cycloisomerisation to macrocyclic synthesis93, 
94. Treatment of enyne 316 with platinum(II)chloride gave the diene 317 containing a ten-
membered ring (Scheme 76). Dienes containing twelve-and fourteen-membered rings were 
also synthesised. The build-up of high complexity from simple starting materials was 
remarkable. The methodology was extended to the synthesis of streptorubin B and 
metacycloprodigiosin, that belong to the prodiginine family of antibiotics95 
 
 
Scheme 76: Cycloisomerisation of 316 
2.2 Gold catalysed cycloisomerisation 
The reactivity of 1,6-ene-ynamides under gold catalysis was investigated by the research 
group of Couty (Scheme 77)96. Ene-ynamide 307 gave rise to cyclobutanone 318 when 
reacted with gold(I)chloride at room temperature. The product of the cycloisomerisation 
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was different when the same substrate was employed under platinum catalysis (see scheme 
74). The mild reaction condition promoted the hydrolysis of cyclobutenamide intermediate 
319 that is generated according to the proposed mechanism (Scheme 77) to yield the final 
product 318. The exposure to air during work-up of the crude reaction mixture was assumed 
to be the source of water that resulted in hydrolysis. Cyclobutanones were equally obtained 
when the substrates were extended to 1,7-ene-ynamides. No product with dienamide 
moiety was isolated. The substrate scope was limited to ene-ynamides with terminal 
alkynes,trimethylsilyl and propargylic alcohol moieties  
 
 
Scheme 77: Gold-catalysed cycloisomerisation of 307 
In 2004, Echavarren and co-workers reported the synthesis of 1,3-dienes 323 from the 
cycloisomerisation of 1,6-enynes 322 in the presence of a gold(I)complex (Scheme 78)97. The 





Scheme 78: Cycloisomerisation of enyne using gold(I)complex 
Similarly Gagosz and co-workers discovered that the use 
bis(trifluoromethanesulfonyl)imidate (Tf2N
-) as a counteranion in the gold complex can 
promote the same reaction98, hence the use of Au(PPh3)NTf2 gave comparable results. 
Despite the huge advances recorded in the field of cycloisomerisation, limitations still exist 
for the synthesis of heterocycles containing dienamide moiety via gold catalysis. In the same 
vein, most of the previous investigations of substrate scope were mainly limited to terminal 
alkynes99, 100. The extensive work on the reactivity of ynamides under gold catalysis9, 101, 102, 
being carried out in our group encouraged us to investigate the gold-catalysed 
cycloisomerisation of substituted ene-ynamides. 
3 Results and discussion 
3.1 Reaction design 
The reactivity of ynamides under oxidative gold catalysis was ongoing in our group when it 
was discovered that the treatment of 1,6-ene-ynamide 324 in the presence of an N-oxide 
can generate the desired cyclopropane 325 alongside the over-oxidised product 326 and the 




Scheme 79: Cyclopropane formation under oxidative gold catalysis 
Keen to increase the yield of cycloisomerised product 327, Fernando Sanchez-Cantalejo (a 
member of Davies group) did some optimisation studies and discovered that 329 can be 
generated in an excellent yield when ene-ynamide 328, was subjected to gold(I)complex,Au-
1 . Higher concentration of nitromethane was required to achieve this result. Following the 
optimisation of the reaction, we decided to investigate the functionalisation of these five 
membered nitrogen heterocycles with dienamide moiety by exploring the substrate scope 
(Figure 2).  
 
 
Figure 2: Variations of 1,6-ene-ynamide towards gold catalysis 
Variations at the C-terminus of alkyne, substituents on the α-position of nitrogen and 
groups on the alkene region can generate heterocycles that can be remarkable. 
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3.2 Variations at the C-terminus of alkyne 
To explore the reactivity of substituted ene-ynamides towards gold catalysis, 1,6-ene-
ynamides bearing various groups at the C-terminus of alkyne were prepared in a two-step 
sequence (Scheme 80) 
Starting from the commercially available aromatic aldehydes 330-339, treatment with 
tetrabromomethane gave the corresponding dibromo olefins 340-349 from good to 
excellent yields. In most cases, the crude reaction mixtures were pure enough that no flash 
column chromatography was required. Access to functionalised ene-ynamides 351-360 was 
achieved by the copper-catalysed cross coupling of homoallyl sulfonamide 350 with 
dibromo olefins 340-349 by the method used by Evano and his research group14. Yields 
ranged from good to excellent ones and groups with different electronics were 
accommodated  
 
Scheme 80: Synthesis of substituted ene-ynamides 
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With the optimised conditions at hand, the substituted 1,6-ene-ynamides 351-360 where 
subjected to gold catalysis (Scheme 81). Intriguingly they were reactive under the optimised 
conditions thereby generating highly functionalised five membered nitrogen heterocycles 
containing 1,3-diene moieties. Fast and clean reactivity (1 h) were observed in all substrates 
except 364 and 366 that were generated in four and six hours respectively. The 
cycloisomerisation chemistry generated motifs with electron rich substituents 362-363 in 
excellent yields. Similarly the catalysis was compatible with electron deficient groups 366 
and 371. Halo substituted products 364-365 were equally tolerated. 
Introduction of heteroaromatic group was possible with the generation of the cyclised 
product 368 in moderate yield. Furan derivative 367 gave a complex mixture under the 
reaction conditions and purification by flash column chromatography led to massive 
degradation as observed by 1H-NMR spectroscopy. Reduction of the reaction temperature 
did not improve the outcome of the reaction as degradation was also seen. Other bicyclic 
aromatic systems 369 and 370 showed high reactivity in the cycloisomerisation conditions. 
Generally, it should be noted that the catalysis does not necessarily require a dry solvent as 
the synthesis of the carbocyclic products 362, 363, 365, and 368 were also achieved with 




Scheme 81: Substrate scope for the formation of 5-membered heterocycle with dienamide 
moiety 
Following the successful synthesis of cyclic dienamide bearing a thiophene group 368, we 
decided to explore the reactivity of thio-ynamides towards gold catalysis as the generation 
of dienamides with a thio group will provide an alternative functionalised heterocycle that 
can be interesting and potentially useful motifs. Thio-ynamide 376 was made in a four step 
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reaction sequence (Scheme 82). Reaction of sulfonamide 350 with formylbenzotriazole 373 
gave the tolylated formamide 374 in good yield. Formamide 374 was converted to 
vinyldichloride 375 with tetrachloromethane and triphenylphosphine. 
 
 
Scheme 82: Synthesis of thio-ynamide 
Subsequent treatment of tolylated vinyldichloride 375 with n-butyllithium and trapping it 
with the electrophile-phenyl benzenethiosulfonate furnished the thio-ynamide 376 in 
moderate yield. 
The cycloisomerisation of thio-ynamide 376 under the optimised reaction conditions failed 
to generate the desired product in reasonable yield (Scheme 83). Although the starting 
material was consumed at a longer reaction time (24 h), complex mixtures along with 
degradation were seen as there are many spots located on TLC. The 1NMR spectrum of the 
crude reaction mixture showed some signals relating to the desired compound and 
subsequent purification by flash column chromatography afforded the dienamide in less 
than 10% yield. In addition, 1NMR spectra of other fractions collected appeared to be very 
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messy. The change in condition to the use of a different gold(I)catalyst-Au-2 and different 
solvent-dichloromethane did not improve the yield as complex mixtures were seen. 
 
 
Scheme 83: Thio-ynamide 376 under gold catalysis 
The use of commercially available catalyst dichloro(picolinate)gold(III) (Au-3) changed the 
course of the reaction (Scheme 84). Treatment of thio-ynamide 376 with the gold(III) 
precatalyst in the presence of toluene, promoted the cycloisomerisation reaction affording 
the cyclic dienamide 377 in very good yield. Longer reaction time was recorded in 
converting the starting material into the desired product as the reaction was completed in 
16 h. 
 
Scheme 84 : Formation of cyclic dienamide from thio-ynamide 376 
Further reactivity of cyclic dienamide with a thio group 377 was shown by one-pot reaction 
of thio-ynamide 376 with 4-phenyl-1,2,3-triazoline-3,5-dione 378 (Scheme 85). Injection of 
triazoline-3,5-dione into the reaction mixture, immediately after the formation of the 
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desired cycloisomerised product (as seen by TLC) generated the tricyclic product 379 in 
good yield. The overall reaction time was 20 h. 
 
Scheme 85: Further reactivity of thio-ynamide under gold catalysis 
Intrigued with the successful synthesis of tricycle 379, attention was focused on the use of 
dienophiles in the one-pot sequence since the gold-catalysed cycloisomerisation protocol 
produces a heterocycle with a dienamide moiety which can be considered as a good 
precursor for a Diels-Alder reaction. Furthermore, toluene has been successfully used to 
drive Diels-Alder reactions103. Exploration of Diels-Alder reaction started with the use of 
maleic anhydride 380 as a dienophile (Scheme 86). Unfortunately, no reactivity was 
observed as the cycloisomerised diene product 377 was isolated at the end of the reaction. 
 
Scheme 86: Diels-Alder reaction with dienamide generated in situ 
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Further increase of the reaction temperature to 100 °C and longer reaction time (48 h) did 
not improve the outcome of the reaction. Employment of other dienophiles like dimethyl 
ethylenedicarboxylate 382, acrolein 383 and methyl propiolate 384 showed absolute no 
reactivity in the reaction sequence. In each case, the cyclic dienamides generated in situ 
were all recovered. The observed non-reactivity seen in these reactions can be explained by 
the presence of the thio-group or other substituted groups located on the exo-cyclic double 
bond of cyclic dienamide 377. It is reasoned that groups on the exo-cyclic double bond of 
cyclic dienamide cause some sort of distortion thereby preventing the diene from adopting 
the s-cis conformation which is a requirement for dienes to undergo Diels-Alder reaction. 
Such distortion can push the dienamide into the non-reactive conformer hence no reaction. 
Additional substituent effect on the alkyne region of ene-ynamide was equally investigated 
by the incorporation of an ester group (Scheme 87) 
 
 
Scheme 87: Formation of ene-ynamide with ethoxycarbonyl group 
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The reaction protocol of ynamide synthesis developed by Anderson and co-workers was 
used in the formation of 386104. Reaction of homoallyl sulfonamide 350 with trichloroethene 
gave the 1,2-dichloroenamide 385 in excellent yield. Further treatment with n-butyllithium 
and trapping with an electrophile-ethyl chloroformate generated ene-ynamide 386 in low 
yield, together with a side product 387 in moderate yield. The side product orginated as a 
result of deprotonation of phenyl hydrogen of the tosyl group and was isolated as the major 
product. The result was rather strange as the authors104 did not report the occurrence of 
such side products in their synthesis especially when tosyl groups are used. The reaction 
was carefully examined and performed by very slow addition of the base and electrophile 
while maintaining the low temperature that is required of the reaction. Dry conditions of 
reaction in terms of solvent and reaction vessel were strictly adhered to. These actions did 
not improve the reaction as the side product 387 was continuously isolated as the main 
product. The exact reason for this outcome is unknown to us. Alternatively the method used 
by Mori and co-workers103 was followed which employs the use of tolylated vinyldichloride 
375 and the desired ene-ynamide 386 was isolated in very good yield without any side 
product. 
Ene-ynamide with ester group 386 was not compatible with the optimised conditions of the 
cycloisomerisation protocol (Scheme 88). Complex mixtures accompanied with massive 





Scheme 88: Cycloisomerisation of 386 
Whilst purification was not achieved, clean and rapid reactivity was seen when ynamide 386 
was treated with gold(III) precatalyst ,as monitored by TLC. The 1H-NMR of the crude 
reaction mixture indicated the formation of the desired diene 388. However, purification by 
flash column chromatography was unsuccessful as degradation was observed. 
In the same context, alternative functionalisation of 386 was carried out (Scheme 89). No 
reactivity was observed when 386 reacted with 4-Phenyl-1,2,4-triazoline-3,5-dione. Diels-
Alder reaction with maleic anhydride completely failed as complex mixtures were observed 





Scheme 89: Functionalisation of 386 
3.3 Alteration at the alkene region 
Following the outcome of the use of substituted ene-ynamide at the alkyne region towards 
the cycloisomerisation process, we examined the outcome with the use of ene-ynamides 
bearing an electron rich methyl group at the alkene region. Substituted homoallylic 
sulfonamide 393 were made via two steps (Scheme 90). Tosylation of commercially 
available primary alcohol 391 gave 392 and further displacement with an amine gave the 
substituted homoallylic sulfonamide 393 in good yield. Copper-catalysed cross coupling 
reaction of 393 with various bromide derivatives 394,342 and 344 formed the substituted 





Scheme 90: Formation of ene-ynamide with substituents at the alkene region 
Ene-ynamide 395 was not compatible with the optimised gold-catalysed cycloisomerisation 
conditions (Scheme 91). The most striking observation is the rapidity of the reaction yet very 
complex mixtures were obtained. In the presence of catalyst Au-1 and solvent-
nitromethane, total consumption of the starting material was seen by TLC in less than 30 
minutes of reaction. Further optimisation of reaction in terms of change of solvents 
(toluene, acetonitrile, dichloromethane, 1,2-dichlorobenzene,1,2-dichloroethane and 
tetrahydrofuran),different sources of gold catalysts and varying reaction temperatures did 
not improve the outcome of the reaction in any form. Extensive efforts to isolate the 
product or characterise the side products were practically impossible due to the complexity 
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of the reaction mixture. The inability of ene-ynamide 395 to cyclise into the desired product 
cannot be clearly defined at this point; however we speculate that different reaction 
pathways may be possible generating side products that cannot be identified. 
 
 
Scheme 91: Reactivity of ynamide 395 under gold catalysis 
Reactivity of analogues ene-ynamide 396 and 397 were tested and both failed to deliver the 
cyclised products (Scheme 92). Complex mixtures that were inseparable by flash column 
chromatography were obtained in each case. Frustrated with these unsuccessful results, no 
further attempts were made to synthesise analogous ene-ynamides with different 




Scheme 92: Reactivity of ynamide 396 and 397 under optimised gold conditions 
3.4 Substituents on the α-position of nitrogen. 
For further substrate scope of the cycloisomerisation reaction, attempts were made to 
synthesise various ene-ynamides with groups at the α-position relative to the nitrogen atom 
(Scheme 93). Condensation of aromatic aldehydes 401-405 with amine led to the formation 
of imines 406-410 with the use of Dean stark apparatus. Treatment of the imines with 
freshly prepared allyl magnesium bromide generated the sulfonamide 411-415 with groups 
on the α-position relative to the nitrogen atom. The imines were used immediately they 
were formed as they are prone to degradation and further purification by flash column 
chromatography wasn’t performed. Following the successful formation of various 
sulfonamide 411-415, they were reacted with freshly prepared bromoalkyne 394 under the 
standard copper catalysed reaction. Higher temperature and longer reaction time were 
required to get the reactions into completion. The substituted ynamides 416-420 were 
made in low to high yields. Low reactivity was seen for the formation of ene-ynamde 420, 
with furan ring. Improvement of its reactivity using different method gave almost the same 





Scheme 93: Functionalised ene-ynamide synthesis 
Catalysis of the ene-ynamides with substituted aromatic groups on the α-position of 
nitrogen atom proved suitable with the optimised conditions (Scheme 94). Carbocylic 
compounds with dienamide moiety 421 and 422 were generated in very good yield. 
Incorporation of bulky group like bromine in ortho position was possible in the formation of 
423. Complex mixtures that are inseparable by flash column chromatography resulted in the 
formation of 424 and 425, bearing a para methoxy phenyl group and furan ring respectively. 
Employment of other sources of gold catalyst and solvent change followed the same trend 





Scheme 94: Catalysis and substrate scope 
3.5 Proposed mechanism 
According to the proposed mechanism (Scheme 95), selective coordination and activation of 
the triple bond by the electrophilic gold catalyst, followed by concomitant nucleophilic 
attack of alkene generates the gold cyclopropylcarbene 428. Ring expansion of carbene 
intermediate 428 produces cyclobutyl cation 426 that is stabilised by the adjacent nitrogen 
atom. Subsequent elimination of gold catalyst furnishes cyclobutenamide 430 and 
electrocyclic ring opening of 430 gives the desired cycloisomerised product 427 with 1,3-
diene moiety. As earlier discussed in (Scheme 74), this proposed mechanism is in total 
agreement with the ones proposed by the research groups of Malacria87, 91 and Cossy96. 
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Experimental data provided through DFT calculations done by Soriano106 and Echavarren89 
supported the mechanism. 
 
Scheme 95: Proposed mechanism for cycloisomerisation of ene-ynamide 426 
3.6. Other reactivity 
Holly Adcock and Elli Chatzopoulou (members of Davies group) reported the synthesis of 
polycycles via gold-catalysed [1,5]-hydride transfer-cyclisation cascades of N-allyl 
ynamides71 (Scheme 96) 
 
 
Scheme 96: Au-catalysed polycycle formation from ynamide 158 
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Treatment of 158 with gold(III)catalyst Au-3,generated the 3D fused nitrogen heterocycle 
431  as a single diastereoisomer in which the migrated hydrogen and the cyclopropane ring 
were in the same face as confirmed by nOe experiments. Substrate scope was quite broad 
as variations on the aromatic and allyl regions were all tolerated. The synthetic versatility of 
this methodology which provides access to highly functionalised molecules motivated us to 
investigate the reactivity of ynamides with substituted dioxolane groups. Ynamides 
234,291,432 and 433 were made from freshly prepared alkynyl bromides in moderate to 
good yields (Figure 97). 
 
 
Scheme 97: Ynamides with substituted dioxolane groups 
Ynamide 291 reacted cleanly in two hours with full consumption of starting material to give 
the tetracycle 434 containing a pinacol group in good yield (Scheme 98). The chiral 





Scheme 98: Formation of tetracycles from ynamides 
When the temperature was increased to 50 °C, ynamide 433 underwent smooth gold-
catalysed [1,5]-hydride transfer/cyclisation process to generate polycycle 435 in high yield 
as a 1:3.5 mixture of diastereoisomers. Unfortunately the two diastereoisomers were 
inseparable by flash column chromatography or recrystallization. 
Chiral ynamides 234 and 432 with an ester group were not reactive under the gold catalysed 
polycyclisation conditions (Scheme 99). Change in reaction conditions employing the use of 
higher temperature and 1,4-dioxane did not improve the outcome. Starting materials and 




Scheme 99: Chiral ynamides under gold catalysis 
It is likely that gold catalyst is also coordinating to the carbonyl oxygen atom of the ester 
group which creates some sort of competition over gold, binding between the triple bond 
and oxygen atom. Such competition will lead to inefficient activation of triple bond and 
possibly shut down the reaction. 
4 Conclusion 
New five-membered nitrogen heterocycles bearing dienamide moieties have been achieved 
through gold-catalysed cycloisomerisation of 1,6-ene-ynamides. Ene-ynamides with internal 
alkynes or substituents at the α-position relative to the nitrogen atom have been 
successfully used as substrates to achieve these important transformations. Introduction of 
thio-ynamide in the catalytic process opens a new route for further functionalisation. 
Finally, additional functionalisation of tetracycles bearing different groups at the dioxolane 
region have been generated through gold-catalysed [1,5] hydride transfer/cascade 











All reagents were purchased from Aldrich, Fluka, Fisher, Acros, Johnson Matthey, Alfa Aesar 
or VWR and used without further purification unless otherwise stated. For all reactions 
carried out under an atmosphere other than air, solvents were purified using a Pure Solv-
MD solvent purification system, except for nitromethane, which was dried over 4 Å 
molecular sieves. The solvents were transfer under nitrogen or argon. Paraffin oil baths and 
stirrer hot plates were used with an external temperature probe. Reaction progress was 
monitored by thin layer chromatography (TLC) performed using Merck Silica gel 60 F254. 
Visualisation was achieved by a combination of ultraviolet light (254 nm) and potassium 
permanganate solution. Flash column chromatography was performed using 60 Å pore size 
(40-63μm) silica gel as the stationary phase. The following cooling bath mixture were used 
for low temperature reactions: 0 °C (ice/water), -40 °C (dry ice/water) and -78 °C (dry 
ice/acetone) All 1H NMR and 13C NMR experiments were recorded using Bruker AVIII400(1H 
= 400 MHz, 13C = 101 MHz) and AVIII300(1H = 300 MHz, 13C = 75 MHz), with the 
spectrometers at 300 K. 13C NMR were recorded using the PENDANT pulse sequence from 
the Bruker standard pulse program library. Chemical shifts (δ) are given in ppm relative to 
TMS and coupling constants (J) are quoted in Hz to one decimal place. For spectra recorded 
in chloroform-d the 7.26 ppm resonance of residual CHCl3 for proton spectra and 77.16 ppm 
resonance of CDCl3 for carbon spectra were used as internal references. Spectral data for 
1H 
NMR is reported as follows: chemical shift (multiplicity, coupling constant, number of 
protons); and for 13C NMR: chemical shift (assignment). The following abbreviations were 
used for multiplicity in 1H NMR: s (singlet), d (doublet), t (triplet), q (quadruplet), br (broad), 
m (multiplet) app.(apparent). Collected NMR spectra were processed using MestReNova 
software. Infra-red spectra were recorded neat on a Perkin-Elmer Spectrum 100 FTIR 
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spectrometer. Wavelengths (ν) are reported in cm-1. Waters Synapt (ES), Waters GCT (EI) or 
Waters LCT (ES) spectrometers were used to obtain the mass spectra. Melting points were 
determined using open glass capillaries on a Gallenkamp melting point. 
Preparation of sulfonamides 
General procedure 1 (GP1) 
The required sulfonyl chloride (1.0 equiv.) was added in a dropwise fashion to a solution of 
the relevant amine (1.2 equiv.), pyridine (3.0 equiv.) in dichloromethane (0.3 M) at 0 °C. The 
resulting solution was warmed up to room temperature and stirred for 16 hours. 1.0 M HCl 
was added and the aqueous layer extracted with CH2Cl2 (× 3). The combined organic layers 
were washed with water (× 2), brine, dried over Na2SO4 and concentrated to give the 
sulfonamide which was used without further purification. 
General procedure 2 (GP2) 
Based on existing literature procedure 107 
The relevant bromide (1.1 equiv.) and K2C03 (2.0 equiv.) were added to a solution of the 
requisite amine (1.0 equiv.) in acetone (1.0 M) and the resulting mixture was at 60 °C for 24 
hours. The reaction mixture was cooled, filtered through celite with EtOAc as eluent. The 
solvent was removed under reduced pressure and the crude residue was purified by flash 
column chromatography  
General procedure 3 (GP3) 
Based on existing literature procedure.108 
A solution of relevant aldehyde (1.0 equiv), 4-methylbenzenesulfonamide (0.9 
equiv.),amberlyst 15 ion-exchange resin (1 0 g) and activated 4 Å molecular sieves (1.0 g) in 
toluene (0.33 M) was heated at reflux using a Dean Stark trap for 16 hours. The reaction 
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mixture was cooled and filtered, concentrated and the residue was washed with hexane to 
give the imine. Freshly prepared allylmagnesium bromide (2.0 equiv.) was added to the 
solution of the imine (1.0 equiv.) in THF and the resulting mixture was stirred at room 
temperature. The reaction was monitored by TLC. The reaction mixture was quenched by 
saturated NH4Cl solution and extracted with EtOAc (× 3). The combined organic extracts 
were successively washed with water, brine, dried over Na2SO4 and solvent removed under 
reduced pressure. The crude residue was purified by flash column chromatography  
N-(3-Methylbut-2-en-1-yl)methanesulfonamide (165) 
 
The sulfonamide was prepared by a group member (Fernando Sanchez-Cantalejo). 
N-Cinnamylmethanesulfonamide (168) 
 
Prepared according to GP2 using methanesulfonamide (1.90 g, 20.0 mmol, 1.0 equiv.) and 
cinnamyl bromide (4.33 g, 22.0 mmol, 1.1 equiv.). Purification by flash column 
chromatography [8:2 (hexane:EtOAc)] gave the sulfonamide as a white soild (1.94 g, 46%); 
mp: 71-73 °C; 1H NMR (300 MHz, CDCl3) δ 7.42 – 7.27 (m, 5H), 6.62 (d J = 15.8 Hz, 1H), 6.20 
(dt, J = 15.8, 6.4 Hz, 1H), 4.57 (br. s, 1H), 3.94 (td, J = 6.3, 1.5 Hz, 2H), 3.00 (s, 3H); 13C NMR  
(101 MHz, CDCl3) δ 136.1 (C), 133.5 (CH), 128.8 (2 × CH), 128.3 (CH), 126.6 (2 × CH), 124.6 
(CH), 45.5 (CH2), 41.3 (CH3). 






Prepared according to modified GP2 using methanesulfonamide (3.14 g, 33.0 mmol, 2.2 
equiv.) and 3-chloro-2-methylprop-1-ene (1.50 mL, 15.0 mmol, 1.0 equiv.). Purification by 
flash column chromatography [7:3 (hexane:EtOAc)] gave the sulfonamide as a colourless oil 
(1.07 g, 48%); 1H NMR (300 MHz, CDCl3) δ 4.99 (d, J = 1.4 Hz, 1H), 4.93 (d, J = 1.4 Hz, 1H), 
4.60 (br. s, 1H), 3.68 (d, J = 6.4 Hz, 2H), 2.96 (s, 3H), 1.78 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 
141.0 (C), 112.9 (CH2), 49.1 (CH2), 41.0 (CH3), 20.1 (CH3); IR vma×/cm
-1 3287, 2972, 2939, 
1658, 1412, 1308, 1142, 1064, 975, 899, 754. 
N-(But-3-en-2-yl)methanesulfonamide (172) 
 
The sulfonamide was prepared by a group member (Fernando Sanchez-Cantalejo). 
N-(2-Bromoallyl)methanesulfonamide (173) 
 
Prepared following literature procedure.110 
2,3-Dibromo-1-propene (2.17 mL, 22.2 mmol, 2.0 equiv.) was added to a mixture of tert-
butyl (methylsulfonyl)carbamate (MsNHBoc), (2.17 g, 11.1 mmol) and K2CO3 (2.45 g, 1.6  
equiv.) dissolved in DMF. The mixture was stirred at 35 °C for 4 h. The reaction was 
quenched with water, extracted with Et2O (× 3) and the solvent removed under reduced 
pressure to give a crude residue that was dissolved in CH2Cl2 (6 mL). Dropwise addition of 
trifluoroacetic acid (8.3 mL) followed and the mixture stirred at room temperature for 
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additional 12 hours. Purification by flash column chromatography [8:2 (hexane:EtOAc)] gave 
the sulfonamide as a brown solid (1.87 g, 67% over two steps) mp: 57-59 °C; 1H NMR (300 
MHz, CDCl3) δ 5.97 (d, J = 2.3 Hz, 1H), 5.65 (d, J = 2.3 Hz, 1H), 4.98 (br. s, 1H), 4.00 (d, J = 6.4 
Hz, 2H), 3.02 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 129.2 (C), 119.8 (CH2), 51.2 (CH2), 42.1 
(CH3); IR vma×/cm
-1 3271, 2936, 1636, 1449, 1410, 1307, 1140, 1073, 898, 747. 
 (E)-N-(4-((Tert-butyldimethylsilyl)oxy)but-2-en-1-yl)methanesulfonamide (174) 
 
The sulfonamide was prepared by a group member (Fernando Sanchez-Cantalejo). 
N-Allylmethanesulfonamide (175) 
 
Prepared according to GP1 using methanesulfonyl chloride (0.78 mL, 10.0 mmol, 1.0 equiv.) 
and allylamine (0.9 mL, 12.0 mmol, 1.2 equiv.) to give the sulfonamide as a yellow oil(0.95 g, 
70%); 1H NMR (300 MHz, CDCl3) δ 5.87 (ddt, J = 17.1, 10.2, 5.8 Hz, 1H), 5.35 – 5.26 (m, 1H), 
5.26 – 5.19 (m, 1H), 4.57 ( br. s, 1H, NH), 3.78 (td, J = 5.1, 2.8 Hz, 2H), 2.97 (s, 3H); IR 
vma×/cm
-1 3280, 2937, 1440, 1413, 1308, 1141, 1064, 926, 752.  
Data matches that reported in the literature.111 
 (E)-N-(But-2-en-1-yl)methanesulfonamide (191) 
 





Prepared according to GP2 using 4-methylbenzenesulfonamide (3.42 g, 20.0 mmol, 1.0 
equiv.) and cinnamyl bromide (4.33 g, 22.0 mmol, 1.1 equiv.). Purification by flash column 
chromatography [8:2 (hexane:EtOAc)] gave the sulfonamide as a yellow soild (2.59 g, 45%); 
mp: 108-110 °C; 1H NMR (300 MHz, CDCl3) δ 7.79 (d, J = 8.3 Hz, 2H), 7.35 – 7.22 (m, 7H), 6.45 
(d, J = 15.8 Hz, 1H), 6.02 (dt, J = 15.8, 6.4 Hz, 1H), 4.56 (t, J = 6.2 Hz, 1H), 3.76 (td, J = 6.4, 1.5 
Hz, 2H), 2.43 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 143.7 (C), 137.3 (C), 136.2 (C), 133.2 (CH), 
129.9 (2 × CH), 128.7 (2 × CH), 128.1 (CH), 127.4 (2 × CH), 126.5 (2 × CH), 124.2 (CH), 45.6 
(CH2), 21.6 (CH3). 
Data matches that reported in the literature.112 
N-(But-3-en-1-yl)-4-methylbenzenesulfonamide (220) 
 
Prepared according to GP1 using 4-methylbenzenesulfonyl chloride (1.91 g, 10.0 mmol, 1.0 
equiv.) and allylamine (0.9 mL, 12.0 mmol, 1.2 equiv.) to give the sulfonamide as a white 
solid (1.94 g, 86%); mp: 63-65 °C; 1H NMR (300 MHz, CDCl3) δ 7.75 (d, J = 8.3 Hz, 2H), 7.36 – 
7.29 (m, 2H), 5.72 (ddt, J = 17.1, 10.2, 5.8 Hz, 1H), 5.24 – 5.06 (m, 2H), 4.49 (t, J = 6.3 Hz, 1H, 
NH), 3.58 (app. tt, J = 6.0, 1.5 Hz, 2H), 2.43 (s, 3H); IR vma×/cm
-1 3240, 3088, 3029, 2849, 
1650, 1330, 1163, 935, 671. 
Data matches that reported in the literature.113 
N-Allyl-4-nitrobenzenesulfonamide (236) 
 




Diethyl allylphosphoramidate (238) 
 
The sulfonamide was prepared by a group member (Holly Adcock). 
N-Allyl-2,4,6-triisopropylbenzenesulfonamide (240) 
 
The sulfonamide was prepared by a group member (Holly Adcock). 
N-(But-3-en-1-yl)-4-methylbenzenesulfonamide (350) 
 
Prepared according to GP2 using 4-methylbenzenesulfonamide (1.71 g, 10.0 mmol, 1.0 
equiv.) and 4-bromobut-1-ene (1.1 mL, 11.0 mmol, 1.1 equiv.). Purification by flash column 
chromatography [8:2 (hexane:EtOAc)] gave the sulfonamide as a clear oil (1.30 g, 58%); 1H 
NMR (300 MHz, CDCl3) δ 7.74 (d, J = 8.3 Hz, 2H), 7.31 (d, J = 8.3 Hz, 2H), 5.62 (ddt, J = 17.1, 
10.4, 6.9 Hz, 1H), 5.12 – 4.97 (m, 2H), 4.44 (t, J = 6.2 Hz, 1H, NH), 3.02 (app. q, J = 6.5 Hz, 
2H), 2.43 (s, 3H), 2.25 – 2.15 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 143.6 (C), 137.1 (C), 134.3 
(CH), 129.8 (2 × CH), 127.2 (2 × CH), 118.3 (CH2), 42.2 (CH2), 33.7 (CH2), 21.7 (CH3); IR 
vma×/cm
-1 3280, 2926, 1596, 1423, 1322, 1156, 1074, 811, 662. 




3-Methylbut-3-en-1-yl 4-methylbenzenesulfonate (392) 
 
A flame dried flask, under nitrogen, was charged with 3-methylbut-3-en-1-ol (1.72 g, 20.0 
mmol, 1.0 equiv.) and dichloromethane (40 mL) at 0 °C. Successively, 4-
dimethylaminopyridine (1.47 g, 12.0 mmol, 0.6 equiv.), tosylchloride (4.58 g, 24.0 mmol, 1.2 
equiv.) and triethylamine (2.8 mL, 20.0 mmol, 1.0 equiv.) were added dropwise and the 
resulting solution was stirred magnetically at same temperature for 48 hours. The reaction 
was quenched by slow addition of water (30 mL) and the organic phase was washed with 
sat.NH4Cl solution and brine. The combined organic layers were dried over Na2SO4, filtered 
and the solvent removed under pressure to yield a colourless oil (3.84 g, 80%) which was 
used without further purification; 1H NMR (300 MHz, CDCl3) δ 7.79 (d, J = 8.3 Hz, 2H), 7.34 
(d, J = 8.3 Hz, 2H), 4.79 (d, J = 0.9 Hz, 1H), 4.68 (d, J = 1.0 Hz, 1H), 4.12 (t, J = 6.9 Hz, 2H), 2.45 
(s, 3H), 2.35 (t, J = 6.3 Hz, 2H), 1.66 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 144.9 (C), 140.3 (C), 
133.4 (C), 130.0 (2 × CH), 128.1 (2 × CH), 113.2 (CH2), 68.7 (CH2), 36.9 (CH2), 22.5 (CH3), 21.8 
(CH3); IR vma×/cm
-1 2970, 1598, 1356, 1173, 1096, 960, 897, 661. 
Data matches that reported in the literature.114 
4-Methyl-N-(3-methylbut-3-en-1-yl)benzenesulfonamide (393) 
 
A round-bottomed flask fitted with a condenser was charged with tosylamine (4.10 g, 24.2 
mmol, 2.3 equiv.), finely powdered potassium hydroxide (0.77 g, 13.7 mmol, 1.3 equiv.), 
dimethylsulfoxide (13 mL) and heated at reflux for 2 hours. The reaction mixture was cooled 
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at room temperature followed by dropwise addition of tosylated alcohol (2.52 g, 10.5 mmol, 
1.0 equiv.) in DMSO (1.5 mL) and sodium iodide (0.47 g, 3.15 mmol, 0.3 equiv.). The 
resulting solution was heated at reflux for 20 hours. Upon cooling, cold water (25 mL) was 
added and e×tracted with CH2Cl2 (3 × 30 mL). The combined organic layers were washed 
with brine, dried over Na2SO4 and the solvent removed under reduced pressure. Purification 
by flash column chromatography [8:2 (hexane:EtOAc)] gave the sulfonamide (1.81 g, 72%) 
as a white solid; mp: 38-39 °C; 1H NMR (300 MHz, CDCl3) δ 7.74 (d, J = 8.3 Hz, 2H), 7.31 (d, J 
= 8.3 Hz, 2H), 4.80 (d, J = 1.7 Hz, 1H), 4.65 (d, J = 1.9 Hz, 1H), 4.34 (t, J = 6.1 Hz, 1H), 3.06 (q, J 
= 6.6 Hz, 2H), 2.43 (s, 3H), 2.14 (t, J = 6.7 Hz, 2H), 1.59 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 
143.6 (C), 141.6 (C), 137.0 (C), 129.9 (2 × CH), 127.3 (2 × CH), 113.5 (CH2), 40.6 (CH2), 37.3 
(CH2), 21.8 (CH3), 21.7 (CH3); IR vma×/cm
-1 2854, 1596, 1487, 1349, 1160, 1086, 1008, 813, 
658. 
Data matches that reported in the literature.115 
4-Methyl-N-(1-phenylbut-3-en-1-yl)benzenesulfonamide (411) 
 
Prepared according to GP3 (80% yield over 2 steps, white solid); mp: 68-70 °C; 1H NMR (300 
MHz, CDCl3) δ 7.55 (d, J = 8.3 Hz, 2H), 7.20 – 7.12 (m, 5H), 7.10 – 7.05 (m, 2H), 5.50 (ddt, J = 
18.9, 9.3, 7.1 Hz, 1H), 5.12 – 5.01 (m, 2H), 4.83 (d, J = 6.4 Hz, 1H, NH), 4.38 (app. q, J = 6.6 
Hz, 1H), 2.51 – 2.41 (m, 2H), 2.37 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 143.0 (C), 140.4 (C), 
137.5 (C), 133.1 (CH), 129.2 (2 × CH), 128.2 (2 × CH), 127.3 (CH), 127.1 (2 × CH), 126.6 (2 × 
CH), 119.1 (CH2), 57.3 (CH), 41.8 (CH2), 21.3 (CH3). 
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Data matches that reported in the literature.116 
N-(1-(2-Bromophenyl)but-3-en-1-yl)-4-methylbenzenesulfonamide (412) 
 
Prepared according to GP3 (70% yield over 2 steps, white solid); mp: 112-114 °C; 1H NMR 
(300 MHz, CDCl3) δ 7.60 (d, J = 8.3 Hz, 2H), 7.42 (dd, J = 7.9, 1.3 Hz, 1H), 7.22 – 7.10 (m, 4H), 
7.09 – 6.96 (m, 1H), 5.54 – 5.38 (m, 1H), 5.13 – 5.03 (m, 2H), 4.98 (d, J = 6.3 Hz, 1H, NH), 
4.76 (dt, J = 7.9, 5.7 Hz, 1H), 2.53 – 2.40 (m, 1H), 2.36 (s, 3H), 2.34 – 2.27 (m, 1H); 13C NMR 
(101 MHz, CDCl3) δ 143.5 (C), 139.6 (C), 136.8 (C), 133.0 (CH), 132.8 (CH), 129.5 (2 × CH), 
128.8 (CH), 128.7 (CH), 127.5 (CH), 127.4 (2 × CH), 122.4 (C), 119.9 (CH2), 56.1 (CH), 40.5 
(CH2), 21.6 (CH3). 
Data matches that reported in the literature.117 
4-Methyl-N-(1-(p-tolyl)but-3-en-1-yl)benzenesulfonamide (413) 
 
Prepared according to GP3 (75% yield over 2 steps, colourless oil); 1H NMR (300 MHz, CDCl3) 
δ 7.56 (d, J = 8.3 Hz, 2H), 7.16 (d, J = 8.0 Hz, 2H), 7.02 – 6.93 (m, 4H), 5.50 (ddt, J = 19.7, 9.5, 
7.1 Hz, 1H), 5.07 (d, J = 1.2 Hz, 1H), 5.05 – 5.00 (m, 1H), 4.77 (d, J = 6.3 Hz, 1H, NH), 4.32 
(app. q, J = 6.6 Hz, 1H), 2.48 – 2.41 (m, 2H), 2.38 (s, 3H), 2.28 (s, 3H); IR vma×/cm
-1 3254, 
1643, 1428, 1324, 1156, 1093, 941, 748, 681,666. 






Prepared according to GP3 (87% yield over 2 steps, colourless oil); 1H NMR (300 MHz, CDCl3) 
δ 7.55 (d, J = 8.3 Hz, 2H), 7.20 – 7.13 (m, 2H), 6.98 (d, J = 8.7 Hz, 2H), 6.71 (d, J = 8.7 Hz, 2H), 
5.50 (ddt, J = 19.5, 9.5, 7.1 Hz, 1H), 5.07 (d, J = 1.1 Hz, 1H), 5.06 – 5.01 (m, 1H), 4.78 (d, J = 
6.2 Hz, 1H, NH), 4.31 (app.q, J = 6.6 Hz, 1H), 3.75 (s, 3H), 2.44 (dd, J = 11.8, 6.9 Hz, 2H), 2.38 
(s, 3H); 13C NMR (101 MHz, CDCl3) δ 159.0 (C), 143.2 (C), 137.7 (C), 133.4 (CH), 132.5 (C), 
129.4 (2 × CH), 127.9 (2 × CH), 127.3 (2 × CH), 119.3 (CH2), 113.9 (2 × CH), 56.8 (CH3), 55.4 
(CH), 42.0 (CH2), 21.6 (CH3). 
Data matches that reported in the literature.116 
N-(1-(Furan-2-yl)but-3-en-1-yl)-4-methylbenzenesulfonamide (415) 
 
Prepared according to GP3 (66% yield over 2 steps, yellow oil); 1H NMR (300 MHz, CDCl3) δ 
7.63 (d, J = 8.3 Hz, 2H), 7.24 – 7.18 (m, 2H), 7.17 (dd, J = 1.9, 0.8 Hz, 1H), 6.14 (dd, J = 3.2, 1.8 
Hz, 1H), 5.96 (dd, J = 3.3, 0.8 Hz, 1H), 5.56 (ddt, J = 15.9, 11.3, 7.1 Hz, 1H), 5.11 – 5.00 (m, 
2H), 4.81 (d, J = 8.3 Hz, 1H), 4.50 (dt, J = 8.4, 6.6 Hz, 1H), 2.64 – 2.43 (m, 2H), 2.39 (s, 3H); 13C 
NMR (101 MHz, CDCl3) δ 152.7 (C), 143.3 (C), 142.0 (CH), 137.8 (C), 132.8 (CH), 129.9 (2 × 
CH), 127.2 (2 × CH), 119.5 (CH2), 110.2 (CH), 107.3 (CH), 51.1 (CH), 39.2 (CH2), 21.6 (CH3). 
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Data matches that reported in the literature.118 
 
Preparation of 2-bromo aldehydes 
2-Bromo-5-methoxybenzaldehyde (264) 
 
Bromine (2.9 mL, 56.0 mmol, 2.8 equiv.) was added dropwise to a solution of m-
anisaldehyde (2.4 mL, 20.0 mmol, 1.0 equiv.) and acetic acid (22 mL, 0.9 M) in an ice bath 
and stirred for 15 minutes. After this time, the ice bath was removed and the reaction 
mixture was warmed up to room temperature for 16 hours. Ice water (100 mL) was added, 
the solid filtered off and the filtrate washed with DCM (3 × 30 mL). This was followed by 
dissolution of the solid in the organics and subsequent washing with saturated NaHCO3 (2 × 
50 mL). The combined organic extracts were washed with brine, dried with Na2SO4 and the 
solvent removed under reduced pressure to afford the product as a pale yellow solid (4.30 
g, 100%); 1H NMR (300 MHz, CDCl3) δ 10.31 (s, 1H), 7.52 (d, J = 8.7 Hz, 1H), 7.41 (d, J = 3.2 
Hz, 2H), 7.03 (dd, J = 8.8, 3.2 Hz, 1H), 3.84 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 191.9 (CHO), 
159.4 (C), 134.7 (CH), 134.1 (C), 123.3 (CH), 118.1 (C), 112.8 (CH), 55.9 (CH3); IR vma×/cm
-1 
2941, 2875, 1674, 1569, 1469, 1382, 1277, 1013, 818, 753. 







Lithium diisopropylamide solution was prepared by dropwise addition of n-butyllithium 
(13.8 mL, 1.6 M solution in hexane, 22.0 mmol, 1.1 equiv.) to a solution of diisopropylamine 
(3.6 mL, 26.0 mmol, 1.3 equiv.) in THF (67 mL, 0.3M) at -78 °C which was warmed to 0 °C. 
After 1 hour, the solution was cooled to -78 °C and freshly distilled 2-bromopyridine (1.9 mL, 
20.0 mmol, 1.0 equiv) was added in a dropwise manner. After further stirring at -78 °C, for 4 
hours, DMF (13 mL) was added dropwise and the reaction mixture was warmed up to room 
temperature over 1 hour. Saturated aqueous NH4Cl was added and the organic layer was 
extracted with Et3O for 3 times. The combined organic extracts were washed with brine, 
dried over Na2SO4 and the solvent was removed under reduced pressure Purification by 
flash column chromatography [85:15 (hexane:EtOAc)] gave the aldehyde 236 as a red oil 
(2.42 g, 65%); 1H NMR (300 MHz, CDCl3) δ 10.34 (d, J = 0.8 Hz, 1H), 8.57 (dd, J = 4.7, 2.1 Hz, 
1H), 8.18 (dd, J = 7.7, 2.1 Hz, 1H), 7.44 (ddd, J = 7.6, 4.7, 0.8 Hz, 1H); 13C NMR (101 MHz, 
CDCl3) δ 191.2 (CHO), 154.5 (CH), 145.4 (C), 138.0 (CH), 130.6 (C), 123.5 (CH); IR vma×/cm
-1 
3024, 2872, 1692, 1571, 1369, 1255, 1049, 802, 704 





Lithium diisopropylamide solution was prepared by dropwise addition of n-butyllithium 
(6.30 mL, 1.6 M solution in hexane, 10.0 mmol, 1.0 equiv.) to a solution of diisopropylamine 
(1.4 mL, 10.0 mmol, 1.0 equiv.) in THF (17 mL, 0.6M) at 0 °C, followed by slow addition of 3-
bromothiophene (0.95 mL, 10.0 mmol, 1.0 equiv.) at the same temperature. After stirring 
for 1 hour, DMF (0.8 mL, 10.0 mmol, 1.0 equiv.) was added dropwise and the reaction 
mixture was warmed up to room temperature for 4 hours. Water was added, followed by 
extraction with Et3O for 3 times. The combined organic extracts were washed with brine, 
dried over Na2SO4 and the solvent was removed under reduced pressure which gave the 
aldehyde 283 as a brown liquid (1.72 g, 90%), and used immediately without further 
purification; 1H NMR (300 MHz, CDCl3) δ 9.99 (d, J = 1.4 Hz, 1H), 7.72 (dd, J = 5.1, 1.4 Hz, 1H), 
7.15 (d, J = 5.1 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 183.2 (CHO), 137.1 (C), 134.9 (CH), 
132.2 (CH), 120.5 (C); IR vma×/cm
-1 3104, 2843, 1657, 1496, 1414, 1208, 886, 661, 606.  
Data matches that reported in the literature 121 
Preparation of 2-ethynyl aldehydes/internal alkynes 
General procedure 4 (GP4) 
The required bromide (1.0 equiv.), Pd(PPh3)Cl2 (5 mol%), CuI (3 mol%), and degassed Et3N 
(0.2 M) were combined in a flame dried round bottom flask and stirred at room 
temperature for 10 minutes. Trimethylsilylacetylene (1.2 equiv.) was added gently and the 
resulting mixture was stirred at 50 °C. The reaction was monitored by TLC. After cooling at 
room temperature, the reaction mixture was filtered through a pad of celite and washed 
with EtOAc. Solvent was removed under reduced pressure and the crude residue was 






Prepared according to GP4 using 2-bromobenzaldehdye (3.70 g, 20.0 mmol). Purification by 
flash column chromatography [98:2 (hexane:EtOAc)] gave the silylated alkyne 161 as a 
brown solid (3.92 g, 97%); mp: 49-51 °C; 1H NMR (300 MHz, CDCl3) δ 10.56 (d, J = 0.8 Hz, 
1H), 7.93 – 7.88 (m, 1H), 7.60 – 7.50 (m, 2H), 7.47 – 7.40 (m, 1H), 0.28 (s, 9H); 13C NMR (101 
MHz, CDCl3) δ 192.0 (CHO), 136.3 (C), 133.8 (CH), 133.6 (CH), 129.0 (CH), 127.0 (CH), 126.9 
(C), 102.6 (C), 100.2 (C), -0.08 (3 × CH3). 




Prepared according to GP4 using 1-bromo-2-methylbenzene (1.71 g, 10.0 mmol). 
Purification by flash column chromatography [100% (hexane)] gave the protected alkyne 
197 as a yellow oil (0.68 g, 36%); 1H NMR (300 MHz, CDCl3) δ 7.43 (dt, J = 7.8, 1.0 Hz, 1H), 
7.22 – 7.18 (m, 2H), 7.14 – 7.08 (m, 1H), 2.44 (s, 3H), 0.26 (s, 9H); 13C NMR (101 MHz, CDCl3) 
δ 140.8 (C), 132.2 (CH), 129.5 (CH), 128.6 (CH), 125.6 (CH), 123.0 (C), 104.2 (C), 98.3 (C), 20.8 
(CH3), 0.22 (3 × CH3); IR vma×/cm
-1 2959, 2155, 1482, 1249, 866, 835, 754, 455. 
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Data matches that reported in the literature.123 
Diethyl (4R,5R)-2-(2-((trimethylsilyl)ethynyl)phenyl)-1,3-dioxolane-4,5-dicarboxylate (229) 
 
Prepared according to GP4 using bromide 228 (1.20 g, 3.2 mmol). Purification by flash 
column chromatography [9:1 (hexane:EtOAc)] gave the protected alkyne 229 as a brown oil 
(0.95 g, 76%); 1H NMR (300 MHz, CDCl3) δ 7.80 – 7.76 (m, 1H), 7.50 – 7.45 (m, 1H), 7.41 – 
7.29 (m, 2H), 6.61 (s, 1H), 4.93 (d, J = 4.2 Hz, 1H), 4.85 (d, J = 4.2 Hz, 1H), 4.37 – 4.25 (m, 4H), 
1.36 (t, J = 5.3 Hz, 3H), 1.31 (t, J = 5.3 Hz, 3H), 0.25 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 169.6 
(CO), 169.3 (CO), 137.1 (C), 132.6 (CH), 129.7 (CH), 128,9 (CH), 127.1 (CH), 123.1 (C), 104.6 
(CH), 101.7 (C), 99.9 (C), 77.9 (2 × CH), 62.2 (CH2), 62.1 (CH2), 14.3 (CH3), 14.3 (CH3), 0.0 (3 × 
CH3); IR vma×/cm
-1 2964, 2160, 1747, 1376, 1227, 839, 755, 685; HRMS(EI-TOF): m/z: calcd 




Prepared according to GP4 using 2-bromo-5-chlorobenzaldehdye (2.19 g, 10.0 mmol). 
Purification by flash column chromatography [98:2 (hexane:EtOAc)] gave the protected 
alkyne 243 as a yellow liquid (1.46 g, 62%); 1H NMR (300 MHz, CDCl3) δ 10.47 (s, 1H), 7.86 
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(dd, J = 1.6, 1.1 Hz, 1H), 7.56 – 7.46 (m, 2H), 0.28 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 190.6 
(CHO), 137.4 (C), 135.5 (C), 134.9 (CH), 133.8 (CH), 127.1 (CH), 125.1 (C), 103.8 (C), 99.1 (C), -
0.15 (3 × CH3); IR vma×/cm




Prepared according to GP4 using 2-bromo-5-fluorobenzaldehdye (2.03 g, 10.0 mmol). 
Purification by flash column chromatography [9:1 (hexane:EtOAc)] gave the protected 
alkyne 250 as a brown oil (1.34 g, 61%); 1H NMR (300 MHz, CDCl3) δ 10.20 (d, J = 3.2 Hz, 1H), 
7.31 – 7.27 (m, 2H), 7.00 – 6.92 (m, 1H), 0.01 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 190.7 
(CHO), 162.6 (d, J C-F = 252.8 Hz, C), 138.4 (d, J C-F = 6.7 Hz, C), 135.7 (d, J C-F = 7.7 Hz, CH), 
123.0 (d, J C-F = 3.6 Hz, C), 121.3 (d, J C-F = 22.8 Hz, CH), 113.6 (d, J C-F = 23.1 Hz,CH), 102.3 (C), 
99.1 (C), -0.11 (3 × CH3); IR vma×/cm
-1 2962, 2158, 1693, 1601, 1483, 1420, 1251, 1146, 839, 
734, 645. 





Prepared according to GP4 using 2-bromo-6-fluorobenzaldehdye (2.03 g, 10.0 mmol). 
Purification by flash column chromatography [98:2 (hexane:EtOAc)] gave the protected 
alkyne 257 as a brown oil (2.13 g, 97%); 1H NMR (300 MHz, CDCl3) δ 10.53 (d, J = 0.6 Hz, 1H), 
7.49 (ddd, J = 8.3, 7.8, 5.3 Hz, 1H), 7.40 – 7.35 (m, 1H), 7.16 – 7.07 (m, 1H), 0.27 (s, 9H); 13C 
NMR (101 MHz, CDCl3) δ 188.9 (CHO), 162.1 (d, J C-F = 263.7 Hz, C), 134.9 (d, J C-F = 10.5 Hz, 
CH), 130.0 (d, J C-F = 3.8 Hz, CH), 127.7 (d, J C-F = 3.8 Hz, C), 124.7 (d, J C-F = 8.3 Hz, C), 117.4 (d, 
J C-F = 21.5 Hz, CH), 103.7 (C), 99.8 (d, J C-F = 4.0 Hz, C), -0.18 (3 × CH3); IR vma×/cm
-1 2960, 
1703, 1599, 1567,1463, 1250, 1187, 1005, 840, 759, 657. 
Data matches that reported in the literature.125 
5-Methoxy-2-((trimethylsilyl)ethynyl)benzaldehyde (265) 
 
Prepared according to GP4 using 2-bromo-5-methoxybenzaldehdye (2.58 g, 12.0 mmol). 
Purification by flash column chromatography [95:5 (hexane:EtOAc)] gave the protected 
alkyne 265 as a white solid (2.45 g, 88%); 1H NMR (300 MHz, CDCl3) δ 10.51 (s, 1H), 7.49 (d, J 
= 8.6 Hz, 1H), 7.38 (d, J = 2.8 Hz, 1H), 7.08 (dd, J = 8.6, 2.8 Hz, 1H), 3.86 (s, 3H), 0.26 (s, 9H); 
13C NMR (101 MHz, CDCl3) δ 191.9 (CHO), 160.0 (C), 137.8 (C), 135.0 (CH), 121.7 (CH), 119.6 
(C), 109.7 (CH), 100.7 (C), 100.3 (C), 55.8 (CH3), 0.0 (3 × CH3); IR vma×/cm
-1 2968, 2845, 2150, 
1693, 1598, 1386, 1313, 846, 719, 646. 






Prepared according to GP4 using 2-bromonicotinaldehyde (1.15 g, 6.20 mmol). Purification 
by flash column chromatography [9:1 (hexane:EtOAc)] gave the protected alkyne 277 as a 
brown solid; mp: 49-51 °C; 1H NMR (300 MHz, CDCl3) δ 10.55 (d, J = 0.9 Hz, 1H), 8.77 (dd, J = 
4.8, 1.8 Hz, 1H), 8.17 (dd, J = 8.0, 1.9 Hz, 1H), 7.39 (ddd, J = 8.0, 4.8, 0.9 Hz, 1H), 0.30 (s, 9H); 
13C NMR (101 MHz, CDCl3) δ 191.1 (CHO), 154.5 (CH), 145.9 (C), 134.7 (CH), 132.2 (C), 123.6 
(CH), 103.1 (C), 99.4 (C), -0.32 (3 × CH3). 
Data matches that reported in the literature.126 
3-((Trimethylsilyl)ethynyl)thiophene-2-carbaldehyde (284) 
 
Prepared according to GP4 using 3-bromothiophene-2-carbaldehyde (1.68 g, 8.8 mmol). 
Purification by flash column chromatography [95:5 (hexane:EtOAc)] gave the protected 
alkyne 284 as an orange oil (1.50 g, 82%); 1H NMR (300 MHz, CDCl3) δ 10.12 (d, J = 1.3 Hz, 
1H), 7.64 (dd, J = 5.0, 1.3 Hz, 1H), 7.17 (d, J = 5.0 Hz, 1H), 0.27 (s, 9H); 13C NMR (101 MHz, 
CDCl3) δ 183.2 (CHO), 144.7 (C), 133.8 (CH), 131.9 (CH), 131.0 (C), 102.6 (C), 96.5 (C), -0.15 (3 
× CH3); IR vma×/cm
-1 3663, 2966, 2154, 1666, 1414, 1249, 997, 835, 707, 654. 
Data matched that reported in the literature.127 
125 
 
Preparation of terminal alkynes 
General procedure 5 (GP5) 
The required trimethylsilyl derivative (1.0 equiv.) was dissolved in methanol (0.2 M). 
Potassium carbonate (0.5 equiv.) was added and the resulting mixture was stirred at room 
temperature for 1 hour. The reaction was quenched with saturated NaHCO3 solution and 
the aqueous layer was extracted with EtOAc (× 2). The combined organic layers were 
washed with brine, dried over Na2SO4 and solvent removed under reduced pressure to give 




Prepared according to GP5 using protected alkyne 161 (2.63 g, 13.0 mmol). Purification by 
flash column chromatography [96:4 (hexane:EtOAc)] gave the terminal alkyne 162 as a 
white solid (1.49 g, 88%); mp: 65-67 °C; 1H NMR (300 MHz, CDCl3) δ 10.54 (d, J = 0.8 Hz, 1H), 
7.93 (dd, J = 7.7, 0.8 Hz, 1H), 7.62 (dd, J = 7.7, 1.5 Hz, 1H), 7.57 (td, J = 7.4, 1.5 Hz, 1H), 7.52 – 
7.44 (m, 1H), 3.46 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 191.5 (CHO), 136.7 (C), 134.1 (CH), 
133.8 (CH), 129.4 (CH), 127.4 (CH), 125.6 (C), 84.4 (CH), 79.4 (C). 







Prepared according to GP5 using protected alkyne 187 (1.52 g, 5.84 mmol). Purification by 
flash column chromatography [9:1 (hexane:EtOAc), 1% Et3N] gave the terminal alkyne 188 
as a yellow oil (0.68 g, 62%); 1H NMR (400 MHz, CDCl3) δ 7.68 (dd, J = 7.8, 1.5 Hz, 1H), 7.49 
(dd, J = 7.8, 1.5, Hz, 1H), 7.39 (td, J = 7.7, 1.4 Hz, 1H), 7.30 (td, J = 7.7, 1.4 Hz, 1H), 5.92 (s, 
1H), 4.27 (ddd, J = 11.9, 5.1, 1.4 Hz, 2H), 4.09 – 3.98 (m, 2H), 3.29 (s, 1H), 2.35 – 2.18 (m, 
1H), 1.51 – 1.38 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 140.6 (C), 132.9 (CH), 129.3 (CH), 
128.8 (CH), 126.1 (CH), 120.6 (C), 100.0 (CH), 81.5 (CH), 81.1 (C), 67.8 (2 × CH2), 25.9 (CH2). 
Data matches that reported in the literature.128 
1-Ethynyl-2-methylbenzene (198) 
 
Prepared according to GP5 using protected alkyne 197 (0.62 g, 3.29 mmol) to give the 
terminal alkyne 198 as a pale yellow oil (240 mg, 63%); 1H NMR (300 MHz, CDCl3) δ 7.47 (dd, 
J = 7.5, 1.4 Hz, 1H), 7.25 – 7.11 (m, 3H), 3.28 (s, 1H), 2.47 (s, 3H); 13C NMR (101 MHz, CDCl3) 
δ 140.9 (C), 132.7 (CH), 129.6 (CH), 128.9 (CH), 125.7 (CH), 122.1 (C), 82.7 (C), 81.1 (CH), 20.7 
(CH3); IR vma×/cm
-1 3291, 1484, 1455, 1248, 841, 755, 610, 452. 






Prepared according to GP5 using protected alkyne 203 (1.60 g, 5.29 mmol). Purification by 
flash column chromatography [9:1 (hexane:EtOAc), 1% Et3N] gave the terminal alkyne 204 
as a yellowish white solid (0.84 g, 69%); mp: 78-80 °C; 1H NMR (300 MHz, CDCl3) δ 7.69 (dd, J 
= 7.8, 1.4 Hz, 1H), 7.50 (dd, J = 7.6, 1.2 Hz, 1H), 7.38 (td, J = 7.6, 1.4 Hz, 1H), 7.30 (dd, J = 7.5, 
1.4 Hz, 1H), 6.38 (s, 1H), 3.31 (s, 1H), 1.35 (s, 6H), 1.31 (s, 6H); 13C NMR (101 MHz, CDCl3) δ 
141.3 (C), 133.2 (CH), 129.1 (CH), 128.6 (CH), 126.0 (CH), 121.6 (C), 97.9 (CH), 82.9 (CH), 82.1 
(2 × C), 81.1 (C), 24.6 (2 × CH3), 22.4 (2 × CH3); IR vma×/cm
-1 3242, 2986, 1394, 1214, 1144, 
1112, 1063, 979, 758, 714. 
Dimethyl (4R,5R)-2-(2-ethynylphenyl)-1,3-dioxolane-4,5-dicarboxylate (230) 
 
Prepared according to GP5 using protected alkyne 229 (1.10 g, 3.03 mmol). Purification by 
flash column chromatography [85:15 (hexane:EtOAc)] gave the terminal alkyne 230 as a 
pink solid (0.60 g, 68%); mp: 62-64 °C; 1H NMR (300 MHz CDCl3) δ 7.78 (dd, J = 7.7, 1.5 Hz, 
1H), 7.52 (dd, J = 7.4, 1.4 Hz, 1H), 7.42 (td, J = 7.6, 1.6 Hz, 1H), 7.36 (td, J = 7.4, 1.6 Hz, 1H), 
6.59 (s, 1H), 5.01 (d, J = 4.0 Hz, 1H), 4.89 (d, J = 4.0 Hz, 1H), 3.88 (s, 3H), 3.82 (s, 3H) 3.33 (s, 
1H); 13C NMR (101 MHz, CDCl3) δ 169.9 (CO), 169.4 (CO), 137.0 (C), 132.9 (CH), 129.6 (CH), 
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129.1 (CH), 126.8 (CH), 121.8 (C), 104.4 (CH), 82.2 (CH), 80.3 (C), 77.5 (CH), 76.6 (CH), 52.8 (2 
× CH3); HRMS (ES-TOF): m/z: calcd for C15H14O6Na: 313.0688, found: 313.0687 [M + Na]
+. 
Diethyl (4R,5R)-2-(2-ethynylphenyl)-1,3-dioxolane-4,5-dicarboxylate (231) 
 
Prepared according to GP5 using protected alkyne 229 (1.10 g, 2.82 mmol) and ethanol to 
give crude 231 as a colourless oil which was used immediately in the next step 
5-Chloro-2-ethynylbenzaldehyde (244) 
 
Prepared according to GP5 using protected alkyne 243 (1.38 g, 5.83 mmol). Purification by 
flash column chromatography [96:4 (hexane:EtOAc)] gave the terminal alkyne 244 as a 
yellow oil (0.82 g, 85%); 1H NMR (300 MHz, CDCl3) δ 10.47 (s, 1H), 7.89 (dd, J = 2.0, 0.8 Hz, 
1H), 7.59 – 7.50 (m, 2H), 3.50 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 190.2 (CHO), 137.8 (C), 
136.0 (C), 135.2 (CH), 133.9 (CH), 127.4 (CH), 123.8 (C), 85.3 (CH), 78.4 (C); IR vma×/cm
-1 
3671, 3247, 2971, 2104, 1692, 1587, 1472, 1396, 1258, 1065, 832, 723, 676; HRMS (EI-TOF): 









Prepared according to GP5 using protected alkyne 251 (0.55 g, 2.32 mmol) to give the 
terminal alkyne 252 as an orange oil (340 mg, 89%); 1H NMR (400 MHz, CDCl3) δ 7.51 (dd, J = 
8.5, 5.5 Hz, 1H), 7.29 (dd, J = 9.3, 2.8 Hz, 1H), 7.02 (td, J = 8.3, 2.8 Hz, 1H), 6.18 (d, J = 1.5 Hz, 
1H), 4.21 – 4.12 (m, 2H), 4.10 – 4.02 (m, 2H), 3.29 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 162.9 
(d, J C-F = 250.5 Hz, C), 142.8 (d, J C-F = 7.5 Hz, C), 135.3 (d, J C-F = 8.3 Hz, CH), 117.4 (d, J C-F = 
3.5 Hz, C), 116.4 (d, J C-F = 22.2 Hz, CH), 113.6 (d, J C-F = 23.7 Hz, CH), 101.2 (CH), 81.8 (CH), 
80.0 (C), 65.8 (2 × CH2); IR vma×/cm
-1 3297, 2891, 1608, 1488, 1270, 1160, 1112, 1063, 881, 
825. 
Data matches that reported in the literature 129 
2-(2-Ethynyl-6-fluorophenyl)-1,3-dioxolane (259) 
 
Prepared according to GP5 using protected alkyne 258 (2.00 g, 7.57 mmol). to give the 
terminal alkyne 259 as reddish brown  oil (1.29 g, 89%); 1H NMR (400 MHz, CDCl3) δ 7.35 – 
7.27 (m, 2H), 7.07 (ddd, J = 10.6, 7.9, 1.7 Hz, 1H), 6.37 (d, J = 0.9 Hz, 1H), 4.30 – 4.19 (m, 2H), 
4.11 – 4.00 (m, 2H), 3.34 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 161.6 (d, J C-F = 251.9 Hz, C), 
130.6 (d, J C-F = 9.8 Hz, CH), 129.8 (d, J C-F = 3.7 Hz, CH), 127.1 (d, J C-F = 11.8 Hz, C), 123.8 (d, J 
C-F = 5.3 Hz, C), 117.3 (d, J C-F = 22.4 Hz, CH), 100.2 (d, J C-F = 3.6 Hz, CH), 82.6 (CH), 80.4 (d, J C-
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F = 4.3 Hz, C), 66.3 (2 × CH2); IR vma×/cm
-1 3290, 2896, 1609, 1574, 1467, 1402, 1212, 1092, 
956, 795, 634. 
Data matches that reported in the literature.71 
2-Ethynyl-5-methoxybenzaldehyde (266) 
 
Prepared according to GP5 using protected alkyne 265 (2.15 g, 9.25 mmol). Purification by 
flash column chromatography [96:4 (hexane:EtOAc)] gave the terminal alkyne 266 as a 
yellow solid (1.34 g, 91%); 1H NMR (300 MHz, CDCl3) δ 10.49 (s, 1H), 7.53 (d, J = 8.6 Hz, 1H), 
7.40 (d, J = 2.8 Hz, 1H), 7.10 (dd, J = 8.6, 2.8 Hz, 1H), 3.86 (s, 3H), 3.37 (s, 1H); 13C NMR (101 
MHz, CDCl3) δ 191.4 (CHO), 160.3 (C), 138.2 (C), 135.3 (CH), 121.6 (CH), 118.2 (C), 110.1 
(CH), 82.9 (C), 79.3 (C), 55.8 (CH3); IR vma×/cm
-1 3253, 2958, 1163, 1600, 1490, 1318, 1088, 
785, 660. 
Data matches that reported in the literature.68 
3-(1,3-Dioxolan-2-yl)-2-ethynylpyridine (279) 
 
Prepared according to GP5 using protected alkyne 278 (1.43 g, 5.78 mmol) to give the 
terminal alkyne 279 as a brown oil (0.88 g, 87%); 1H NMR (300 MHz, CDCl3) δ 8.58 (dd, J = 
4.8, 1.7 Hz, 1H), 7.89 (dd, J = 7.9, 1.7 Hz, 1H), 7.31 (dd, J = 7.9, 4.8 Hz, 1H), 6.19 (s, 1H), 4.20 
– 4.13 (m, 2H), 4.10 – 4.03 (m, 2H), 3.39 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 150.6 (CH), 
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141.4 (C), 136.0 (C), 134.3 (CH), 123.6 (CH), 100.9 (CH), 81.6 (CH), 80.3 (C), 65.8 (2 × CH2); IR 
vma×/cm
-1 3257, 2889, 2109, 1567, 1436, 1380, 1116, 1068, 940, 786, 631; HRMS (EI-TOF): 




Prepared according to GP5 using protected alkyne 285 (1.11 g, 4.40 mmol) to give the 
terminal alkyne 286 as an orange oil (0.68 g, 86%); 1H NMR (300 MHz, CDCl3) δ 7.30 (d, J = 
5.1 Hz, 1H), 7.11 (d, J = 5.1 Hz, 1H), 6.34 (s, 1H), 4.27 – 4.15 (m, 2H), 4.14 – 4.03 (m, 2H), 
3.30 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 145.7 (C), 130.5 (CH), 125.6 (CH), 120.6 (C), 99.2 
(CH), 81.0 (CH), 77.1 (C), 65.6 (2 × CH2); IR vma×/cm
-1 3282, 2971, 2889, 1668, 1535, 1443, 
1364, 1187, 1069, 934, 612, 546. 
Data matches that reported in the literature.71 
Preparation of acetals 
General procedure 6 (GP6) 
The required aldehyde (1.0 equiv.) was dissolved in toluene (0.1 M) followed by addition of 
the requisite diol (1.2 equiv.) and p-TsOH.H2O (5 mol%). The resulting mixture was heated at 
reflux using Dean Stark apparatus. The reaction was monitored by TLC. After cooling, the 
reaction mixture was quenched with saturated NaHCO3 solution, extracted with EtOAc (× 2), 
washed with brine, dried over Na2SO4 and solvent removed under reduced pressure. The 





Prepared according to GP6 using aldehyde 162 (1.30 g, 10.0 mmol) and ethylene glycol. 
Purification by flash column chromatography [9:1 (hexane:EtOAc), 1% Et3N] gave the acetal 
163 as an orange oil (1.46 g, 84%); 1H NMR (300 MHz, CDCl3) δ 7.59 (dd, J = 7.6, 1.5 Hz, 1H), 
7.55 – 7.51 (m, 1H), 7.39 (app. td, J = 7.6, 1.6 Hz, 1H), 7.33 (app. td, J = 7.4, 1.6 Hz, 1H), 6.22 
(s, 1H), 4.23 – 4.12 (m, 2H), 4.10 – 4.02 (m, 2H), 3.32 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 
139.8 (C), 133.4 (CH), 129.1 (2 × CH), 126.2 (CH), 121.5 (C), 101.9 (CH), 82.0 (CH), 81.0 (C), 
65.7 (2 × CH2). 
Data matches that reported in the literature.66 
 ((2-(1,3-Dioxan-2-yl)phenyl)ethynyl)trimethylsilane (187) 
 
Prepared according to GP6 using aldehyde 161 (1.21 g, 5.98 mmol) and propane-1,3-diol to 
give the crude acetal 187 as a brown solid which was used immediately in the next step 





2-Ethynylbenzaldehyde 162 (1.00 g, 7.68 mmol) was dissolved in CH2Cl2 (77 mL, 0.1 M) and 
1,2-ethanedithiol (1.4 mL, 16.9 mmol, 1.12 equiv.), p-TsOH.H20 (3 mol%) and silica gel (4.0 g) 
were added. The reaction mixture was heated at reflux and monitored by TLC. After cooling, 
the mixture was filtered through a plug of cotton wool and solvent removed under reduced 
pressure. Purification by flash column chromatography [97:3 (hexane:EtOAc), 1% Et3N] gave 
the dithiol 194 as an orange oil (0.51 g, 32%); 1H NMR (300 MHz, CDCl3) δ 7.81 (dd, J = 7.8, 
0.9 Hz, 1H), 7.46 (dd, J = 7.7, 1.3 Hz, 1H), 7.36 (td, J = 7.7, 1.4 Hz, 1H), 7.21 (td, J = 7.6, 1.3 Hz, 
1H), 6.22 (s, 1H), 3.53 – 3.43 (m, 2H), 3.41 (s, 1H), 3.40 – 3.32 (m, 2H); IR vma×/cm
-1 3662, 
3283, 2970, 2921, 1471, 1443, 1274, 1041, 753, 618, 546 
Data matches that reported in the literature.71 
Trimethyl((2-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)phenyl)ethynyl)silane (203) 
 
Prepared according to GP6 using aldehyde 161 (1.21 g, 5.98 mmol) and pinacol to give the 
acetal 203 as a brown oil (1.61 g, 89%); 1H NMR (300 MHz, CDCl3) δ 7.65 (dd, J = 7.7, 1.4 Hz, 
1H), 7.47 – 7.42 (m, 1H), 7.37 – 7.30 (m, 1H), 7.29 – 7.22 (m, 1H), 6.39 (s, 1H), 1.35 (s, 6H), 
1.31 (s, 6H), 0.25 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 141.1 (C), 132.5 (CH), 128.8 9 (CH), 
128.5 (CH), 125.8 (CH), 122.6 (C), 102.4 (C), 99.5 (C), 98.0 (CH), 82.8 (2 × C), 24.7 (2 × CH3), 






Prepared according to GP6 using aldehyde 162 (0.71 g, 5.45 mmol) and (S,S)-(-)-




Prepared according to GP6 using aldehyde 162 (0.60 g, 4.61 mmol) and (2R, 3R)-butane-2,3-
diol. Purification by flash column chromatography [9:1 (hexane:EtOAc), 1% Et3N] gave the 
acetal 216 as a colourless oil (0.59 g, 63%); 1H NMR (300 MHz, CDCl3) δ 7.61 (dd, J = 7.7, 1.3 
Hz, 1H), 7.51 (dd, J = 7.7, 1.3 Hz, 1H), 7.39 (td, J = 7.6, 1.5 Hz, 1H), 7.31 (td, J = 7.6, 1.5 Hz, 
1H), 6.35 (s, 1H), 3.90 – 3.78 (m, 2H), 3.31 (s, 1H), 1.40 (d, J = 5.9 Hz, 3H), 1.34 (d, J = 5.9 Hz, 
3H); 13C NMR (101 MHz, CDCl3) δ 140.5 (C), 133.3 (CH), 129.2 (CH), 129.0 (CH), 126.5 (CH), 
121.4 (C), 100.8 (CH), 82.0 (CH), 81.1 (C), 80.7 (CH), 78.9 (CH), 17.3 (CH3), 16.9 (CH3); IR 
vma×/cm
-1 3282, 2974, 1449, 1379, 1080, 978, 759, 648. 




Diethyl (4R,5R)-2-(2-bromophenyl)-1,3-dioxolane-4,5-dicarboxylate (228) 
 
Prepared according to GP6 using 2-bromobenzaldehyde (3.70 g, 20.0 mmol) and (+)-diethyl-
L-tartrate. Purification by flash column chromatography [8:2 (hexane:EtOAc)] gave the 
acetal 228 as a colourless oil (2.83 g, 38%); 1H NMR (400 MHz, CDCl3) δ 7.84 (dd, J = 7.8, 1.7 
Hz, 1H), 7.56 (dd, J = 7.9, 1.2 Hz, 1H), 7.37 (td, J = 7.6, 1.2 Hz, 1H), 7.30 – 7.22 (m, 1H), 6.48 
(s, 1H), 4.98 (d, J = 3.8 Hz, 1H), 4.87 (d, J = 3.8 Hz, 1H), 4.41 – 4.30 (m, 2H), 4.30 – 4.24 (m, 
2H), 1.37 (t, J = 7.1 Hz, 3H), 1.30 (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 169.6 (CO), 
169.2 (CO), 134.6 (C), 132.9 (CH), 131.4 (CH), 129.0 (CH), 127.7 (CH), 123.4 (C), 105.4 (CH), 
78.0 (CH), 77.4 (CH), 62.3 (CH2), 62.2 (CH2), 14.3 (CH3), 14.2 (CH3). 
Data matches that reported in the literature.130 
2-(5-Chloro-2-ethynylphenyl)-1,3-dioxolane (245) 
 
Prepared according to GP6 using aldehyde 244 (1.65 g, 10.0 mmol) and ethylene glycol. 
Purification by flash column chromatography [95:5 (hexane:EtOAc), 1% Et3N] gave the acetal 
245 as a red solid (1.42 g, 68%); 1H NMR (300 MHz, CDCl3) δ 7.57 (d, J = 2.2 Hz, 1H), 7.45 (d, J 
= 8.3 Hz, 1H), 7.30 (dd, J = 8.3, 2.2 Hz, 1H), 6.17 (s, 1H), 4.22 – 4.12 (m, 2H), 4.12 – 4.02 (m, 
2H), 3.36 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 141.7 (C), 135.3 (C), 134.5 (CH), 129.4 (CH), 
126.6 (CH), 119.9 (C), 101.2 (CH), 82.9 (CH), 80.0 (C), 65.8 (2 × CH2); IR vma×/cm
-1 3675, 3242, 
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2971, 2900, 1595, 1476, 1390, 1259, 1214, 1095, 1065, 964, 878, 556; HRMS (EI-TOF): m/z: 
calcd for C11H9O2Cl: 208.0291, found: 208.0284 [M]
+. 
 ((2-(1,3-Dioxolan-2-yl)-4-fluorophenyl)ethynyl)trimethylsilane (251) 
 
Prepared according to GP6 using aldehyde 250 (1.29 g, 5.86 mmol) and ethylene glycol 
Purification by flash column chromatography [95:5 (hexane:EtOAc), 1% Et3N] gave the acetal 
250 as a colourless oil (1.11 g, 72%); 1H NMR (300 MHz, CDCl3) δ 7.46 (dd, J = 8.5, 5.5 Hz, 
1H), 7.28 – 7.23 (m, 1H), 6.99 (td, J = 8.3, 2.8 Hz, 1H), 6.14 (d, J = 1.5 Hz, 1H), 4.22 – 4.14 (m, 
2H), 4.09 – 4.01 (m, 2H), 0.25 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 162.7 (d, J C-F = 250.4 Hz, 
C), 142.4 (d, J C-F = 7.3 Hz, C), 134.9 (d, J C-F = 8.1 Hz, CH), 118.6 (d, J C-F = 3.7 Hz, C), 116.3 (d, J 
C-F = 22.2 Hz, CH), 113.6 (d, J C-F = 23.3 Hz, CH), 101.4 (CH), 101.2 (C), 99.2 (C), 65.7 (2 × CH2), 
0.04 (3 × CH3); IR vma×/cm
-1 2960, 2892, 2158, 1607, 1491, 1251, 1160, 1064, 839,758. 
Data matches that reported in the literature.71 
 ((2-(1,3-Dioxolan-2-yl)-3-fluorophenyl)ethynyl)trimethylsilane (258) 
 
Prepared according to GP6 using aldehyde 257 (1.52 g, 6.90 mmol) and ethylene glycol. 
Purification by flash column chromatography [95:5 (hexane:EtOAc), 1% Et3N] gave the acetal 
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258 as a brown oil (1.52 g, 84%); 1H NMR (300 MHz, CDCl3) δ 7.32 – 7.28 (m, 1H), 7.25 – 7.21 
(m, 1H), 7.02 (ddd, J = 10.6, 7.6, 1.9 Hz, 1H), 6.35 (d, J = 0.9 Hz, 1H), 4.30 – 4.21 (m, 2H), 4.11 
– 4.01 (m, 2H), 0.25 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 161.6 (d, J C-F = 251.9 Hz, C), 130.5 
(d, J C-F = 10.0 Hz, CH), 129.8 (d, J C-F = 3.3 Hz, CH), 126.6 (d, J C-F = 11.5 Hz, C), 124.8 (d, J C-F = 
5.3 Hz, C), 116.8 (d, J C-F = 22.5 Hz, CH), 101.5 (d, J C-F = 4.0 Hz, C), 100.2 (d, J C-F = 3.8 Hz, CH), 
100.1 (C), 66.3 (2 × CH2), 0.04 (3 × CH3); IR vma×/cm
-1 2959, 2897, 2153, 1573, 1467, 1401, 
1249, 1095, 1004, 838, 648. 
Data matches that reported in the literature.71 
2-(2-Ethynyl-5-methoxyphenyl)-1,3-dioxolane (267) 
 
Prepared according to GP6 using aldehyde 266 (1.10 g, 6.87 mmol) and ethylene glycol. 
Purification by flash column chromatography [85:15 (hexane:EtOAc), 1% Et3N] gave the 
acetal 267 as an orange solid (0.93 g, 65%); mp: 45-47 °C; 1H NMR (300 MHz, CDCl3) δ 7.45 
(d, J = 8.5 Hz, 1H), 7.12 (d, J = 2.7 Hz, 1H), 6.85 (dd, J = 8.5, 2.7 Hz, 1H), 6.18 (s, 1H), 4.21 – 
4.14 (m, 2H), 4.10 – 4.03 (m, 2H), 3.83 (s, 3H), 3.24 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 
160.2 (C), 141.5 (C), 134.8 (CH), 115.2 (CH), 113.6 (C), 111.3 (CH), 101.7 (CH), 81.0 (C), 80.5 
(C), 65.7 (2 × CH2), 55.5 (CH3); IR vma×/cm
-1 3251, 2976, 2899, 1610, 1487, 1397, 1297, 1063, 







 Prepared according to GP6 using aldehyde 277 (1.00 g, 4.92 mmol) and ethylene glycol 
Purification by flash column chromatography [8:2 (hexane:EtOAc), 1% Et3N] gave the acetal 
278 as a colourless oil (360 mg, 30%); 1H NMR (300 MHz, CDCl3) δ 8.46 (dd, J = 4.8, 1.8 Hz, 
1H), 7.76 (dd, J = 7.9, 1.8 Hz, 1H), 7.21 – 7.13 (m, 1H), 6.06 (s, 1H), 4.12 – 4.04 (m, 2H), 4.00 
– 3.92 (m, 2H), 0.17 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 150.6 (CH), 142.2 (C), 135.6 (C), 
134.3 (CH), 123.2 (CH), 101.1 (CH), 101.0 (C), 99.9 (C), 65.8 (2 × CH2), -0.17 (3 × CH3); IR 
vma×/cm
-1 3675, 2971, 1116, 1057, 661, 573; HRMS (ES-TOF): m/z: calcd for C13H18NO2Si: 
248.1107, found: 248.1106 [M + H]+. 
 ((2-(1,3-Dioxolan-2-yl)thiophen-3-yl)ethynyl)trimethylsilane (285) 
 
Prepared according to GP6 using aldehyde 284 (1.21 g, 5.81 mmol) and ethylene glycol. 
Purification by flash column chromatography [95:5 (hexane:EtOAc), 1% Et3N] gave the acetal 
285 as a yellow oil (1.15 g, 78%); 1H NMR (300 MHz, CDCl3) δ 7.22 (dd, J = 5.1, 0.6 Hz, 1H), 
7.02 (d, J = 5.1 Hz, 1H), 6.26 (s, 1H), 4.20 – 4.14 (m, 2H), 4.06 – 4.00 (m, 2H), 0.24 (s, 9H); 13C 
NMR (101 MHz, CDCl3) δ 145.0 (C), 130.3 (CH), 125.5 (CH), 122.1 (C), 99.3 (CH), 98.3 (C), 98.0 
139 
 
(C), 65.6 (2 × CH2), 0.09 (3 × CH3).; IR vma×/cm
-1 2959, 2892, 2153, 1531, 1248, 1189, 1073, 
834, 758, 646. 
Data matches that reported in the literature.71 
Preparation of bromoalkynes 
General procedure 7 (GP7) 
The required terminal alkyne (1.0 equiv.) was combined with NBS (1.1 equiv.), AgNO3 (0.1 
equiv.) in acetone (0.2 M) and the resulting solution was stirred at room temperature for 1 
hour. 2-3 Spatula of silica gel was added to the flask and the solvent removed under 
reduced pressure. The resulting solid was loaded onto a pad of silica gel and elution was 
done using (hexane:EtOAc, 9:1). Solvent was concentrated to give the pure bromoalkyne 
which is used directly in the next step. Further purification by flash column chromatography 
was done for impure substrates  
2-(2-(Bromoethynyl)phenyl)-1,3-dioxolane (164) 
 
Prepared according to GP7 using terminal alkyne 163 (0.68 g, 3.90 mmol) and N-
bromosuccinimde. Purification by flash column chromatography [9:1 (hexane:EtOAc), 1% 
Et3N] gave the alkynyl bromide 164 as a yellow oil (0.92 g, 93%); 
1H NMR (300 MHz, CDCl3) δ 
7.56 (dd, J = 7.6, 1.6 Hz, 1H), 7.51 – 7.47 (m, 1H), 7.38 (app. td, J = 7.6, 1.6 Hz, 1H), 7.32 (app. 
td, J = 7.5, 1.6 Hz, 1H), 6.14 (s, 1H), 4.24 – 4.13 (m, 2H), 4.11 – 4.02 (m, 2H); 13C NMR (101 
MHz, CDCl3) δ 139.9 (C), 133.3 (CH), 130.2 (C), 129.2 (CH), 129.0 (CH), 126.5 (CH), 121.0 (C), 
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103.5 (C), 102.1 (CH), 65.8 (2 × CH2); IR vma×/cm
-1 2971, 2885, 2195, 1698, 1449, 1392, 1114, 




Prepared according to GP7 using terminal alkyne 188 (0.67 g, 3.56 mmol) and N-
bromosuccinimde to give the alkynyl bromide 189 as a yellow oil which was used 
immediately without further purification. 
1-(Bromoethynyl)-2-methylbenzene (199) 
 
Prepared according to GP7 using terminal alkyne 198 (0.21 g, 1.81 mmol) and N-
bromosuccinimde. Purification by flash column chromatography [9:1 (hexane:EtOAc)] gave 
the alkynyl bromide 199 as a brown oil (320 mg, 91%); 1H NMR (300 MHz, CDCl3) δ 7.41 (dd, 
J = 7.6, 1.4 Hz, 1H), 7.25 – 7.09 (m, 3H), 2.43 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 141.0 (C), 
132.5 (CH), 129.6 (CH), 128.8 (CH), 125.7 (CH), 122.7 (C), 79.2 (C), 52.9 (C), 20.7 (CH3); IR 
vma×/cm
-1 3675, 2971,2901, 1669, 1411, 1250, 1066, 842, 759, 709; HRMS(EI-TOF): m/z: 







Prepared according to GP7 using terminal alkyne 204 (311 mg, 1.35 mmol) and N-
bromosuccinimde to give the alkynyl bromide 205 as a colourless oil which was used 
immediately without further purification. 
 (4S,5S)-2-(2-(Bromoethynyl)phenyl)-4,5-diphenyl-1,3-dioxolane (211) 
 
Prepared according to GP7 using terminal alkyne 210 (0.72 g, 2.21 mmol) and N-
bromosuccinimde to give the alkynyl bromide 211 as a yellow oil which was used 
immediately without further purification. 
 (4R,5R)-2-(2-(Bromoethynyl)phenyl)-4,5-dimethyl-1,3-dioxolane (217) 
 
Prepared according to GP7 using terminal alkyne 216 (0.70 g, 3.46 mmol) and N-
bromosuccinimde to give the alkynyl bromide 217 as a colourless oil (0.96 g, 99%); 1H NMR 
(300 MHz, CDCl3) δ 7.57 (dd, J = 7.7, 1.5 Hz, 1H), 7.50 – 7.45 (m, 1H), 7.37 (td, J = 7.6, 1.6 Hz, 
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1H), 7.30 (td, J = 7.6, 1.6 Hz, 1H), 6.25 (s, 1H), 3.93 – 3.78 (m, 2H), 1.41 (d, J = 5.8 Hz, 3H), 
1.34 (d, J = 5.8 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 140.5 (C), 133.4 (CH), 129.1 (CH), 129.0 
(CH), 126.9 (CH), 121.9 (C), 101.0 (CH), 80.7 (CH), 79.1 (CH), 77.8 (C), 54.1 (C), 17.4 (CH3), 
16.9 (CH3); IR vma×/cm
-1 2973, 2878, 1449, 1379, 1080, 978, 751, 625; HRMS(EI-TOF): m/z: 
calcd for C13H12O2Br: 279.0021, found: 279.0029 [M]
+. 
Diethyl (4R,5R)-2-(2-(bromoethynyl)phenyl)-1,3-dioxolane-4,5-dicarboxylate (232) 
 
Prepared according to GP7 using terminal alkyne 231 (0.53 g, 1.66 mmol) and N-
bromosuccinimde to give the alkynyl bromide 232 as an off white solid which was used 
immediately without further purification. 
2-(2-(Bromoethynyl)-5-chlorophenyl)-1,3-dioxolane (246) 
 
Prepared according to GP7 using terminal alkyne 245 (430 mg, 2.06 mmol) and N-
bromosuccinimde. Purification by flash column chromatography [8:2 (hexane:EtOAc),1%  
Et3N] gave the alkynyl bromide 246 as a light brown solid (0.59 g, 100%); mp: 100-112 °C;  
1H NMR (300 MHz, CDCl3) δ 7.55 (d, J = 2.2 Hz, 1H), 7.41 (d, J = 8.3 Hz, 1H), 7.29 (dd, J = 8.3, 
2.2 Hz, 1H), 6.09 (s, 1H), 4.22 – 4.12 (m, 2H), 4.11 – 4.02 (m, 2H); 13C NMR (101 MHz, CDCl3) 
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δ 141.8 (C), 135.1 (C), 134.4 (CH), 129.4 (CH), 126.8 (CH), 120.5 (C), 101.3 (CH), 76.7 (C), 65.8 
(2 × CH2), 55.5 (C); IR vma×/cm
-1 2986, 2883, 2193, 1592, 1466, 1123, 1095, 1069, 958, 944, 




Prepared according to GP7 using terminal alkyne 252 (300 mg, 1.56 mmol) and N-
bromosuccinimde. Purification by flash column chromatography [9:1 (hexane:EtOAc), 1% 
Et3N] gave the alkynyl bromide 253 as a pale yellow solid (390 mg, 92%); 
1H NMR (400 MHz, 
CDCl3) δ 7.46 (dd, J = 8.5, 5.4 Hz, 1H), 7.30 – 7.25 (m, 1H), 7.01 (td, J = 8.3, 2.8 Hz, 1H), 6.11 
(d, J = 1.5 Hz, 1H), 4.21 – 4.14 (m, 2H), 4.10 – 4.03 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 
162.8 (d, J C-F = 250.7 Hz, C), 142.8 (d, J C-F = 7.4 Hz, C), 135.2 (d, J C-F = 8.3 Hz, CH), 118.0 (d, J 
C-F = 3.7 Hz, C), 116.5 (d, J C-F = 22.3 Hz, CH), 113.8 (d, J C-F = 23.7 Hz, CH), 101.3 (CH), 76.6 (C), 
65.8 (2 × CH2), 54.1 (C); IR vma×/cm
-1 3675, 2971, 2903, 1606, 1476, 1401, 1054, 881, 540; 




Prepared according to GP7 using terminal alkyne 259 (400 mg, 2.08 mmol) and N-
bromosuccinimde. Purification by flash column chromatography [9:1 (hexane:EtOAc), 1% 
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Et3N] gave the alkynyl bromide 260 as a yellow soild (0.55 g, 98%); mp: 35-38 °C; 
1H NMR 
(300 MHz, CDCl3) δ 7.32 – 7.27 (m, 2H), 7.05 (ddd, J = 10.5, 6.0, 3.6 Hz, 1H), 6.30 (d, J = 0.7 
Hz, 1H), 4.32 – 4.18 (m, 2H), 4.14 – 4.01 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 161.5 (d, J C-F = 
252.2 Hz, C), 130.7 (d, J C-F = 9.8 Hz, CH), 129.8 (d, J C-F = 3.6 Hz, CH), 127.2 (d, J C-F = 11.7 Hz, 
C), 124.2 (d, J C-F = 5.4 Hz, C), 117.1 (d, J C-F = 22.4 Hz, CH), 99.9 (d, J C-F = 4.4 Hz, CH), 66.3 (2 × 
CH2), 55.1 (C), (one quaternary carbon unaccounted for); IR vma×/cm
-1 3674, 2973, 2901, 
2190, 1577, 1461, 1212, 1088, 1057, 959, 793,521; HRMS(EI-TOF): m/z: calcd for C11H7O2BrF: 
268.9613, found: 268.9617 [M]+. 
2-(2-(Bromoethynyl)-5-methoxyphenyl)-1,3-dioxolane (268) 
 
Prepared according to GP7 using terminal alkyne 267 (0.58 g, 2.84 mmol) and N-
bromosuccinimde. Purification by flash column chromatography [9:1 (hexane:EtOAc), 1% 
Et3N] gave the alkynyl bromide 268 as a white soild (0.67 g, 84%); mp: 83-85 °C; 
1H NMR 
(300 MHz, CDCl3) δ 7.41 (d, J = 8.5 Hz, 1H), 7.09 (d, J = 2.7 Hz, 1H), 6.84 (dd, J = 8.6, 2.7 Hz, 
1H), 6.10 (s, 1H), 4.21 – 4.15 (m, 2H), 4.10 – 4.04 (m, 2H), 3.82 (s, 3H); 13C NMR (101 MHz, 
CDCl3) δ 160.1 (C), 141.6 (C), 134.7 (CH), 115.3 (CH), 114.4 (C), 114.2 (C), 111.5 (CH), 101.9 
(CH), 65.7 (2 × CH2), 55.6 (CH3), 52.2 (C); IR vma×/cm
-1 3674, 2973, 2899, 1607, 1395, 1294, 
1067, 891, 818, 548; HRMS(ES-TOF): m/z: calcd for C12H12O3Br: 282.9970, found: 282.9971 






Prepared according to GP7 using terminal alkyne 271 (320 mg, 1.44 mmol) and N-
bromosuccinimde. Purification by flash column chromatography [9:1 (hexane:EtOAc), 1% 
Et3N] gave the alkynyl bromide 272 as a colourless oil (386 mg, 89%); 
1H NMR (300 MHz, 
CDCl3) δ 7.54 – 7.49 (m, 1H), 7.45 – 7.29 (m, 6H), 7.25 – 7.17 (m, 2H), 5.71 (s, 1H), 3.40 (s, 
3H); 13C NMR (101 MHz, CDCl3) δ 144.9 (C), 141.3 (C), 132.8 (CH), 129.3 (CH), 128.4 (2 × CH), 
127.7 (CH), 127.4 (CH), 127.2 (2 × CH), 126.3 (CH), 121.6 (C), 82.7 (CH), 78.7 (C), 57.3 (CH3), 
54.5 (C); IR vma×/cm
-1 3028, 2926, 2822, 2194, 1450, 1189, 1100, 1083, 756, 696, 524; 




Prepared according to GP7 using terminal alkyne 279 (200 mg, 1.14 mmol) and N-
bromosuccinimde. Purification by flash column chromatography [6:4 (hexane:EtOAc), 1% 
Et3N] gave the alkynyl bromide 280 as a black liquid (270 mg, 93%); 
1H NMR (300 MHz, 
CDCl3) δ 8.57 (dd, J = 4.8, 1.7 Hz, 1H), 7.88 (dd, J = 7.9, 1.7 Hz, 1H), 7.31 (dd, J = 7.9, 4.8 Hz, 
1H), 6.13 (s, 1H), 4.22 – 4.14 (m, 2H), 4.12 – 4.05 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 150.7 
(CH), 141.8 (C), 136.1 (C), 134.5 (CH), 123.5 (CH), 100.9 (CH), 65.9 (2 × CH2), 56.0 (C), (one 
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quaternary carbon is unaccounted for); IR vma×/cm
-1 3662, 2971, 2901, 1393, 1075, 904, 727, 




Prepared according to GP7 using terminal alkyne 286 (0.64 g, 3.55 mmol) and N-
bromosuccinimde. Purification by flash column chromatography [9:1 (hexane:EtOAc), 1% 
Et3N] gave the alkynyl bromide 287 as a brown soild (0.83 g, 90%); mp: 38-40 °C; 
1H NMR 
(300 MHz, CDCl3) δ 7.24 (dd, J = 5.1, 0.6 Hz, 1H), 7.02 (d, J = 5.1 Hz, 1H), 6.25 (d, J = 0.6 Hz, 
1H), 4.22 – 4.10 (m, 2H), 4.10 – 3.99 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 145.6 (C), 130.3 
(CH), 125.6 (CH), 121.2 (C), 99.1 (CH), 73.8 (C), 65.6 (2 × CH2), 53.4 (C); IR vma×/cm
-1 3088, 
2898, 1658, 1537, 1199, 1012, 939, 728, 648, 520; HRMS(EI-TOF): m/z: calcd for C9H7O2BrS: 
257.9350, found: 257.9341 [M]+. 
Preparation of dibromoalkenes 
General procedure 8 (GP8) 
A solution of PPh3 (4.0 equiv.) and CBr4 (2.0 equiv.) in CH2Cl2 (0.15 M) was stirred at 0 °C for 
10 minutes. The relevant aldehyde was added over a period of 5 minutes while maintaining 
the temperature at 0 °C. After the addition, the reaction mixture was warmed up to room 
temperature and monitored by TLC. The reaction was quenched by addition of water and 
the layers were separated. The aqueous layer was extracted with CH2Cl2 (× 3) and the 
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combined organic layers were dried over Na2SO4. The solvent was removed under reduced 
pressure and the crude residue was purified by flash column chromatography  
1-(2,2-Dibromovinyl)-4-methylbenzene (340) 
 
Prepared according to GP8 (87% yield, colourless oil); 1H NMR (300 MHz, CDCl3) δ 7.47 – 
7.42 (m, 3H), 7.18 (d, J = 8.1 Hz, 2H), 2.35 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 138.8 (C), 
136.9 (CH), 132.6 (C), 129.3 (2 × CH), 128.5 (2 × CH), 88.7 (C), 21.5 (CH3). 
Data matches that reported in the literature.131 
1-(2,2-Dibromovinyl)-4-methoxybenzene (341) 
 
Prepared according to GP8 (82% yield, yellow solid); 1H NMR (300 MHz, CDCl3) δ 7.55 – 7.49 
(m, 2H), 7.41 (s, 1H), 6.93 – 6.86 (m, 2H), 3.82 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 159.8 (C), 
136.5 (CH), 130.0 (2 × CH), 128.0 (C), 114.0 (2 × CH), 87.4 (C), 55.4 (CH3); IR vma×/cm
-1 2964, 
2840, 1602, 1506, 1455, 1253, 1176, 1025, 802, 731. 





Prepared according to GP8 (98% yield, yellow oil); 1H NMR (300 MHz, CDCl3) δ 7.52 – 7.47 
(m, 2H), 7.42 (br. s, 2H), 7.39 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 135.9 (C), 134.3 (C), 131.8 
(2 × CH), 130.1 (2 × CH), 122.8 (C), 90.7 (CH). 
Data matches that reported in the literature.133 
1-(2,2-Dibromovinyl)-4-fluorobenzene (343) 
 
Prepared according to GP8 (94% yield, yellow oil); 1H NMR (300 MHz, CDCl3) δ 7.56 – 7.49 
(m, 2H), 7.44 (s, 1H), 7.12 – 7.02 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 162.6 (d, JC-F = 249.5 
Hz, C), 135.9 (CH), 131.6 (d, JC-F = 3.3 Hz, C), 130.4 (d, JC-F = 8.3 Hz, 2 × CH), 115.6 (d, JC-F = 
21.7 Hz, 2 × CH), 89.8 (C). 
Data matches that reported in the literature.134 
Methyl 4-(2,2-dibromovinyl)benzoate (344) 
 
Prepared according to GP8 (91% yield, yellow solid); mp: 57-59 °C; 1H NMR (300 MHz, CDCl3) 
δ 8.03 (d, J = 8.4 Hz, 2H), 7.64 – 7.56 (m, 2H), 7.52 (s, 1H), 3.92 (s, 3H). 





Prepared according to GP8 (94% yield, colourless oil); 1H NMR (300 MHz, CDCl3) δ 7.63 (s, 
4H), 7.52 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 138.9 (C), 135.7 (CH), 130.5 (q, JC-F = 32.3 Hz, 
C)), 128.8 (2 × CH), 125.6 (q, JC-F = 3.3 Hz, 2 × CH)), 124.1 (q, JC-F = 272.4 Hz, C)), 92.5 (C). 
Data matches that reported in the literature.136 
2-(2,2-Dibromovinyl)thiophene (346) 
 
Prepared according to GP8 (97% yield, brown solid); mp: 55-56 °C; 1H NMR (300 MHz, CDCl3) 
δ 7.66 (s, 1H), 7.39 (ddd, J = 5.1, 1.3, 0.6 Hz, 1H), 7.25 (dd, J = 1.3, 0.6 Hz, 1H), 7.04 (dd, J = 
5.1, 3.7 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 138.2 (C), 131.0 (CH), 130.2 (CH), 127.3 (CH), 
126.7 (CH), 87.1 (C). 
Data matches that reported in the literature 137 
5-(2,2-Dibromovinyl)benzo[d][1,3]dioxole (347) 
 
Prepared according to GP8 (82% yield, colourless oil); 1H NMR (300 MHz, CDCl3) δ 7.37 (s, 
1H), 7.19 (d, J = 1.8 Hz, 1H), 6.95 (ddd, J = 8.1, 1.8, 0.7 Hz, 1H), 6.80 (d, J = 8.1 Hz, 1H), 5.99 
(s, 2H); 13C NMR (101 MHz, CDCl3) δ 147.9 (C), 147.8 (C), 136.4 (CH), 129.3 (C), 123.5 (CH), 
108.4 (CH), 108.3 (CH), 101.5 (CH2), 88.0 (C) 






Prepared according to GP8 (62% yield, brown oil); 1H NMR (300 MHz, CDCl3) δ 7.44 (dd, J = 
1.8, 0.7 Hz, 1H), 7.41 (s, 1H), 6.95 (d, J = 3.6 Hz, 1H), 6.46 (dd, J = 3.6, 1.8 Hz, 1H); changed 
colour and appeared to degrade which was used immediately in the ne×t step 
Data matches that reported in the literature.138 
2-(2,2-Dibromovinyl)naphthalene (349) 
 
Prepared according to GP8 (80% yield, colourless oil); 1H NMR (300 MHz, CDCl3) δ 8.02 (s, 
1H), 7.88 – 7.80 (m, 3H), 7.67 – 7.62 (m, 2H), 7.54 – 7.48 (m, 2H); 13C NMR (101 MHz, CDCl3) 
δ 137.1 (CH), 133.1 (C), 133.1 (C), 132.9 (C), 128.4 (CH), 128.3 (CH), 128.2 (CH), 127.9 (CH), 
126.9 (CH), 126.7 (CH), 125.8 (CH), 90.0 (C). 
Data matches that reported in the literature.139 
N-(But-3-en-1-yl)-N-tosylformamide (374) 
 
Prepared following literature procedure.140 
N-BuLi (4.1 mL, 1.6 M in hexane, 6.60 mmol) was gently added to a solution of N-(But-3-en-
1-yl)-4-methylbenzenesulfonamide 350 (1.35 g, 6.00 mmol) in THF (30 mL) at -10 °C. After 
stirring for 30 minutes, a solution of formylbenzotriazole (0.97 g, 1.10 mmol) in THF (6 mL) 
was added and the resulting mixture was warmed at room temperature. The reaction was 
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monitored by TLC. It was then quenched with saturated NH4Cl solution and extracted with 
Et2O (× 3). The combined organic layers were washed with brine, dried over Na2SO4 and 
solvent removed under reduced pressure. Purification by flash column chromatography [8:2 
(hexane:EtOAc)] gave the formamide 374 as a colourless oil (1.29 g, 85%); 1H NMR (300 
MHz, CDCl3) δ 9.09 (s, 1H), 7.74 (d, J = 8.3 Hz, 2H), 7.37 (d, J = 8.3 Hz, 2H), 5.65 (ddt, J = 18.1, 
9.2, 6.9 Hz, 1H), 5.02 (app. t, J = 1.3 Hz, 1H), 5.00 – 4.95 (m, 1H), 3.57 – 3.42 (m, 2H), 2.46 (s, 
3H), 5.65 (dt, J = 11.1, 5.0 Hz, 2H); 13C NMR (101 MHz, CDCl3) δ 161.4 (CHO), 145.7 (C), 135.3 
(C), 134.0 (CH), 130.4 (2 × CH), 127.6 (2 × CH), 117.7 (CH2), 42.2 (CH2), 32.7 (CH2), 21.8 (CH3); 
IR vma×/cm
-1 3067, 2979, 1692, 1596, 1415, 1354, 1222, 1157, 670; HRMS (EI-TOF): m/z: 




Prepared following literature protocol.140 
To a flask containing formamide (0.91 g, 3.60 mmol, 1.0 equiv.) and PPh3 (2.80 g, 10.8 mmol, 
3.0 equiv.) dissolved in THF (24 mL) was added a solution of CCl4 (3.5 mL, 36.0 mmol, 10.0 
equiv.) in THF (12 mL) for over a period of 6 hours with the help of a syringe. The reaction 
mixture was heated at 60 °C and monitored by TLC. Quenching was done using saturated 
NaHCO3 solution and extracted with Et2O (× 3). The combined organic layers were washed 
with brine, dried over Na2SO4 and solvent removed under reduced pressure. Purification by 
flash column chromatography [8:2 (hexane:EtOAc)] gave the vinylchloride 375 as a white 
soild (1.03 g, 89%); mp: 53-55 °C; 1H NMR (300 MHz, CDCl3) δ 7.62 (d, J = 8.2 Hz, 2H), 7.26 (d, 
J = 8.2 Hz, 2H), 6.26 (s, 1H), 5.64 (ddt, J = 17.0, 10.2, 6.8 Hz, 1H), 5.05 – 4.99 (m, 1H), 4.99 – 
4.96 (m, 1H), 3.40 – 3.31 (m, 2H), 2.37 (s, 3H), 2.29 – 2.17 (m, 2H); 13C NMR (101 MHz, 
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CDCl3) δ 144.3 (C), 135.8 (C), 134.2 (CH), 130.0 (2 × CH), 127.4 (2 × CH), 125.0 (CH), 124.2 (C), 
117.7 (CH2), 48.7 (CH2), 33.1 (CH2), 21.7 (CH3). 
Data matches that reported in the literature 100 
 (E)-N-(But-3-en-1-yl)-N-(1,2-dichlorovinyl)-4-methylbenzenesulfonamide (385) 
 
Sulfonamide 310 (450 mg, 2.00 mmol, 1.0 equiv.), Cs2CO3 (0.98 g, 3.00 mmol, 1.5 equiv.) and 
DMF (1.5 mL) were heated at 50 °C with dropwise addition of CHCl3 (0.2 mL, 2.20 mmol, 1.1 
equiv.) for 10 minutes. After 3 hours, the reaction was cooled and extracted with EtOAc:H2O 
(2:1). The combined organic layers were washed with brine, dried over Na2SO4 and solvent 
removed under reduced pressure. Purification by flash column chromatography [8:2 
(hexane:EtOAc)] gave the dichloroenamide 385 as a clear oil (0.59 g, 92%); 1H NMR (300 
MHz, CDCl3) δ 7.80 (d, J = 8.3 Hz, 2H), 7.19 (d, J = 8.2 Hz, 2H), 6.51 (s, 1H), 5.74 (ddt, J = 17.0, 
10.2, 6.7 Hz, 1H), 5.08 (ddd, J = 11.0, 6.3, 1.5 Hz, 2H), 3.29 (br. s, 2H), 2.44 (s, 3H), 2.30 (dd, J 
= 14.4, 7.4 Hz, 2H); 13C NMR (101 MHz, CDCl3) δ 144.7 (C), 135.3 (C), 134.0 (CH), 129.8 (2 × 
CH), 129.8 (CH), 128.5 (2 × CH), 121.7 (CH), 117.6 (CH2), 47.6 (CH2), 32.2 (CH2), 21.8 (CH3); 
HRMS (EI-TOF): m/z: calcd for C13H15NO2NaSCl2: 342.0098, found: 342.0100 [M + Na]
+. 
Preparation of ynamides 
General procedure 9 (GP9) 
Prepared following literature procedure.15 
Sulfonamide (1.0 equiv.), K2CO3 (2.0 equiv.), CuSO4·5H2O (10 mol%) and 1,10-
phenanthroline (20 mol%) were added to a solution of 1-bromoalkyne (1.1 equiv.) in dry 
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toluene (1.0 M). The reaction mixture was stirred under argon atmosphere at 70 °C and 
monitored by TLC. The mixture was cooled to room temperature, diluted with EtOAc and 
filtered through a plug of silica gel. The filtrate was concentrated under reduced pressure 
and the crude residue was purified by flash column chromatography. 
General procedure 10 (GP10) 
Prepared following literature procedure.12 
A reaction vessel was charged with sulfonamide (1.0 equiv.), 1,1-dibromo-1-alkene (1.5 
equiv.), Cs2CO3 (4.0 equiv.) and CuI (12 mol%). The vessel was fitted with a rubber septum, 
evacuated under high vacuum and backfilled with argon (this operation was repeated three 
times). Dry 1,4-dioxane (0.5 M with respect to the sulfonamide) and N,N’-
dimethylethylenediamine (DMEDA) (18 mol%) were then added and the mixture was stirred 
at 60 °C until complete consumption of the limiting reagent by TLC. The mixture was cooled 
to room temperature, diluted with EtOAc and filtered through a plug of silica gel. The filtrate 
was concentrated under reduced pressure and the crude residue was purified by flash 
column chromatography. 
General procedure 11 (GP11) 
Prepared following literature protocol.104 
Under an argon atmosphere, n-BuLi (1.2 equiv.) was added carefully added to a solution of 
dichloroenamide (1.0 equiv) in THF (0.006 M with respect to dichloroenamide) at -78 °C. 
After stirring at this temperature for 5 minutes, the solution was warmed up to -41 °C for 30 
minutes. The mixture was cooled back to -78 °C and another portion of n-BuLi (1.0 equiv.) 
was added for over 10 minutes and also stirred for another additional 10 minutes. Following 
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this, the required electrophile (1.2 equiv.) was added (at -78 °C) and the resulting solution 
was warmed up to room temperature for 1 hour. Quenching was done with water followed 
by extraction with Et2O (× 2). The combined organic layers were washed with brine, dried 
over Na2SO4 and solvent removed under reduced pressure. Crude residue was purified by 




Prepared according to GP9 using freshly prepared 2-(2-(bromoethynyl)phenyl)-1,3-
dioxolane 164 (310 mg, 1.22 mmol) and sulfonamide 165 (180 mg, 1.10 mmol). Purification 
by flash column chromatography [8:2 (hexane:EtOAc) + 1% Et3N] gave the ynamide 166 as a 
colourless oil (150 mg, 41%); 1H NMR (300 MHz, CDCl3) δ 7.60 – 7.55 (m, 1H), 7.39 – 7.34 (m, 
1H), 7.33 – 7.28 (m, 2H), 6.12 (s, 1H), 5.48 – 5.40 (m, 1H), 4.21 – 4.13 (m, 4H), 4.07 – 4.01 
(m, 2H), 3.14 (s, 3H), 1.81 (s, 3H), 1.78 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 140.1 (C), 138.4 
(C), 131.3 (CH), 129.0 (CH), 127.8 (CH), 126.0 (CH), 122.3 (C), 117.2 (CH), 102.1 (CH), 87.1 (C), 
69.0 (C), 65.5 (2 × CH2), 49.8 (CH2), 39.1 (CH3), 26.0 (CH3), 18.3 (CH3); IR vma×/cm
-1 2973, 
1621, 1440, 1321, 1160, 1073, 578, 501; HRMS (EI-TOF): m/z: calcd for C17H22NO4S: 







Prepared according to GP9 using freshly prepared diethyl (4R,5R)-2-(2-
(bromoethynyl)phenyl)-1,3-dioxolane-4,5-dicarboxylate 232 (0.52 g, 1.31 mmol) and 
sulfonamide 220 (250 mg, 1.18 mmol). Purification by flash column chromatography [8:2 
(hexane:EtOAc)] gave the ynamide 234 as a colourless oil (410 mg, 66%); [ ] 
   = -117.73; 1H 
NMR (300 MHz, CDCl3) δ 7.85 (d, J = 8.3 Hz, 2H), 7.77 – 7.72 (m, 1H), 7.37 – 7.29 (m, 5H), 
6.49 (s, 1H), 5.78 (ddt, J = 16.6, 10.1, 6.4 Hz, 1H), 5.29 (dd, J = 17.0, 1.3 Hz, 1H), 5.22 (dd, J = 
10.1, 1.2 Hz, 1H), 4.93 (d, J = 4.4 Hz, 1H), 4.85 (d, J = 4.4 Hz, 1H), 4.35 – 4.20 (m, 4H), 4.06 
(dd, J = 6.4, 1.2 Hz, 2H), 2.43 (s, 3H), 1.35 – 1.31 (m, 3H), 1.31 – 1.27 (m, 3H); 13C NMR (101 
MHz, CDCl3) δ 169.7 (CO), 169.3 (CO), 144.9 (C), 135.9 (C), 135.0 (C), 131.4 (CH), 131.1 (CH), 
130.1 (2 × CH), 129.7 (CH), 128.1 (2 × CH), 128.0 (CH), 127.0 (CH), 123.1 (C), 120.4 (CH2), 
104.6 (CH), 87.5 (C), 77.8 (CH), 77.5 (CH), 68.6 (C), 62.3 (CH2), 62.2 (CH2), 54.5 (CH2), 21.8 
(CH3), 14.4 (CH3), 14.3 (CH3); IR vma×/cm
-1 2984, 2233, 1739, 1365, 1202, 1169, 1087, 1023, 








Prepared according to GP9 using freshly prepared 2-(2-(bromoethynyl)phenyl)-4,4,5,5-
tetramethyl-1,3-dioxolane 205 (370 mg, 1.20 mmol) and sulfonamide 220 (210 mg, 0.994 
mmol). Purification by flash column chromatography [8:2 (hexane:EtOAc)] gave the ynamide 
291 as a white solid (340 mg, 78%); mp: 43-45 °C; 1H NMR (300 MHz, CDCl3) δ 7.90 (d, J = 8.3 
Hz, 2H), 7.65 (dd, J = 6.8, 2.7 Hz, 1H), 7.36 – 7.27 (m, 4H), 7.25 – 7.20 (m, 1H), 6.31 (s, 1H), 
5.80 (ddt, J = 16.6, 10.1, 6.3 Hz, 1H), 5.29 (app. ddd, J = 17.0, 2.6, 1.2 Hz, 1H), 5.22 (dd, J = 
10.1, 1.2 Hz, 1H), 4.05 (app. dt, J = 6.3, 1.2 Hz, 2H), 2.43 (s, 3H), 1.32 (s, 6H), 1.30 (s, 6H); 13C 
NMR (101 MHz, CDCl3) δ 144.7 (C), 139.8 (C), 135.0 (C), 131.4 (CH), 131.1 (CH), 129.9 (2 × 
CH), 128.5 (CH), 128.1 (2 × CH), 127.7 (CH), 125.8 (CH), 122.5 (C), 120.1 (CH2), 98.1 (CH), 87.0 
(C), 82.8 (2 × C), 69.0 (C), 54.5 (CH2), 24.7 (2 × CH3), 22.4 (2 × CH3), 21.8 (CH3); IR vma×/cm
-1 
2977, 2238, 1597, 1363, 1168, 1057, 984, 769, 662; HRMS (ES-TOF): m/z: calcd for 








Prepared according to GP9 using freshly prepared 1-((2-
(bromoethynyl)phenyl)(methoxy)methyl)naphthalene 298 (0.7 g, 1.99 mmol) and 
sulfonamide 175 (240 mg, 1.78 mmol). Purification by flash column chromatography [8:2 
(hexane:EtOAc)] gave the ynamide 299 as a pale yellow oil (510 mg, 71%); 1H NMR (300 
MHz, CDCl3) δ 8.10 (d, J = 8.2 Hz, 1H), 7.87 – 7.82 (m, 1H), 7.78 (d, J = 8.2 Hz, 1H), 7.55 – 7.41 
(m, 5H), 7.33 (dd, J = 7.4, 1.3 Hz, 2H), 7.29 (t, J = 1.8 Hz, 1H), 6.43 (s, 1H), 5.71 (ddt, J = 16.5, 
10.1, 6.3 Hz, 1H), 5.24 (app. ddd, J = 16.8, 2.4, 1.2 Hz, 1H), 5.18 (dd, J = 10.1, 1.2 Hz, 1H), 
3.99 (ddt, J = 15.0, 6.3, 1.2 Hz, 1H), 3.89 (ddt, J = 14.9, 6.3, 1.2 Hz, 1H), 3.55 (s, 3H), 2.71 (s, 
3H); 13C NMR (101 MHz, CDCl3) δ 143.0 (C), 136.8 (C), 134.1 (C), 132.5 (CH), 131.8 (C),130.9 
(CH), 128.8 (CH), 128.6 (CH), 128.5 (CH), 127.7 (CH), 127.6 (CH), 126.4 (CH), 125.8 (CH), 
125.5 (CH), 124.9 (CH), 124.0 (CH), 122.4 (C), 120.5 (CH2), 86.5 (C), 79.9 (CH), 69.3 (C), 58.0 
(CH3), 54.3 (CH2), 38.7 (CH3); IR vma×/cm
-1 2931, 2231, 1418, 1356, 1162, 960, 781, 653; 







Prepared according to GP9 using freshly prepared 3-(bromoethynyl)-2-
(methoxy(phenyl)methyl)thiophene 304 (0.89 g, 2.90 mmol) and sulfonamide 175 (320 mg, 
2.37 mmol). Purification by flash column chromatography [9:1 (hexane:EtOAc)] gave the 
ynamide 305 as a pale yellow oil (370 mg, 43%);. 1H NMR (300 MHz, CDCl3) δ 7.48 – 7.43 (m, 
2H), 7.38 – 7.27 (m, 3H), 7.18 (d, J = 5.2 Hz, 1H), 6.94 (d, J = 5.2 Hz, 1H), 5.96 (ddt, J = 16.5, 
10.1, 6.4 Hz, 1H), 5.72 (s, 1H), 5.47 – 5.32 (m, 2H), 4.15 (dd, J = 6.4, 1.2 Hz, 2H), 3.41 (s, 3H), 
3.08 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 149.8 (C), 141.2 (C), 131.1 (CH), 129.8 (CH), 128.6 
(2 × CH), 128.0 (CH), 126.8 (2 × CH), 124.7 (CH), 120.7 (CH2), 119.0 (C), 84.7 (C), 80.3 (CH), 
65.5 (C), 57.3 (CH3), 54.5 (CH2), 39.1 (CH3); IR vma×/cm
-1 2824, 2237, 1419, 1355, 1161, 1083, 
1879, 776, 699, 669; HRMS (ES-TOF): m/z: calcd for C18H19NO3S2Na: 384.0704, found: 
384.0710 [M + Na]+. 
N-(But-3-en-1-yl)-4-methyl-N-(p-tolylethynyl)benzenesulfonamide (351) 
 
Prepared according to GP10 using sulfonamide 350 (360 mg, 1.60 mmol) and 
dibromoalkene 340 (0.66 g, 2.39 mmol). Purification by flash column chromatography [9:1 
(hexane:EtOAc)] gave the ynamide 351 as a colourless liquid (450 mg, 83%); 1H NMR (300 
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MHz, CDCl3) δ 7.83 (d, J = 8.3 Hz, 2H), 7.35 (d, J = 8.1 Hz, 2H), 7.30 – 7.24 (m, 2H), 7.10 (d, J = 
7.9 Hz, 2H), 5.75 (ddt, J = 17.0, 10.2, 6.8 Hz, 1H), 5.17 – 5.01 (m, 2H), 3.45 (t, J = 7.4 Hz, 2H), 
2.51 – 2.40 (m, 5H), 2.34 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 144.7 (C), 138.2 (C), 134.8 (C), 
133.9 (CH), 131.6 (2 × CH), 129.9 (2 × CH), 129.2 (2 × CH), 127.9 (2 × CH), 119.8 (C), 117.8 
(CH2), 81.6 (C), 71.1 (C), 51.1 (CH2), 32.4 (CH2), 21.8 (CH3), 21.6 (CH3); IR vma×/cm
-1 2923, 
2234, 1597, 1362, 1167, 1089, 955, 812, 735, 661; HRMS (ES-TOF): m/z: calcd for 




Prepared according to GP10 using sulfonamide 350 (360 mg, 1.60 mmol) and 
dibromoalkene 341 (0.70 g, 2.40 mmol). Purification by flash column chromatography [9:1 
(hexane:EtOAc)] gave the ynamide 352 as a colourless oil (460 mg, 81%); 1H NMR (300 MHz, 
CDCl3) δ 7.83 (d, J = 8.3 Hz, 2H), 7.38 – 7.29 (m, 4H), 6.83 (d, J = 8.8 Hz, 2H), 5.75 (ddt, J = 
17.0, 10.2, 6.8 Hz, 1H), 5.18 – 5.00 (m, 2H), 3.81 (s, 3H), 3.44 (t, J = 7.4 Hz, 2H), 2.51 – 2.38 
(m, 5H); 13C NMR (101 MHz, CDCl3) δ 159.7 (C), 144.6 (C), 134.8 (C), 133.9 (CH), 133.5 (2 × 
CH), 129.8 (2 × CH), 127.8 (2 × CH), 117.8 (CH2), 114.9 (C), 114.0 (2 × CH), 80.8 (C), 70.7 (C), 
55.4 (CH3), 51.1 (CH2), 32.4 (CH2), 21.8 (CH3); IR vma×/cm
-1 2842, 2235, 1605, 1511, 1360, 
1246, 1167, 1089, 1028, 830, 734, 662; HRMS (ES-TOF): m/z: calcd for C20H21NO3SNa: 






Prepared according to GP10 using sulfonamide 350 (360 mg, 1.60 mmol) and 
dibromoalkene 342 (0.82 g, 2.41 mmol). Purification by flash column chromatography [9:1 
(hexane:EtOAc)] gave the ynamide 353 as a yellow oil (570 mg, 88%); 1H NMR (300 MHz, 
CDCl3) δ 7.82 (d, J = 8.3 Hz, 2H), 7.42 (d, J = 8.5 Hz, 2H), 7.36 (d, J = 8.0 Hz, 2H), 7.22 (d, J = 
8.5 Hz, 2H), 5.74 (ddt, J = 17.0, 10.2, 6.8 Hz, 1H), 5.18 – 5.02 (m, 2H), 3.46 (t, J = 7.4 Hz, 2H), 
2.49 – 2.39 (m, 5H); 13C NMR (101 MHz, CDCl3) δ 144.9 (C), 134.7 (C), 133.7 (CH), 132.8 (2 × 
CH), 131.7 (2 × CH), 130.0 (2 × CH), 127.8 (2 × CH), 122.0 (C), 118.0 (2 × CH)|, 83.4 (C), 70.3 
(C), 51.0 (CH2), 32.5 (CH2), 21.8 (CH3). One quaternary carbon unaccounted for; IR vma×/cm
-1 
2903, 2231, 1488, 1360, 1167, 1089, 956, 917, 810, 688, 656; HRMS (ES-TOF): m/z: calcd for 




Prepared according to GP10 using sulfonamide 350 (360 mg, 1.60 mmol) and 
dibromoalkene 343 (0.67 g, 2.39 mmol). Purification by flash column chromatography [9:1 
(hexane:EtOAc)] gave the ynamide 354 as a colourless oil (490 mg, 89%); 1H NMR (300 MHz, 
CDCl3) δ 7.83 (d, J = 8.3 Hz, 2H), 7.40 – 7.31 (m, 4H), 7.03 – 6.95 (m, 2H), 5.74 (ddt, J = 17.0, 
10.2, 6.8 Hz, 1H), 5.18 – 5.02 (m, 2H), 3.46 (t, J = 7.4 Hz, 2H), 2.51 – 2.38 (m, 5H); 13C NMR 
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(101 MHz, CDCl3) δ 162.4 (d, JC-F = 249.0 Hz, C), 144.8 (C), 134.8 (C), 133.8 (CH), 133.6 (d, JC-F 
= 8.4 Hz, 2 × CH), 129.9 (2 × CH), 127.8 (2 × CH), 119.0 (d, JC-F = 3.5 Hz C), 117.9 (CH2), 115.7 
(d, JC-F = 22.2 Hz, 2 × CH), 81.9 (C), 70.0 (C), 51.1 (CH2), 32.4 (CH2), 21.8 (CH3); IR vma×/cm
-1 
2936, 2237, 1598, 1508, 1363, 1229, 1169, 1090, 956, 834, 813, 737, 662; HRMS (ES-TOF): 
m/z: calcd for C19H18NO2SFNa: 366.0940, found: 366.0941 [M + Na]
+. 
Methyl 4-(((N-(but-3-en-1-yl)-4-methylphenyl)sulfonamido)ethynyl)benzoate (355) 
 
Prepared according to GP10 using sulfonamide 350 (360 mg, 1.60 mmol) and 
dibromoalkene 344 (0.77 g, 2.41 mmol). Purification by flash column chromatography [9:1 
(hexane:EtOAc)] gave the ynamide 355 as a white solid (460 mg, 75%); mp: 72-74 °C; 1H 
NMR (300 MHz, CDCl3) δ 7.96 (d, J = 8.4 Hz, 2H), 7.83 (d, J = 8.4 Hz, 2H), 7.43 – 7.33 (m, 4H), 
5.75 (ddt, J = 17.0, 10.2, 6.8 Hz, 1H), 5.16 – 5.04 (m, 2H), 3.92 (s, 3H), 3.49 (t, J = 7.4 Hz, 2H), 
2.52 – 2.40 (m, 5H); 13C NMR (101 MHz, CDCl3) δ 166.7 (CO), 145.0 (C), 134.7 (C), 133.6 (CH), 
130.7 (2 × CH), 130.0 (2 × CH), 129.6 (2 × CH), 128.9 (C), 128.0 (C), 127.8 (2 × CH), 118.1 
(CH2), 85.6 (C), 71.2 (C), 52.3 (CH3), 51.0 (CH2), 32.5 (CH2), 21.8 (CH3); IR vma×/cm
-1 2949, 
2229, 1716, 1603, 1440, 1361,1272, 1166,763, 655; HRMS (ES-TOF): m/z: calcd for 








Prepared according to GP10 using sulfonamide 350 (360 mg, 1.60 mmol) and 
dibromoalkene 345 (0.79 g, 2.39 mmol). Purification by flash column chromatography [9:1 
(hexane:EtOAc)] gave the ynamide 356 as a yellow oil (510 mg, 81%); 1H NMR (300 MHz, 
CDCl3) δ 7.83 (d, J = 8.3 Hz, 2H), 7.55 (d, J = 8.2 Hz, 2H), 7.44 (d, J = 8.0 Hz, 2H), 7.37 (d, J = 
8.0 Hz, 2H), 5.75 (ddt, J = 17.0, 10.2, 6.8 Hz, 1H), 5.21 – 5.01 (m, 2H), 3.49 (t, J = 7.4 Hz, 2H), 
2.51 – 2.41 (m, 5H); 13C NMR (101 MHz, CDCl3) δ 145.1 (C), 134.7 (C), 133.6 (CH), 131.1 (2 × 
CH), 130.0 (2 × CH), 129.4 (q, JC-F = 31.8 Hz, C)), 127.8 (2 × CH), 127.1 (C), 125.4 (q, JC-F = 3.9 
Hz, 2 × CH)), 124.1 (q, JC-F = 273.0 Hz, C)), 118.1 (CH2), 85.0 (C), 70.5 (C), 51.0 (CH2), 32.5 
(CH2), 21.8 (CH3); IR vma×/cm
-1 2934, 2233, 1614, 1367, 1319, 1166, 1103, 1064, 840, 812, 




Prepared according to GP10 using sulfonamide 350 (360 mg, 1.60 mmol) and 
dibromoalkene 346 (0.64 g, 2.39 mmol). Purification by flash column chromatography [9:1 
(hexane:EtOAc)] gave the ynamide 357 as a brown solid (430 mg, 81%); mp: 38-40 °C; 1H 
NMR (300 MHz, CDCl3) δ 7.82 (d, J = 8.3 Hz, 2H), 7.36 (d, J = 8.0 Hz, 2H), 7.29 – 7.26 (m, 1H), 
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7.18 (dd, J = 3.6, 1.1 Hz, 1H), 6.97 (dd, J = 5.2, 3.6 Hz, 1H), 5.73 (ddt, J = 17.1, 10.2, 6.8 Hz, 
1H), 5.17 – 5.00 (m, 2H), 3.46 (t, J = 7.4 Hz, 2H), 2.47 (s, 3H), 2.45 – 2.38 (m, 2H); 13C NMR 
(101 MHz, CDCl3) δ 144.9 (C), 134.7 (C), 133.7 (CH), 133.1 (CH), 129.9 (2 × CH), 127.9 (CH), 
127.8 (2 × CH), 127.1 (CH), 123.0 (C), 118.0 (CH2), 85.9 (C), 64.4 (C), 51.2 (CH2), 32.4 (CH2), 
21.8 (CH3); IR vma×/cm
-1 2929, 2225, 1493, 1431, 1364, 1167, 1089, 920, 813, 702, 662; 




Prepared according to GP10 using sulfonamide 350 (360 mg, 1.60 mmol) and 
dibromoalkene 347 (0.73 g, 2.39 mmol). Purification by flash column chromatography [9:1 
(hexane:EtOAc)] gave the ynamide 358 as a colourless oil (460 mg, 78%); 1H NMR (300 MHz, 
CDCl3) δ 7.82 (d, J = 8.3 Hz, 2H), 7.35 (d, J = 8.0 Hz, 2H), 6.90 (dd, J = 8.0, 1.6 Hz, 1H), 6.82 (d, 
J = 1.6 Hz, 1H), 6.74 (d, J = 8.0 Hz, 1H), 5.96 (s, 2H), 5.74 (ddt, J = 17.0, 10.2, 6.8 Hz, 1H), 5.15 
– 5.02 (m, 2H), 3.44 (t, J = 7.4 Hz, 2H), 2.46 (s, 3H), 2.45 – 2.38 (m, 2H); 13C NMR (101 MHz, 
CDCl3) δ 147.9 (C), 147.5 (C), 144.7 (C), 134.7 (C), 133.8 (CH), 129.9 (2 × CH), 127.8 (2 × CH), 
126.6 (CH), 117.8 (CH2), 116.0 (C), 112.0 (CH), 108.5 (CH), 101.4 (CH2), 80.6 (C), 70.8 (C), 51.1 
(CH2), 32.4 (CH2), 21.8 (CH3); IR vma×/cm
-1 2896, 2234, 1598, 1491, 1444, 1361; 1221; 1168; 
1089, 1036; 811; 745, 677; HRMS (ES-TOF): m/z: calcd for C20H19NO4SNa: 392.0932, found: 






Prepared according to GP10 using sulfonamide 350 (360 mg, 1.60 mmol) and 
dibromoalkene 348 (0.60 g, 2.38 mmol). Purification by flash column chromatography [9:1 
(hexane:EtOAc)] gave the ynamide 359 as a reddish brown solid (440 mg, 87%); mp: 63-65 
°C; 1H NMR (300 MHz, CDCl3) δ 7.82 (d, J = 8.3 Hz, 2H), 7.39 (dd, J = 1.9, 0.7 Hz, 1H), 7.36 (d, J 
= 8.0 Hz, 2H), 6.62 (dd, J = 3.4, 0.7 Hz, 1H), 6.39 (dd, J = 3.4, 1.9 Hz, 1H), 5.71 (ddt, J = 17.0, 
10.2, 6.8 Hz, 1H), 5.18 – 5.01 (m, 2H), 3.46 (t, J = 7.5 Hz, 2H), 2.46 (s, 3H), 2.45 – 2.38 (m, 
2H); 13C NMR (101 MHz, CDCl3) δ 145.0 (C), 144.1 (CH), 136.9 (C), 134.8 (C), 133.6 (CH), 
130.0 (2 × CH), 127.8 (2 × CH), 118.0 (CH), 117.3 (CH), 111.2 (CH2), 86.3 (C), 61.9 (C), 51.2 
(CH2), 32.4 (CH2), 21.8 (CH3); IR vma×/cm
-1 2971, 1707, 1353, 1157, 1086, 813, 663; HRMS (ES-




Prepared according to GP10 using sulfonamide 350 (360 mg, 1.60 mmol) and 
dibromoalkene 349 (0.75 g, 2.40 mmol). Purification by flash column chromatography [9:1 
(hexane:EtOAc)] gave the ynamide 360 as a colourless oil (540 mg, 90%); 1H NMR (300 MHz, 
CDCl3) δ 7.90 – 7.85 (m, 3H), 7.82 – 7.74 (m, 3H), 7.52 – 7.45 (m, 2H), 7.42 (dd, J = 8.5, 1.6 
Hz, 1H), 7.37 (d, J = 8.0 Hz, 2H), 5.78 (ddt, J = 17.0, 10.2, 6.8 Hz, 1H), 5.19 – 5.05 (m, 2H), 
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3.51 (t, J = 7.4 Hz, 2H), 2.54 – 2.48 (m, 2H), 2.46 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 144.8 
(C), 134.8 (C), 133.8 (CH), 133.1 (C), 132.7 (C), 130.9 (CH), 129.9 (2 × CH), 128.5 (CH), 128.0 
(CH), 127.9 (2 × CH), 127.8 (CH), 127.7 (CH), 126.7 (CH), 126.6 (CH), 120.3 (C), 118.0 (CH2), 
82.6 (C), 71.6 (C), 51.1 (CH2), 32.5 (CH2), 21.8 (CH3); IR vma×/cm
-1 HRMS (ES-TOF): m/z: calcd 




Prepared according to GP9 using sulfonamide 310 (230 mg, 1.02 mmol) and freshly 
prepared bromoalkyne (bromoethynyl)benzene (314 mg, 1.20 mmol). Purification by flash 
column chromatography [9:1 (hexane:EtOAc)] gave the ynamide 361 as a colourless oil (290 
mg, 87%); 1H NMR (300 MHz, CDCl3) δ 7.84 (d, J = 8.3 Hz, 2H), 7.40 – 7.33 (m, 4H), 7.32 – 
7.27 (m, 3H), 5.75 (ddt, J = 17.0, 10.2, 6.8 Hz, 1H), 5.18 – 5.02 (m, 2H), 3.47 (t, J = 7.4 Hz, 2H), 
2.51 – 2.40 (m, 5H); 13C NMR (101 MHz, CDCl3) δ 144.8 (C), 134.7 (C), 133.8 (CH), 131.5 (2 × 
CH), 129.9 (2 × CH), 128.4 (2 × CH), 127.9 (CH), 127.9 (2 × CH), 123.0 (C), 117.9 (CH2), 82.3 
(C), 71.1 (C), 51.1 (CH2), 32.4 (CH2), 21.8 (CH3); IR vma×/cm
-1 2938, 2234, 1597, 1442, 1362, 
1168, 1089, 912, 752, 676. 






Prepared according to GP11 using dichlorovinylamide 375 (380 mg, 1.19 mmol) and 
electrophile- Phenyl benzenethiosulfonate  (390 mg, 1.56 mmol). Purification by flash 
column chromatography [9:1 (hexane:EtOAc)] gave the ynamide 376 as a colourless liquid 
(240 mg, 56%); 1H NMR (300 MHz, CDCl3) δ 7.82 (d, J = 8.3 Hz, 2H), 7.34 (d, J = 8.0 Hz, 2H), 
7.30 – 7.27 (m, 4H), 7.25 – 7.17 (m, 1H), 5.71 (ddt, J = 17.0, 10.2, 6.8 Hz, 1H), 5.14 – 5.02 (m, 
2H), 3.52 (t, J = 7.3 Hz, 2H), 2.46 (s, 3H), 2.45 – 2.38 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 
145.0 (C), 134.8 (C), 134.5 (C), 133.6 (CH), 129.9 (2 × CH), 129.2 (2 × CH), 128.0 (2 × CH), 
126.5 (CH), 125.7 (2 × CH), 118.1 (CH2), 92.7 (C), 61.9 (C), 51.2 (CH2), 32.6 (CH2), 21.8 (CH3); 
IR vma×/cm
-1 2921, 2155, 1582, 1478, 1441, 1364, 1169, 1089, 740, 689, 665; HRMS (ES-TOF): 
m/z: calcd for C19H19NO2S2Na: 380.0755, found: 380.0752 [M + Na]
+. 
Ethyl 3-((N-(but-3-en-1-yl)-4-methylphenyl)sulfonamido)propiolate (386) 
 
Prepared according to GP11 using dichlorovinylamide 375 (0.61 g, 1.90 mmol) and 
electrophile- chloroethylformate   (250 mg, 2.28 mmol). Purification by flash column 
chromatography [9:1 (hexane:EtOAc)] gave the ynamide 386 as a colourless oil (530 mg, 
87%); 1H NMR (300 MHz, CDCl3) δ 7.82 (d, J = 8.3 Hz, 2H), 7.37 (d, J = 8.0 Hz, 2H), 5.66 (ddt, J 
= 17.0, 10.2, 6.8 Hz, 1H), 5.16 – 5.02 (m, 2H), 4.23 (q, J = 7.1 Hz, 2H), 3.48 (t, J = 7.4 Hz, 2H), 
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2.46 (s, 3H), 2.44 – 2.36 (m, 2H), 1.31 (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 154.3 
(CO), 145.7 (C), 134.4 (C), 133.0 (CH), 130.2 (2 × CH), 128.0 (2 × CH), 118.6 (CH2), 82.4 (C), 
68.2 (C), 61.7 (CH2), 50.8 (CH2), 32.5 (CH2), 21.9 (CH3), 14.3 (CH3); IR vma×/cm
-1 2982, 2214, 
1699, 1597, 172, 1231, 1168, 1088, 1026, 877, 708, 657; HRMS (ES-TOF): m/z: calcd for 





Prepared according to GP11 using 1,2-dichlorovinylamide 385 (0.83 g, 2.59 mmol) and 
electrophile- chloroethylformate (340 mg, 3.12 mmol). Purification by flash column 
chromatography [90:10 (hexane:EtOAc)] gave the ynamide 387 as a colourless oil (510 mg, 
50%); 1H NMR (300 MHz, CDCl3) δ 7.97 (d, J = 8.2 Hz, 1H), 7.43 (d, J = 8.2 Hz, 1H), 7.38 (s, 
1H), 5.73 (ddt, J = 17.0, 10.2, 6.8 Hz, 1H), 5.19 – 5.03 (m, 2H), 4.42 (q, J = 7.1 Hz, 2H), 4.21 (q, 
J = 7.1 Hz, 2H), 3.62 (t, J = 7.4 Hz, 2H), 2.53 – 2.39 (m, 5H), 1.39 (t, J = 7.1 Hz, 3H), 1.29 (t, J = 
7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 167.1 (CO), 154.3 (CO), 145.5 (C), 133.5 (C), 133.2 
(CH), 131.9 (C), 131.3 (CH), 130.8 (CH), 129.6 (CH), 118.4 (CH2), 82.3 (C), 68.7 (C), 62.7 (CH2), 
61.7 (CH2), 50.9 (CH2), 32.7 (CH2), 21.6 (CH3), 14.3 (CH3), 14.2 (CH3); IR vma×/cm
-1; HRMS (ES-







Prepared according to GP9 using sulfonamide 393 (290 mg, 1.21 mmol) and freshly 
prepared bromoalkyne (bromoethynyl)benzene 394 (260 mg, 1.44 mmol). Purification by 
flash column chromatography [9:1 (hexane:EtOAc)] gave the ynamide 395 as a colourless 
liquid (350 mg, 85%); 1H NMR (300 MHz, CDCl3) δ 7.85 (d, J = 8.3 Hz, 2H), 7.40 – 7.33 (m, 
4H), 7.32 – 7.27 (m, 3H), 4.80 (br. s, 1H), 4.74 (br. s, 1H), 3.52 (t, J = 7.5 Hz 2H), 2.46 (s, 3H), 
2.40 (t, J = 7.5 Hz, 2H), 1.75 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 144.8 (C), 141.4 (C), 134.8 
(C), 131.5 (2 × CH), 129.9 (2 × CH), 128.4 (2 × CH), 127.9 (CH), 127.9 (2 × CH), 123.0 (C), 113.0 
(CH2), 82.3 (C), 71.1 (C), 50.2 (CH2), 36.1 (CH2), 22.5 (CH3), 21.8 (CH3); IR vma×/cm
-1 2935, 
2234, 1443, 1363, 1166, 1091, 956, 813, 753, 690; HRMS (ES-TOF): m/z: calcd for 





Prepared according to GP10 using sulfonamide 393 (380 mg, 1.59 mmol) and 
dibromoalkene 342 (0.82 g, 2.41 mmol). Purification by flash column chromatography [9:1 
(hexane:EtOAc)] gave the ynamide 396 as a white solid (0.60 g, 90%); mp: 58-60 °C; 1H NMR 
(300 MHz, CDCl3) δ 7.82 (d, J = 8.3 Hz, 2H), 7.42 (d, J = 8.5 Hz, 2H), 7.36 (d, J = 8.1 Hz, 2H), 
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7.22 (d, J = 8.5 Hz, 2H), 4.80 ( br. s, 1H), 4.73 (br. s, 1H), 3.52 (t, J = 7.5 Hz, 2H), 2.46 (s, 3H), 
2.38 (t, J = 7.5 Hz, 2H), 1.74 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 144.9 (C), 141.3 (C), 134.8 
(C), 132.8 (2 × CH), 131.7 (2 × CH), 130.0 (2 × CH), 127.8 (2 × CH), 122.0 (C), 122.0 (C), 113.1 
(CH2), 83.5 (C), 70.3 (C), 50.1 (CH2), 36.2 (CH2), 22.5 (CH3), 21.8 (CH3); IR vma×/cm
-1 2935, 
2229, 1487, 1364, 1186, 1168, 1092, 953, 894, 823, 707, 687; HRMS (ES-TOF): m/z: calcd for 





Prepared according to GP10 using sulfonamide 393 (380 mg, 1.59 mmol) and 
dibromoalkene 344 (0.77 g, 2.41 mmol). Purification by flash column chromatography [8:2 
(hexane:EtOAc)] gave the ynamide 397 as a white solid (560 mg, 89%); mp: 89-91 °C; 1H 
NMR (300 MHz, CDCl3) δ 7.96 (d, J = 8.5 Hz, 2H), 7.84 (d, J = 8.3 Hz, 2H), 7.43 – 7.34 (m, 4H), 
4.81 (br. s, 1H), 4.74 (br. s, 1H), 3.92 (s, 3H), 3.54 (t, J = 7.5 Hz, 2H), 2.46 (s, 3H), 2.40 (t, J = 
7.5 Hz, 2H), 1.75 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 166.7 (CO), 145.0 (C), 141.2 (C), 134.8 
(C), 130.7 (2 × CH), 130.0 (2 × CH), 129.6 (2 × CH), 128.9 (C), 128.0 (C), 127.8 (2 × CH), 113.2 
(CH2), 85.8 (C), 71.2 (C), 52.3 (CH3), 50.1 (CH2), 36.2 (CH2), 22.5 (CH3), 21.8 (CH3); IR vma×/cm
-1 
2944, 2227, 1715, 1601, 1430, 1363, 1271, 1163, 1091, 898, 770, 687; HRMS (ES-TOF): m/z: 







Prepared according to GP9 using freshly prepared (bromoethynyl)benzene 394 (430 mg, 
2.38 mmol) and sulfonamide 411 (0.60 g, 1.99 mmol). Purification by flash column 
chromatography [9:1 (hexane:EtOAc)] gave the ynamide 416 as a yellow solid (0.67 g, 84%); 
mp: 43-45 °C; 1H NMR (300 MHz, CDCl3) δ 7.58 (d, J = 8.3 Hz, 2H), 7.40 – 7.28 (m, 7H), 7.25 – 
7.20 (m, 3H), 7.15 (d, J = 8.0 Hz, 2H), 5.66 (ddt, J = 17.1, 10.1, 6.9 Hz, 1H), 5.13 (dd, J = 17.1, 
1.6 Hz, 1H), 5.06 (dd, J = 9.1, 6.5 Hz, 1H), 5.00 (dd, J = 10.1, 1.6 Hz, 1H), 2.92 – 2.79 (m, 1H), 
2.72 – 2.59 (m, 1H), 2.38 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 144.3 (C), 138.9 (C), 135.4 (C), 
133.6 (CH), 131.3 (2 × CH), 129.4 (2 × CH) , 128.5 (2 × CH), 128.4 (2 × CH), 128.2 (CH), 127.9 
(2 × CH), 127.8 (CH), 127.3 (2 × CH), 123.3 (C), 118.5 (CH2), 80.7 (C), 73.7 (C), 63.5 (CH), 38.5 
(CH2), 21.7 (CH3); IR vma×/cm
-1 3033, 2234, 1598, 1493, 1359, 1167, 1088, 959, 657, 





Prepared according to GP9 using freshly prepared (bromoethynyl)benzene 394 (220 mg, 
1.22 mmol) and sulfonamide 412 (380 mg, 1.00 mmol). Purification by flash column 
chromatography [8:2 (hexane:EtOAc)] gave the ynamide 417 as a yellow oil (380 mg, 79%); 
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1H NMR (300 MHz, CDCl3) δ 7.64 (d, J = 8.3 Hz, 2H), 7.54 – 7.48 (m, 2H), 7.45 – 7.39 (m, 2H), 
7.36 – 7.30 (m, 3H), 7.16 (d, J = 8.0 Hz, 2H), 7.10 – 7.04 (m, 2H), 5.69 (ddt, J = 17.0, 10.1, 6.9 
Hz, 1H), 5.51 (dd, J = 9.8, 5.3 Hz, 1H), 5.16 (dd, J = 17.1, 1.5 Hz, 1H), 5.01 (dd, J = 10.1, 1.5 Hz, 
1H), 2.83 – 2.69 (m, 1H), 2.66 – 2.55 (m, 1H), 2.37 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 144.5 
(C), 139.3 (C), 135.1 (C), 133.2 (CH), 132.9 (CH), 131.3 (2 × CH), 129.4 (2 × CH), 129.2 (CH), 
128.5 (2 × CH), 127.9 (CH), 127.9 (2 × CH), 127.7 (CH), 127.5 (CH), 123.2 (C), 122.9 (C), 118.8 
(CH2), 81.2 (C), 73.7 (C), 62.0 (CH), 38.8 (CH2), 21.7 (CH3); IR vma×/cm
-1 3057, 2234, 1596, 
1440, 1360, 1165, 1185, 746, 654; HRMS(ES-TOF): m/z: calcd for C25H22NO2SNaBr: 502.0452, 
found: 502.0447 [M + Na]+. 
4-Methyl-N-(phenylethynyl)-N-(1-(p-tolyl)but-3-en-1-yl)benzenesulfonamide (418) 
 
Prepared according to GP9 using freshly prepared (bromoethynyl)benzene 394 (220 mg, 
1.22 mmol) and sulfonamide 413 (320 mg, 1.01 mmol). Purification by flash column 
chromatography [8:2 (hexane:EtOAc)] gave the ynamide 418 as a colourless oil (340 mg, 
81%); 1H NMR (300 MHz, CDCl3) δ 7.61 (d, J = 8.3 Hz, 2H), 7.39 – 7.34 (m, 2H), 7.33 – 7.28 
(m, 3H), 7.22 – 7.14 (m, 4H), 7.03 (d, J = 7.9 Hz, 2H), 5.64 (ddt, J = 17.1, 10.1, 6.9 Hz, 1H), 
5.12 (dd, J = 17.1, 1.6 Hz, 1H), 5.07 – 4.95 (m, 2H), 2.89 – 2.77 (m, 1H), 2.71 – 2.58 (m, 1H), 
2.39 (s, 3H), 2.30 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 144.2 (C), 138.0 (C), 135.8 (C), 135.5 
(C), 133.8 (CH), 131.3 (2 × CH), 129.3 (2 × CH), 129.1 (2 × CH), 128.4 (2 × CH), 127.9 (2 × CH), 
127.8 (CH), 127.3 (2 × CH), 123.3 (C), 118.4 (CH2), 80.7 (C), 73.6 (C), 63.3 (CH), 38.4 (CH2), 
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21.7 (CH3), 21.3 (CH3); IR vma×/cm
-1 2922, 2232, 1597, 1362, 1166, 1089, 967, 754, 659; 





Prepared according to GP9 using freshly prepared (bromoethynyl)benzene 394 (220 mg, 
1.22 mmol) and sulfonamide 414 (330 mg, 0.996 mmol). Purification by flash column 
chromatography [8:2 (hexane:EtOAc)] gave the ynamide 419 as a yellow oil (350 mg, 81%); 
1H NMR (300 MHz, CDCl3) δ 7.61 (d, J = 8.3 Hz, 2H), 7.39 – 7.34 (m, 2H), 7.33 – 7.27 (m, 3H), 
7.23 (d, J = 8.7 Hz, 2H), 7.17 (d, J = 8.1 Hz, 2H), 6.75 (d, J = 8.7 Hz, 2H), 5.64 (ddt, J = 17.1, 
10.2, 6.9 Hz, 1H), 5.11 (dd, J = 17.1, 1.6 Hz, 1H), 5.06 – 4.95 (m, 2H), 3.77 (s, 3H), 2.89 – 2.75 
(m, 1H), 2.70 – 2.57 (m, 1H), 2.39 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 159.6 (C), 144.2 (C), 
135.6 (C), 133.8 (CH), 131.3 (2 × CH), 130.9 (C), 129.4 (2 × CH), 128.6 (2 × CH), 128.4 (2 × CH), 
127.9 (2 × CH), 127.8 (CH), 123.3 (C), 118.4 (CH2), 113.8 (2 × CH), 80.7 (C), 73.7 (C), 63.1 
(CH3), 55.4 (CH), 38.4 (CH2), 21.7 (CH3); IR vma×/cm
-1 2933, 2231, 1610, 1513, 1360, 1167, 






Prepared according to GP9 using freshly prepared (bromoethynyl)benzene 394 (220 mg, 
1.22 mmol) and sulfonamide 415 (290 mg, 0.995 mmol). Purification by flash column 
chromatography [9:1 (hexane:EtOAc)] gave the ynamide 420 as a brown oil (150 mg, 38%); 
1H NMR (300 MHz, CDCl3) δ 7.77 (d, J = 8.4 Hz, 2H), 7.34 – 7.25 (m, 7H), 7.23 (dd, J = 1.8, 0.8 
Hz, 1H), 6.23 (dd, J = 3.3, 1.8 Hz, 1H), 6.20 (d, J = 3.3 Hz, 1H), 5.71 (ddt, J = 17.1, 10.1, 6.9 Hz, 
1H), 5.22 – 5.12 (m, 2H), 5.06 (dd, J = 10.2, 1.6 Hz, 1H), 2.81 – 2.73 (m, 2H), 2.42 (s, 3H); 13C 
NMR (101 MHz, CDCl3) δ 151.5 (C), 144.5 (C), 142.3 (CH), 135.5 (C), 133.0 (CH), 131.4 (2 × 
CH), 129.5 (2 × CH), 128.4 (2 × CH), 128.1 (2 × CH), 127.8 (CH), 123.2 (C), 118.9 (CH2), 110.3 
(CH), 108.5 (CH), 79.8 (C), 73.5 (C), 57.5 (CH), 36.3 (CH2), 21.8 (CH3; IR vma×/cm
-1 3079, 2984, 
2234, 1597, 1360, 1167, 1089, 753, 663; HRMS(ES-TOF): m/z: calcd for C23H21NO3SNa: 




Prepared according to GP9 using freshly prepared dimethyl (4R,5R)-2-(2-
(bromoethynyl)phenyl)-1,3-dioxolane-4,5-dicarboxylate  (530 mg, 1.44 mmol) and 
sulfonamide 220 (250 mg, 1.18 mmol). Purification by flash column chromatography [8:2 
(hexane:EtOAc)] gave the ynamide 432 as a colourless oil (210 mg, 36%); 1H NMR (300 MHz, 
CDCl3) δ 7.85 (d, J = 8.3 Hz, 2H), 7.78 – 7.71 (m, 1H), 7.39 – 7.29 (m, 5H), 6.49 (s, 1H), 5.77 
(ddt, J = 16.6, 10.1, 6.3 Hz, 1H), 5.29 (dd, J = 17.0, 1.3 Hz, 1H), 5.22 (dd, J = 10.1, 1.2 Hz, 1H), 
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4.98 (d, J = 4.3 Hz, 1H), 4.90 (d, J = 4.3 Hz, 1H), 4.06 (d, J = 6.3 Hz, 2H), 3.84 (s, 3H), 3.83 (s, 
3H), 2.44 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 170.1 (CO), 169.6 (CO), 144.9 (C), 135.6 (C), 
134.9 (C), 131.2 (CH), 131.0 (CH), 130.0 (2 × CH), 129.7 (CH), 128.0 (2 × CH), 127.9 (CH), 
126.9 (CH), 123.0 (C), 120.3 (CH2), 104.6 (CH), 87.4 (C), 77.6 (CH), 77.3 (CH), 68.5 (C), 54.4 
(CH2), 53.0. (CH3), 53.0 (CH3), 21.8 (CH3); IR vma×/cm
-1 2956, 2233, 1743, 1205, 1168, 1107, 





Prepared according to GP9 using freshly prepared diethyl (4S,5S)-2-(2-
(bromoethynyl)phenyl)-4,5-diphenyl-1,3-dioxolane 211 (280 mg, 0.690 mmol) and 
sulfonamide 220 (130 mg, 0.615 mmol). Purification by flash column chromatography [8:2 
(hexane:EtOAc) + 1% Et3N] gave the ynamide 433 as a colourless oil (190 mg, 58%); [ ] 
   = -
93.21; 1H NMR (300 MHz, CDCl3) δ 7.90 – 7.82 (m, 3H), 7.43 – 7.29 (m, 13H), 7.14 (d, J = 8.0 
Hz, 2H), 6.77 (s, 1H), 5.78 (ddt, J = 16.6, 10.1, 6.3 Hz, 1H), 5.27 (dd, J = 17.0, 1.3 Hz, 1H), 5.18 
(dd, J = 10.1, 1.3 Hz, 1H), 5.02 – 4.93 (m, 2H), 4.06 (dd, J = 6.3, 1.3 Hz, 2H), 2.33 (s, 3H); 13C 
NMR (101 MHz, CDCl3) δ 144.7 (C), 138.5 (C), 138.4 (C), 136.7 (C), 134.9 (C), 131.6 (CH), 
131.0 (CH), 129.9 (2 × CH), 129.2 (CH), 128.7 (2 × CH), 128.7 (2 × CH), 128.6 (CH), 128.3 (CH), 
128.0 (2 × CH), 127.1 (2 × CH), 126.7 (2 × CH), 126.2 (CH), 122.7 (C), 120.3 (CH2), 102.9 (CH), 
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87.4 (CH), 87.3 (C), 85.6 (CH), 68.9 (C), 54.4 (CH2), 21.7 (CH3), (one CH unaccounted for); IR 
vma×/cm
-1 3670, 2987, 2901, 2231, 1494, 1454, 1364, 1168, 1060, 757, 697, 599, 544; 
HRMS(ES-TOF): m/z: calcd for C33H29NO4SNa: 558.1715, found: 558.1718 [M + Na]
+. 
Catalysis products 
General procedure 12 (GP12) 
Sulfonamide (1.0 equiv.), bromoalkyne (1.2 equiv.), K2CO3 (2.0 equiv.), 1, 10-phenanthroline 
(20 mol%),CuSO4 (10 mol%) and toluene (1.0 M) were stirred at 70 °C until TLC indicated 
complete consumption of ynamide formed. The reaction temperature was then raised to 
100 °C and stirred at the indicated time. The mixture was cooled to room temperature, 
diluted with EtOAc and filtered through a plug of silica gel. The filtrate was concentrated 
under reduced pressure and the crude residue was purified by flash column 
chromatography. 
General procedure 13 (GP13) 
The required ynamide (1.0 equiv.) was dissolved in CH3NO2 (0.1 M), XphosAuNTf2 (5 mol%) 
was added and the resulting mixture was heated 80 °C until complete by TLC. The mixture 
was cooled to room temperature, diluted with EtOAc and filtered through a plug of silica 
gel. The filtrate was concentrated under reduced pressure and the crude residue was 
purified by flash column chromatography. 
General procedure 14 (GP14) 
The required ynamide (1.0 equiv.) was dissolved in toluene (0.1 M), dichloro-2-
pyridinecarboxylato gold (III) (5 mol%) was added and the resulting mixture was heated 
80 °C until complete by TLC. The mixture was cooled to room temperature, diluted with 
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EtOAc and filtered through a plug of silica gel. The filtrate was concentrated under reduced 
pressure and the crude residue was purified by flash column chromatography. 
2-(Methylsulfonyl)-4-(1-phenylallyl)-2H-spiro[isoquinoline-1,2'-[1,3]dioxolane] (169) 
 
Prepared according to GP12 using freshly prepared bromoalkyne 2-(2-
(bromoethynyl)phenyl)-1,3-dioxolane (GP7, 330 mg, 1.30 mmol) and sulfonamide 168 (250 
mg, 1.18 mmol) at 70 °C for 16 h. Purification by flash column chromatography [8:2 
(hexane:EtOAc), 1% Et3N] gave dihydroisoquinoline 169 as a white foam (380 mg, 84%); 
1H 
NMR (300 MHz, CDCl3) δ 7.53 – 7.46 (m, 1H), 7.34 – 7.26 (m, 5H), 7.25 – 7.16 (m, 3H), 6.92 
(s, 1H), 6.20 (ddd, J = 16.9, 10.2, 6.5 Hz, 1H), 5.24 (app. dt, J = 10.2, 1.4 Hz, 1H), 4.94 (app. dt, 
J = 17.1, 1.3 Hz, 1H), 4.81 (d, J = 6.2 Hz, 1H), 4.63 – 4.49 (m, 2H), 4.28 – 4.15 (m, 2H), 3.10 (s, 
3H); 13C NMR (101 MHz, CDCl3) δ 141.2 (C), 139.2 (CH), 131.3 (C), 131.2 (C), 129.4 (CH), 
128.7 (2 × CH), 128.6 (2 × CH), 127.2 (CH), 126.8 (CH), 124.6 (CH), 123.5 (CH), 123.1 (CH), 
119.2 (C), 117.6 (CH2), 112.8 (C), 67.0 (CH2), 66.3 (CH2), 49.0 (CH), 43.5 (CH3); IR vma×/cm
-1 
2987, 2901, 1450, 1343, 1264, 1165, 1073,959, 702, 618; HRMS (ES-TOF): m/z: calcd for 








Prepared according to GP12 using freshly prepared bromoalkyne 2-(2-
(bromoethynyl)phenyl)-1,3-dioxolane (GP7, 280 mg, 1.11 mmol) and sulfonamide 165 (160 
mg, 0.980 mmol) for 20 h. Purification by flash column chromatography [9:1 
(hexane:EtOAc), 1% Et3N] gave dihydroisoquinoline 167 as a colourless liquid (210 mg, 64%); 
1H NMR (300 MHz, CDCl3) δ 7.74 – 7.68 (m, 1H), 7.54 – 7.48 (m, 1H), 7.38 – 7.27 (m, 2H), 
7.02 (s, 1H), 6.10 (dd, J = 17.5, 10.6 Hz, 1H), 5.11 (d, J = 7.2 Hz, 1H), 5.06 (s, 1H), 4.58 – 4.46 
(m, 2H), 4.26 – 4.16 (m, 2H), 3.08 (s, 3H), 1.43 (s, 6H); 13C NMR (101 MHz, CDCl3) δ 148.2 
(CH), 132.0 (C), 131.0 (C), 128.5 (CH), 126.7 (CH), 126.1 (CH), 124.2 (C), 123.4 (CH), 122.3 
(CH), 112.4 (C), 112.3 (C), 66.6 (2 × CH2), 43.5 (CH3), 40.1 (C), 28.8 (2 × CH3); IR vma×/cm
-1 
2970, 1623, 1485, 1340, 1267, 1160, 1073, 948, 756, 516; HRMS (ES-TOF): m/z: calcd for 




Prepared according to GP12 using freshly prepared bromoalkyne 2-(2-
(bromoethynyl)phenyl)-1,3-dioxolane (GP7, 280 mg, 1.11 mmol) and sulfonamide 171 (150 
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mg, 1.01 mmol) for 24 h. Purification by flash column chromatography [9:1 (hexane:EtOAc), 
1% Et3N] gave dihydroisoquinoline 176 as a colourless liquid (300 mg, 92%); 
1H NMR (300 
MHz, CDCl3) δ 7.53 – 7.48 (m, 1H), 7.45 – 7.30 (m, 3H), 6.88 (s, 1H), 4.84 (br. s, 1H), 4.78 (br. 
s, 1H), 4.59 – 4.47 (m, 2H), 4.27 – 4.17 (m, 2H), 3.22 (s, 2H), 3.06 (s, 3H), 1.76 (s, 3H); 13C 
NMR (101 MHz, CDCl3) δ 143.3 (C), 131.7 (C), 131.0 (C), 129.5 (CH), 127.3 (CH), 123.7 (CH), 
123.5 (CH), 122.8 (CH), 116.1 (C), 112.8 (C), 112.5 (CH2), 66.6 (2 × CH2), 43.3 (CH3), 38.5 
(CH2), 22.5 (CH3); IR vma×/cm
-1 3675, 2988, 2901, 1650, 1451, 1342,1260, 1163, 1066, 1026, 
768, 514; HRMS (ES-TOF): m/z: calcd for C16H19NO4NaS: 344.0932, found: 344.0934 [M + 
Na]+. 
 (E)-4-(But-2-en-1-yl)-2-(methylsulfonyl)-2H-spiro[isoquinoline-1,2'-[1,3]dioxolane] (177) 
 
Prepared according to GP12 using freshly prepared bromoalkyne 2-(2-
(bromoethynyl)phenyl)-1,3-dioxolane (GP7, 310 mg, 1.22 mmol) and sulfonamide 172 (160 
mg, 1.07 mmol) at 70 °C for 48 h. Purification by flash column chromatography [9:1 
(hexane:EtOAc), 1% Et3N] gave dihydroisoquinoline 177 as a yellow oil (280 mg, 81%, 
mixture of E/Z isomers in 0.4:1 ratio); 1H NMR (400 MHz, CDCl3) δ 7.53 – 7.49 (m, 1H), 7.47 – 
7.41 (m, 1H), 7.39 – 7.32 (m, 2H), 6.85 (s, 1H), 5.68 – 5.47 (m, 2H), 4.59 – 4.47 (m, 2H), 4.25 
– 4.16 (m, 2H), 3.28 – 3.17 (m, 2H), 3.06 (s, 3H), 1.75 – 1.65 (m, 3H); 13C NMR (101 MHz, 
CDCl3) δ 131.8 (C, minor), 131.7 (C, major), 131.1 (C, minor), 131.0 (C, major), 129.6 (CH, 
minor), 129.6 (CH, major), 128.0 (CH, major), 127.8 (CH, major), 127.4 (CH, minor), 127.3 
(CH, minor), 127.3 (CH, major), 126.3 (CH, minor), 123.7 (CH, minor), 123.6 (CH, major), 
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122.7 (CH, major), 122.6 (CH, major), 122.5 (CH, minor), 122.3 (CH, minor), 117.1 (C, major), 
116.9 (C, minor), 112.8 (C, major and minor), 66.6 (2 × CH2, major and minor), 43.3 (CH3, 
major and minor), 32.9 (CH2, major), 27.5 (CH2, minor), 18.1 (CH3, major), 13.1 (CH3, minor); 
IR vma×/cm
-1 2988, 1647, 1587, 1527, 1174, 1038, 767,523; HRMS (ES-TOF): m/z: calcd for 




Prepared according to GP12 using freshly prepared bromoalkyne 2-(2-
(bromoethynyl)phenyl)-1,3-dioxolane (GP7, 280 mg, 1.11 mmol) and sulfonamide 173 (210 
mg, 0.981 mmol) for 16 h. Purification by flash column chromatography [8:2 
(hexane:EtOAc), 1% Et3N] gave dihydroisoquinoline 178 as a brown solid (320 mg, 84%); mp: 
123 – 125 °C; 1H NMR (300 MHz, CDCl3) δ 7.52 (dd, J = 7.6, 1.3 Hz, 1H), 7.48 – 7.33 (m, 2H), 
7.29 (dd, J = 7.7, 1.3 Hz, 1H), 7.00 (s, 1H), 5.60 (d, J = 1.9 Hz, 1H), 5.50 (d, J = 1.9 Hz, 1H), 4.61 
– 4.47 (m, 2H), 4.28 – 4.16 (m, 2H), 3.63 (s, 2H), 3.09 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 
131.1 (C), 131.0 (C), 130.8 (C), 129.7 (CH), 127.6 (CH), 125.3 (CH), 123.7 (CH), 122.4 (CH), 
118.4 (CH2), 114.2 (C),112.8 (C), 66.7 (2 × CH2), 43.6 (CH3), 42.1 (CH2); IR vma×/cm
-12894, 
1650, 1348, 1257, 1168, 1013, 769, 522; HRMS (ES-TOF): m/z: calcd for C15H16NO4NaSBr: 







Prepared according to GP12 using freshly prepared bromoalkyne 2-(2-
(bromoethynyl)phenyl)-1,3-dioxolane (GP7, 330 mg, 1.30 mmol) and sulfonamide 174 (330 
mg, 1.18 mmol) for 48 h. Purification by flash column chromatography [9:1 (hexane:EtOAc), 
1% Et3N] gave dihydroisoquinoline 179 as a light yellow liquid (280 mg, 53%); 
1H NMR (300 
MHz, CDCl3) δ 7.51 (d, J = 7.6 Hz, 1H), 7.44 – 7.41 (m, 2H), 7.40 – 7.30 (m, 1H), 6.91 (s, 1H), 
6.06 – 5.92 (m, 1H), 5.19 (app. dt, J = 6.3, 1.5 Hz, 1H), 5.15 (d, J = 1.3 Hz, 1H), 4.60 – 4.45 (m, 
2H), 4.26 – 4.15 (m, 2H), 3.90 – 3.75 (m, 2H), 3.65 (app. q, J = 5.7 Hz, 1H), 3.06 (s, 3H), 0.87 
(s, 9H), 0.03 (s, 6H); 13C NMR (101 MHz, CDCl3) δ 138.0 (CH), 131.6 (C), 131.2 (C), 129.4 (CH), 
127.1 (CH), 123.6 (CH), 123.3 (CH), 122.4 (CH), 117.5 (C), 117.0 (CH2), 112.6 (C), 66.7 (CH2), 
66.5 (CH2), 65.5 (CH2), 45.1 (CH), 43.4 (CH3), 26.0 (3 × CH3), 18.4 (C), -5.21 (2 × CH3); IR 
vma×/cm
-1  2929, 2856, 1472, 1349, 1258, 1167, 1093, 948, 834, 770, 520; HRMS (ES-TOF): 






Prepared according to GP12 using freshly prepared bromoalkyne 2-(2-
(bromoethynyl)phenyl)-1,3-dioxane (GP7, 290 mg, 1.09 mmol) and sulfonamide 168 (210 
mg, 0.994 mmol) for 24 h. Purification by flash column chromatography [9:1 
(hexane:EtOAc), 1% Et3N] gave dihydroisoquinoline 190 as a white foam (280 mg, 71%); 
1H 
NMR (300 MHz, CDCl3) δ 7.69 – 7.65 (m, 1H), 7.33 – 7.26 (m, 2H), 7.25 – 7.14 (m, 6H), 6.57 
(s, 1H), 6.17 (ddd, J = 16.9, 10.2, 6.4 Hz, 1H), 5.22 (app. dt, J = 10.2, 1.3 Hz, 1H), 4.93 (app. dt, 
J = 17.1, 1.4 Hz, 1H), 4.81 (dd, J = 6.4, 1.0 Hz, 1H), 4.58 (ddd, J = 11.2, 10.2, 4.6 Hz, 1H), 4.45 
(ddd, J = 11.2, 10.2, 4.8 Hz, 1H), 4.11 – 4.01 (m, 1H), 4.00 – 3.90 (m, 1H), 2.57 (s, 3H), 2.24 – 
2.06 (m, 1H), 2.00 – 1.86 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 141.0 (C), 139.0 (CH), 133.7 
(C), 131.0 (C), 129.3 (CH), 128.8 (2 × CH), 128.7 (2 × CH), 127.8 (CH), 127.5 (C), 126.8 (CH), 
125.8 (CH), 123.7 (CH), 123.5 (CH), 117.6 (CH2), 103.6 (C), 61.7 (CH2), 60.6 (CH2), 49.1 (CH), 
40.2 (CH3), 23.7 (CH2); IR vma×/cm
-1 2971, 1651, 1450, 1340, 1164, 1039, 927, 754, 522; 




Prepared according to GP12 using freshly prepared bromoalkyne 2-(2-
(bromoethynyl)phenyl)-1,3-dioxane (GP7, 290 mg, 1.09 mmol) and sulfonamide 191 (150 
mg, 1.01 mmol) for 24 h. Purification by flash column chromatography [9:1 (hexane:EtOAc), 
1% Et3N] gave dihydroisoquinoline 192 as a colourless viscous oil (250 mg, 74%); 
1H NMR 
(300 MHz, CDCl3) δ 7.74 – 7.69 (m, 1H), 7.47 – 7.33 (m, 3H), 6.50 (s, 1H), 5.97 (ddd, J = 17.3, 
10.3, 6.1 Hz, 1H), 5.17 – 5.03 (m, 2H), 4.58 – 4.41 (m, 2H), 4.04 – 3.89 (m, 2H), 3.70 – 3.58 
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(m, 1H), 2.52 (s, 3H), 2.23 – 2.04 (m, 1H), 1.96 – 1.81 (m, 1H), 1.34 (d, J = 6.9 Hz, 3H); 13C 
NMR (101 MHz, CDCl3) δ 141.4 (CH), 133.9 (C), 131.0 (C), 129.5 (C), 129.3 (CH), 127.9 (CH), 
123.7 (CH), 123.2 (CH), 123.1 (CH), 115.1 (C), 115.0 (CH2), 61.4 (CH2), 61.0 (CH2), 39.7 (CH3), 
36.5 (CH), 23.7 (CH2), 18.9 (CH3); IR vma×/cm
-1 2968, 1650, 1607, 1449, 1328, 1223, 1157, 




Prepared according to GP12 using freshly prepared bromoalkyne 2-(2-
(bromoethynyl)phenyl)-1,3-dioxane (GP7, 290 mg, 1.09 mmol) and sulfonamide 175 (140 
mg, 1.04 mmol) for 24 h. Purification by flash column chromatography [8:2 (hexane:EtOAc), 
1% Et3N] gave dihydroisoquinoline 193a as a colourless liquid (35.0 mg, 10%); 
1H NMR (300 
MHz, CDCl3) δ 7.73 – 7.69 (m, 1H), 7.45 – 7.33 (m, 3H), 6.54 (s, 1H), 5.94 (ddt, J = 17.1, 10.2, 
6.0 Hz, 1H), 5.17 – 5.06 (m, 2H), 4.51 (ddd, J = 11.4, 10.4, 4.7 Hz, 2H), 4.03 – 3.93 (m, 2H), 
3.29 (ddd, J = 6.0, 2.8, 1.5 Hz, 2H), 2.56 (s, 3H), 2.22 – 2.07 (m, 1H), 1.95 – 1.84 (m, 1H); 13C 
NMR (101 MHz, CDCl3) δ 135.3 (CH), 133.6 (C), 131.0 (C), 129.5 (CH), 128.1 (CH), 124.6 (C), 
124.4 (CH), 123.7 (CH), 123.3 (CH), 117.3 (CH2), 103.7 (C), 61.2 (2 × CH2), 39.8 (CH3), 34.0 
(CH2), 23.7 (CH2); IR vma×/cm
-1 3661, 2971, 2923, 1651, 1450, 1325, 1161, 1039, 768, 552; 







Prepared according to GP12 using freshly prepared bromoalkyne 2-(2-
(bromoethynyl)phenyl)-1,3-dioxane (GP7, 290 mg, 1.09 mmol) and sulfonamide 175 (140 
mg, 1.04 mmol) for 24 h. Purification by flash column chromatography [8:2 (hexane:EtOAc), 
1% Et3N] gave dihydroisoquinoline 193b as a colourless liquid (49.0 mg, 19%); 
1H NMR (300 
MHz, CDCl3) δ 8.33 – 8.20 (m, 1H), 7.87 (d, J = 8.4 Hz, 1H), 7.79 (s, 1H), 7.73 – 7.66 (m, 1H), 
7.58 – 7.51 (m, 1H), 6.05 (ddt, J = 16.7, 10.4, 6.2 Hz, 1H), 5.11 (dd, J = 3.8, 1.7 Hz, 1H), 5.07 
(app. dq, J = 10.7, 1.6 Hz, 1H), 4.73 (t, J = 5.8Hz 2H), 3.72 (t, J = 5.8 Hz, 2H), 3.64 (dd, J = 6.2, 
0.7 Hz, 2H), 2.12 – 2.03 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 160.5 (C), 138.5 (CH), 137.1 (C), 
136.6 (C), 130.7 (CH), 126.5 (CH), 124.9 (CH), 123.4 (CH), 123.4 (CH), 119.6 (C), 116.5 (CH2), 
63.0 (CH2), 58.8 (CH2), 34.1 (CH2), 32.9 (CH2); IR vma×/cm
-1 3662, 2970, 2901, 1621, 1570, 
1506, 1407, 1325, 1086, 913, 765, 673; HRMS (ES-TOF): m/z: calcd for C15H18NO2: 244.1338, 






Prepared according to GP12 using freshly prepared bromoalkyne 2-(2-
(bromoethynyl)phenyl)-4,4,5,5-tetramethyl-1,3-dioxolane (GP7, 400 mg, 1.29 mmol) and 
sulfonamide 168 (250 mg, 1.18 mmol) for 18 h. Purification by flash column 
chromatography [9:1 (hexane:EtOAc), 1% Et3N] gave dihydroisoquinoline 206 as a light 
yellow foam (410 mg, 79%); 1H NMR (300 MHz, CDCl3) δ 7.58 – 7.53 (m, 2H), 7.39 – 7.26 (m, 
5H), 7.25 – 7.22 (m, 2H), 6.57 (s, 1H), 6.19 (ddd, J = 16.9, 10.2, 6.4 Hz, 1H), 5.22 (app. dt, J = 
10.2, 1.4 Hz, 1H), 4.94 (app. dt, J = 17.0, 1.4 Hz, 1H), 4.85 (dd, J = 6.4, 0.9 Hz, 1H), 2.59 (s, 
3H), 1.62 (s, 3H), 1.60 (s, 3H), 1.32 (s, 3H), 1.25 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 141.1 
(C), 139.2 (CH), 133.0 (C), 132.1 (C), 129.1 (CH), 128.9 (2 × CH), 128.6 (2 × CH), 127.7 (CH), 
127.2 (C), 126.8 (CH), 123.3 (CH), 122.5 (CH), 117.6 (CH2), 109.7 (C),87.2 (C), 87.0 (C) 48.9 
(CH), 41.1 (CH3), 25.8 (CH3), 25.1 (CH3), 23.6 (CH3), 23.1 (CH3).(One CH unaccounted for); IR 
vma×/cm
-1 3675, 2974, 1450, 1343, 1264, 1158, 1074, 960, 749, 544; HRMS (ES-TOF): m/z: 





Prepared according to GP12 using freshly prepared bromoalkyne 2-(2-
(bromoethynyl)phenyl)-4,4,5,5-tetramethyl-1,3-dioxolane (GP7, 370 mg, 1.20 mmol) and 
sulfonamide 191 (160 mg, 1.07 mmol) for 48 h. Purification by flash column 
chromatography [9:1 (hexane:EtOAc), 1% Et3N] gave dihydroisoquinoline 207 as a colourless 
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gummy liquid (290 mg, 72%); 1H NMR (300 MHz, CDCl3) δ 7.62 – 7.57 (m, 1H), 7.43 – 7.30 
(m, 3H), 6.51 (s, 1H), 6.00 (ddd, J = 17.3, 10.3, 6.1 Hz, 1H), 5.14 (app. dt, J = 17.3, 1.4 Hz, 1H), 
5.07 (d, J = 10.3 Hz, 1H), 3.70 – 3.59 (m, 1H), 2.55 (s, 3H), 1.60 (s, 6H), 1.36 (d, J = 6.9 Hz, 3H), 
1.30 (s, 3H), 1.26 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 141.6 (C), 133.0 (C), 132.1 (C), 129.1 
(CH), 127.8 (CH), 127.6 (CH), 124.3 (CH), 123.0 (CH), 122.8 (CH), 114.8 (CH2), 109.6 (C), 86.8 
(C), 86.3 (C), 40.8 (CH3), 36.4 (CH), 25.6 (CH3), 25.3 (CH3), 23.4 (CH3), 23.2 (CH3), 19.0 (CH3); 
IR vma×/cm
-1 2974, 1450, 1343,1264, 1159, 1067, 1030, 955, 749, 513; HRMS (ES-TOF): m/z: 





Prepared according to GP12 using freshly prepared bromoalkyne 2-(2-
(bromoethynyl)phenyl)-4,4,5,5-tetramethyl-1,3-dioxolane (GP7, 340 mg, 1.10 mmol) and 
sulfonamide 172 (150 mg, 1.01 mmol) for 16 h. Purification by flash column 
chromatography [95:5 (hexane:EtOAc), 1% Et3N] gave dihydroisoquinoline 208 as a white 
solid (300 mg, 79%, mixture of E/Z isomers in 0.4:1 ratio); mp: 128 -130 °C; 1H NMR (300 
MHz, CDCl3) δ 7.64 – 7.54 (m, 1H), 7.46 – 7.30 (m, 3H), 6.51 (s, 1H), 5.70 – 5.48 (m, 2H), 3.34 
– 3.18 (m, 2H), 2.56 (s, 3H), 1.77 – 1.66 (m, 3H), 1.60 (s, 6H), 1.29 (s, 6H); 13C NMR (101 MHz, 
CDCl3) δ 132.7 (C, minor), 132.7 (C, major), 132.4 (C, minor), 132.3 (C, major), 129.3 (CH, 
minor), 129.2 (CH, major), 127.9 (CH, major and minor), 127.8 (CH, major), 127.8 (CH, 
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minor), 127.2 (CH, major and minor), 126.5 (CH, major and minor), 125.1 (CH, major), 124.9 
(CH, minor), 124.8 (C, major and minor), 123.0 (CH, minor), 122.9 (CH, major), 109.7 (2 × C, 
major and minor), 86.6 (C, major and minor), 42.2 (CH3, minor), 40.7 (CH3, major), 32.8 (CH2, 
major), 27.6 (CH2, minor), 25.5 (2 × CH3, major and minor), 23.3 (2 × CH3, major and minor), 
18.1 (CH3, major), 13.1 (CH3, minor); IR vma×/cm
-1 2982, 1484, 1338, 1150, 1032, 963, 749, 





Prepared according to GP12 using freshly prepared bromoalkyne (4'S,5'S)-2-
(methylsulfonyl)-4',5'-diphenyl-4-(1-phenylallyl)-2H-spiro[isoquinoline-1,2'-[1,3]dioxolane] 
(GP7, 440 mg, 1.09 mmol) and sulfonamide 168 (210 mg, 0.994 mmol) for 24 h. Purification 
by flash column chromatography [95:5 (hexane:EtOAc), 1% Et3N] gave dihydroisoquinoline 
212 as a white foam (420 mg, 79% dr. 1:1); [ ] 
   = -114.12; 1H NMR (300 MHz, CDCl3) δ 7.85 
– 7.76 (m, 2H), 7.63 – 7.53 (m, 4H), 7.42 – 7.29 (m, 27H), 7.25 – 7.21 (m, 5H), 7.15 (s, 1H), 
7.09 (s, 1H), 6.30 – 6.16 (m, 2H), 5.89 (d, J = 9.3 Hz, 2H), 5.29 – 5.20 (m, 2H), 5.08 (d, J = 3.5 
Hz, 1H), 5.05 (d, J = 3.5 Hz, 1H), 5.03 – 4.89 (m, 2H), 4.87 – 4.80 (m, 2H), 3.27 (s, 3H), 3.25 (s, 
3H); 13C NMR (101 MHz, CDCl3) δ 141.3, 141.1, 139.3, 139.2, 136.0, 134.8, 134.4, 132.3, 
132.2, 131.5, 131.3, 129.4, 129.3, 129.2, 128.9, 128.8, 128.8, 128.7, 128.7, 128.6, 128.6, 
128.5, 126.9, 126.7, 126.6, 126.4, 124.9, 124.5, 123.5, 123.4, 118.4, 118.2, 117.6, 112.3, 
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112.2, 85.5, 85.1, 84.8, 84.7, 49.1, 49.0, 44.4, 44.3 IR vma×/cm
-1 3031, 1488, 1346, 1255, 
1064, 1024, 959, 698, 520; HRMS (ES-TOF): m/z: calcd for C33H29NO4SNa: 558.1715, found: 




Prepared according to GP12 using freshly prepared bromoalkyne (4'S,5'S)-2-
(methylsulfonyl)-4',5'-diphenyl-4-(1-phenylallyl)-2H-spiro[isoquinoline-1,2'-[1,3]dioxolane] 
(GP7, 440 mg, 1.09 mmol) and sulfonamide 213 (290 mg, 1.01 mmol) for 30 h. Purification 
by flash column chromatography [95:5 (hexane:EtOAc), 1% Et3N] gave dihydroisoquinoline 
214 as a off-white foam (420 mg, 68% dr. 1:1); [ ] 
   = -190.03; 1H NMR (300 MHz, CDCl3) δ 
7.65 – 7.48 (m, 11H), 7.45 – 7.27 (m, 21H), 7.25 – 7.04 (m, 16H), 6.35 – 6.21 (m, 2H), 5.98 
(dd, J = 9.1, 6.7 Hz, 2H), 5.31 (d, J = 10.2 Hz, 1H), 5.25 (d, J = 10.2 Hz, 1H), 5.08 – 4.89 (m, 
4H), 4.88 – 4.79 (m, 2H), 2.32 (s, 3H), 2.31 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 143.6, 143.6, 
141.4, 141.2, 139.4, 139.3, 138.8, 138.7, 136.4, 135.5, 135.1, 132.1, 131.2, 131.0, 129.3, 
129.2, 129.2, 129.1, 129.0, 129.0, 128.8, 128.8, 128.7, 128.7, 128.5, 128.4, 128.4, 127.2, 
127.0, 126.8, 126.7, 126.6, 126.3, 125.8, 125.3, 123.5, 123.5, 123.1, 120.4, 119.9, 117.6, 
117.6, 112.2, 112.1, 85.2, 84.9, 84.8, 84.5, 49.1, 48.9, 21.6; IR vma×/cm
-1 2988, 2901, 1449, 
1349, 1256, 1170, 1065, 750, 697, 547; HRMS (ES-TOF): m/z: calcd for C39H33NO4SNa: 






Prepared according to GP12 using freshly prepared bromoalkyne (4R,5R)-2-(2-
(bromoethynyl)phenyl)-4,5-dimethyl-1,3-dioxolane (GP7, 250 mg, 0.889 mmol) and 
sulfonamide 213 (230 mg, 0.800 mmol) for 24 h. Purification by flash column 
chromatography [9:1 (hexane:EtOAc), 1% Et3N] gave dihydroisoquinoline 218 as a white 
foam (310 mg, 79% dr. 1:1); [ ] 
   = -18.84; 1H NMR (300 MHz, CDCl3) δ 7.62 – 7.55 (2 × m, 
2H), 7.32 – 7.27 (2 × m, 5H), 7.25 – 7.09 (2 × m, 7H), 6.33 – 6.20 (2 × m, 1H), 5.26 (2 × ddd, J 
= 10.2, 2.9, 1.5 Hz, 1H), 4.94 (2 × ddd, J = 17.1, 3.2, 1.6 Hz, 1H), 4.86 – 4.77 (2 × m, 1H), 4.60 
– 4.48 (2 × m, 1H), 3.96 – 3.81 (2 × m, 1H), 2.33 (2 × s, 3H), 1.47 (2 × dd, J = 6.1, 5.3 Hz, 3H), 
1.33 (2 × dd, J = 6.1, 4.4 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 143.3 (C), 141.4 (C), 139.5 (CH), 
132.5 (C), 131.0 and 130.9 (C), 129.3 (2 × CH), 128.8 (CH), 128.8 (2 × CH), 128.7 (2 × CH), 
126.9 (2 × CH), 126.8 (CH), 126.7 (CH), 125.6 (CH), 123.4 and 123.3 (CH), 122.8 (CH), 119.1 
and 119.0 (C), 117.5 and 117.4 (CH2), 111.6 (C), 81.5 and 81.0 (CH), 78.9 and 78.6 (CH), 49.0 
(CH), 21.6 (CH3), 16.4 and 16.3 (CH3), 15.4 and 15.3 (CH3), (one quartenary carbon 
unaccounted for); IR vma×/cm
-1 2974, 1450, 1345, 1260, 1170, 1077, 702, 545; HRMS (ES-








 Prepared according to GP12 using freshly prepared bromoalkyne (4R,5R)-2-(2-
(bromoethynyl)phenyl)-4,5-dimethyl-1,3-dioxolane (GP7, 190 mg, 0.676 mmol) and 
sulfonamide 175 (81.0 mg, 0.599 mmol) for 24 h. Purification by flash column 
chromatography [9:1 (hexane:EtOAc), 1% Et3N] gave dihydroisoquinoline 221 as a colourless 
liquid (150 mg, 75%); [ ] 
   = -8.12; 1H NMR (300 MHz, CDCl3) δ 7.56 – 7.50 (m, 1H), 7.45 – 
7.39 (m, 1H), 7.37 – 7.31 (m, 2H), 6.98 (s, 1H), 5.96 (ddt, J = 16.3, 10.1, 6.2 Hz, 1H), 5.21 – 
5.08 (m, 2H), 4.51 (dq, J = 9.0, 6.1 Hz, 1H), 3.98 (dq, J = 8.9, 6.1 Hz, 1H), 3.27 (ddd, J = 6.1, 
2.6, 1.3 Hz, 2H), 3.15 (s, 3H), 1.44 (d, J = 6.1 Hz, 3H), 1.37 (d, J = 6.1 Hz, 3H); 13C NMR (101 
MHz, CDCl3) δ 135.8 (CH), 132.3 (C), 131.4 (C), 129.2 (CH), 127.0 (CH), 123.4 (CH), 123.1 
(CH), 122.5 (CH), 117.1 (CH2), 114.8 (C), 111.8 (C), 81.4 (CH), 79.0 (CH), 44.2 (CH3), 34.1 
(CH2), 16.5 (CH3), 15.3 (CH3); IR vma×/cm
-1 2975, 1643, 1342, 1256, 1166, 1076, 960, 753, 519; 








Prepared according to GP12 using freshly prepared bromoalkyne (4R,5R)-2-(2-
(bromoethynyl)phenyl)-4,5-dimethyl-1,3-dioxolane (GP7, 150 mg, 0.534 mmol) and 
sulfonamide 171 (74.6 mg, 0.500 mmol) for 24 h. Purification by flash column 
chromatography [9:1 (hexane:EtOAc), 1% Et3N] gave dihydroisoquinoline 222 as a colourless 
liquid (140 mg, 80%); [ ] 
   = 3.32; 1H NMR (300 MHz, CDCl3) δ 7.55 – 7.49 (m, 1H), 7.42 – 
7.29 (m, 3H), 6.97 (s, 1H), 4.84 (br. s, 1H), 4.79 (br. s, 1H), 4.51 (dq, J = 8.9, 6.1 Hz, 1H), 3.98 
(dq, J = 8.9, 6.1 Hz, 1H), 3. 20 (s, 2H), 3.14 (s, 3H), 1.76 (s, 3H), 1.44 (d, J = 6.1 Hz, 3H), 1.36 
(d, J = 6.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 143.4 (C), 132.4 (C), 131.6 (C), 129.2 (CH), 
126.9 (CH), 123.8 (CH), 123.3 (CH), 122.8 (CH), 114.6 (C), 112.5 (CH2), 111.8 (C), 81.4 (CH), 
79.0 (CH), 44.1 (CH3), 38.5 (CH2), 22.6 (CH3), 16.5 (CH3), 15.3 (CH3); IR vma×/cm
-1 3675, 
2972,2901, 1342, 1256, 1166, 1077, 962, 753, 515; HRMS (ES-TOF): m/z: calcd for 








Prepared according to GP12 using freshly prepared bromoalkyne (4R,5R)-2-(2-
(bromoethynyl)phenyl)-4,5-dimethyl-1,3-dioxolane (GP12, 150 mg, 0.534 mmol) and 
sulfonamide 173 (110 mg, 0.514 mmol) for 24 h. Purification by flash column 
chromatography [9:1 (hexane:EtOAc), 1% Et3N] gave dihydroisoquinoline 223 as a brown 
liquid (130 mg, 61%); [ ] 
   = -4.49; 1H NMR (300 MHz, CDCl3) δ 7.53 (dd, J = 7.6, 1.4 Hz, 1H), 
7.46 – 7.27 (m, 3H), 7.09 (s, 1H), 5.59 (d, J = 1.5 Hz, 1H), 5.50 (d, J = 1.5 Hz, 1H), 4.52 (dq, J = 
8.9, 6.1 Hz, 1H), 3.98 (dq, J = 8.9, 6.1 Hz, 1H), 3.62 (s, 2H), 3.17 (s, 3H), 1.45 (d, J = 6.1 Hz, 
3H), 1.37 (d, J = 6.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 132.3 (C), 131.2 (C), 130.7 (C), 
129.4 (CH), 127.3 (CH), 125.4 (CH), 123.5 (CH), 122.4 (CH), 118.4 (CH2), 112.9 (C), 111.8 (C), 
81.5 (CH), 79.1 (CH), 44.3 (CH3), 42.2 (CH2), 16.5 (CH3), 15.2 (CH3); IR vma×/cm
-1 3675, 2987, 
2901, 1342, 1256, 1075, 961, 754, 519; HRMS (ES-TOF): m/z: calcd for C17H20NO4SBrNa: 







 Prepared according to GP12 using freshly prepared bromoalkyne (4'S,5'S)-2-
(methylsulfonyl)-4',5'-diphenyl-4-(1-phenylallyl)-2H-spiro[isoquinoline-1,2'-[1,3]dioxolane] 
(GP7, 440 mg, 1.09 mmol) and sulfonamide 171 (150 mg, 1.01 mmol) for 40 h. Purification 
by flash column chromatography [95:5 (hexane:EtOAc), 1% Et3N] gave dihydroisoquinoline 
224 as a white foam (380 mg, 79%); [ ] 
   = -134.04; 1H NMR (300 MHz, CDCl3) δ 7.86 – 7.80 
(m, 1H), 7.57 – 7.51 (m, 2H), 7.44 – 7.32 (m, 11H), 7.09 (s, 1H), 5.87 (d, J = 9.2 Hz, 1H), 5.05 
(d, J = 9.2 Hz, 1H), 4.84 (br. s, 1H), 4.80 (br. s, 1H), 3.36 – 3.12 (m, 5H), 1.76 (s, 3H); 13C NMR 
(101 MHz, CDCl3) δ 143.3 (C), 135.9 (C) , 134.7 (C), 132.0 (C), 131.8 (C), 129.4 (CH), 129.2 
(CH), 128.9 (2 × CH), 128.8 (2 × CH), 128.6 (CH), 128.6 (2 × CH), 127.1 (CH), 126.5 (2 × CH), 
123.8 (CH), 123.5 (CH), 123.2 (CH), 115.3 (C), 112.6 (CH2), 112.3 (C), 85.1 (CH), 85.1 (CH), 
44.1 (CH3), 38.5 (CH2), 22.6 (CH3); IR vma×/cm
-1 2972, 2901, 1650, 1450, 1347, 1254, 1168, 
1168, 958, 751, 698, 520; HRMS (ES-TOF): m/z: calcd for C28H27NO4SNa: 496.1558, found: 




 (4'S,5'S)-4-Allyl-4',5'-diphenyl-2-tosyl-2H-spiro[isoquinoline-1,2'-[1,3]dioxolane] (225) 
 
Prepared according to GP12 using freshly prepared bromoalkyne (4'S,5'S)-2-
(methylsulfonyl)-4',5'-diphenyl-4-(1-phenylallyl)-2H-spiro[isoquinoline-1,2'-[1,3]dioxolane] 
(GP7, 310 mg, 0.764 mmol) and sulfonamide 220 (150 mg, 0.710 mmol) for 32 h. 
Purification by flash column chromatography [95:5 (hexane:EtOAc), 1% Et3N] gave 
dihydroisoquinoline 225 as a white foam (230 mg, 61%); [ ] 
   = -174.16; 1H NMR (300 MHz, 
CDCl3) δ 7.65 – 7.50 (m, 5H), 7.44 – 7.27 (m, 10H), 7.23 (s, 1H), 7.23 – 7.18 (m, 1H), 7.08 (d, J 
= 7.8 Hz, 2H), 6.08 – 5.92 (m, 2H), 5.23 – 5.10 (m, 2H), 4.96 (d, J = 9.2 Hz, 1H), 3.32 (ddd, J = 
7.3, 5.1, 1.4 Hz, 2H), 2.31 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 143.6 (C), 138.9 (C), 136.3 (C), 
135.8 (CH), 135.2 (C), 131.9 (C), 131.3 (C), 129.2 (2 × CH), 129.1 (CH), 128.8 (2 × CH), 128.8 (2 
× CH), 128.8 (2 × CH), 128.7 (CH), 128.4 (CH), 127.1 (2 × CH), 127.0 (CH), 126.3 (2 × CH), 
123.9 (CH), 123.6 (CH), 122.7 (CH), 117.1 (CH2), 116.9 (C), 112.2 (C), 85.0 (CH), 84.5 (CH), 
34.1 (CH2), 21.6 (CH3); IR vma×/cm
-1 2973, 1643, 1450, 1349, 1254, 1170, 1024, 674, 547; 








Prepared according to GP12 using freshly prepared bromoalkyne (4'S,5'S)-2-
(methylsulfonyl)-4',5'-diphenyl-4-(1-phenylallyl)-2H-spiro[isoquinoline-1,2'-[1,3]dioxolane] 
(GP7, 405 mg, 1.00 mmol) and sulfonamide 175 (122 mg, 0.903 mmol) for 24 h. Purification 
by flash column chromatography [95:5 (hexane:EtOAc), 1% Et3N] gave dihydroisoquinoline 
226 as a white solid (310 mg, 75%); [ ] 
   = -113.57; mp: 96-98 °C; Dihydoisoquinoline 226 
(90% purity): 1H NMR (300 MHz, CDCl3) δ 7.88 – 7.80 (m, 1H), 7.59 – 7.53 (m, 2H), 7.49 – 
7.33 (m, 11H), 7.09 (s, 1H), 6.05 – 5.93 (m, 1H), 5.89 (d, J = 9.3 Hz, 1H), 5.23 – 5.09 (m, 2H), 
5.05 (d, J = 9.3 Hz, 1H), 3.32 – 3.27 (m, 2H), 3.24 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 135.9 
(C), 135.7 (CH), 134.5 (C), 132.0 (C), 131.6 (C), 129.5 (CH), 129.3 (CH), 129.1 (CH), 128.9 (2 × 
CH), 128.8 (2 × CH), 128.7 (2 × CH), 128.6 (CH), 126.4 (2 × CH), 123.7 (CH), 123.1 (CH), 122.8 
(CH), 117.2 (CH2), 115.2 (C), 112.3 (C), 85.0 (2 × CH), 44.3 (CH3), 34.1 (CH2); IR vma×/cm
-1 
2988, 2901, 1670, 1347, 1167, 1064, 963, 698, 516; HRMS (ES-TOF): m/z: calcd for 







Prepared according to GP12 using freshly prepared bromoalkyne 2-(2-
(bromoethynyl)phenyl)-1,3-dioxolane (GP7, 280 mg, 1.11 mmol) and sulfonamide 236 (240 
mg, 0.929 mmol) for 18 h. Purification by flash column chromatography [8:2 
(hexane:EtOAc), 1% Et3N] gave dihydroisoquinoline 237 as a yellow solid (340 mg, 88%); mp: 
93 – 95 °C; 1H NMR (300 MHz, CDCl3) δ 8.14 (d, J = 8.9 Hz, 2H), 7.84 (d, J = 8.9 Hz, 2H), 7.38 – 
7.27 (m, 2H), 7.25 – 7.17 (m, 2H), 6.99 (s, 1H), 5.98 (ddt, J = 16.5, 10.3, 6.1 Hz, 1H), 5.18 
(app. dq, J = 7.6, 1.5 Hz, 1H), 5.13 (app. t, J = 1.5 Hz, 1H), 4.64 – 4.51 (m, 2H), 4.26 – 4.13 (m, 
2H), 3.32 (dd, J = 6.1, 1.2 Hz, 2H); 13C NMR (101 MHz, CDCl3) δ 149.9 (C), 147.2 (C), 135.3 
(CH), 131.0 (C), 130.4 (C), 129.7 (CH), 128.0 (2 × CH), 127.8 (CH), 123.9 (2 × CH), 123.5 (CH), 
123.0 (CH), 122.7 (CH), 119.7 (C), 117.4 (CH2), 112.7 (C), 66.4 (2 × CH2), 34.0 (CH2); IR 
vma×/cm
-1 2900, 1526, 1348, 1306, 1172, 1079, 737, 606, 572; HRMS (ES-TOF): m/z: calcd for 







Prepared according to GP12 using freshly prepared bromoalkyne 2-(2-
(bromoethynyl)phenyl)-1,3-dioxolane (GP7, 170 mg, 0.672 mmol) and sulfonamide 240 (190 
mg, 0.587 mmol) for 48 h. Purification by flash column chromatography [90:10 
(hexane:EtOAc), 1% Et3N] gave dihydroisoquinoline 241 as a colourless liquid (100 mg, 34%); 
1H NMR (300 MHz, CDCl3) δ 7.37 – 7.32 (m, 2H), 7.26 – 7.18 (m, 2H), 7.09 (s, 1H), 7.04 (s, 
2H), 5.99 (ddt, J = 17.1, 10.1, 6.2 Hz, 1H), 5.21 (app. dq, J = 17.1, 1.6 Hz, 1H),  5.13 (ddd, J = 
10.1, 2.9, 1.4 Hz, 1H), 4.50 – 4.36 (m, 2H), 4.16 – 4.07 (m, 2H), 4.01 (sep, J =  6.7 Hz, 2H), 
3.35 (dd, J = 6.2, 1.1 Hz, 2H), 2.84 (sep, J =  6.9 Hz, 1H), 1.20 (d, J = 6.9 Hz, 6H), 1.04 (d, J = 
6.8 Hz, 12H); 13C NMR (101 MHz, CDCl3) δ 152.6 (C), 150.3 (2 × C), 136.1 (CH), 135.8 (C), 
131.8 (C), 131.8 (C), 129.1 (CH), 127.1 (CH), 123.8 (2 × CH), 123.6 (CH), 122.4 (CH), 117.2 (C), 
117.0 (CH2), 113.3 (C), 66.5 (2 × CH2), 34.2 (CH2), 34.1 (CH), 29.1 (2 × CH), 24.7 (4 × CH3), 23.6 
(2 × CH3), (one CH unaccounted for); IR vma×/cm
-1  2928, 1600, 1364, 1333, 1166, 1066, 
1020,673, 578, 553; HRMS (ES-TOF): m/z: calcd for C29H38NO4S: 496.2522, found: 496.2517 
[M + H]+. 
4-Allyl-7-chloro-2-(methylsulfonyl)-2H-spiro[isoquinoline-1,2'-[1,3]dioxolane] (247) 
 
Prepared according to GP12 using freshly prepared bromoalkyne 2-(2-(bromoethynyl)-5-
chlorophenyl)-1,3-dioxolane (GP7, 160 mg, 0.556 mmol) and sulfonamide 175 (68.0 mg, 
0.503 mmol) for 41 h. Purification by flash column chromatography [9:1 (hexane:EtOAc), 1% 
Et3N] gave dihydroisoquinoline 247 as an orange liquid (140 mg, 81%);.
1H NMR (300 MHz, 
CDCl3) δ 7.44 (d, J = 2.2 Hz, 1H), 7.36 (dd, J = 8.4, 2.2 Hz, 1H), 7.23 (s, 1H), 6.86 (s, 1H), 5.90 
197 
 
(ddt, J = 16.5, 10.3, 6.1 Hz, 1H), 5.15 – 5.06 (m, 2H), 4.56 – 4.44 (m, 2H), 4.25 – 4.16 (m, 2H), 
3.22 (dd, J = 6.2, 1.1 Hz, 2H), 3.04 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 135.3 (CH), 132.9 (C), 
132.4 (C), 130.2 (C), 129.7 (CH), 124.0 (CH), 123.9 (CH), 123.4 (CH), 117.3 (CH2), 115.4 (C), 
112.2 (C), 66.8 (2 × CH2), 43.5 (CH3), 34.0 (CH2); IR vma×/cm
-1 3675, 2988, 2901, 1640, 1488, 
1344, 1250, 1166, 1067, 960, 761, 509; HRMS (ES-TOF): m/z: calcd for C15H17NO4S35Cl: 




Prepared according to GP12 using freshly prepared bromoalkyne 2-(2-(bromoethynyl)-5-
fluorophenyl)-1,3-dioxolane (GP7, 150 mg, 0.553 mmol) and sulfonamide 173 (110 mg, 
0.514 mmol) for 48 h. Purification by flash column chromatography [9:1 (hexane:EtOAc), 1% 
Et3N] gave dihydroisoquinoline 254 as a white solid (130 mg, 63%);.mp: 94-96 °C; 
1H NMR 
(300 MHz, CDCl3) δ 7.27 (dd, J = 9.2, 4.7 Hz, 1H), 7.21 (dd, J = 9.1, 2.7 Hz, 1H), 7.13 (td, J = 
8.4, 2.7 Hz, 1H), 6.96 (s, 1H), 5.59 (d, J = 1.7 Hz, 1H), 5.51 (d, J = 1.7 Hz, 1H), 4.61 – 4.47 (m, 
2H), 4.28 – 4.18 (m, 2H), 3.61 (s, 2H), 3.09 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 162.1 (d, JC-F 
= 247.2 Hz, C), 132.9 (d, JC-F = 6.8 Hz, C), 130.9 (C), 127.2 (d, JC-F = 3.1 Hz, C), 124.7 (CH), 
124.4 (d, JC-F = 7.8 Hz, CH), 118.5 (CH2), 116.9 (d, JC-F = 22.1 Hz, CH), 113.6 (C), 112.3 (C), 
110.9 (d, JC-F = 23.8 Hz, CH), 66.8 (2 × CH2), 43.6 (CH3), 42.2 (CH2); IR vma×/cm
-1 3110, 2907, 
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1634, 1499, 1339, 1155, 1028, 966, 819, 518; HRMS (ES-TOF): m/z: calcd for C15H16NO4SBrF: 




Prepared according to GP12 using freshly prepared bromoalkyne 2-(2-(bromoethynyl)-5-
fluorophenyl)-1,3-dioxolane (GP7, 150 mg, 0.553 mmol) and sulfonamide 171 (74.6 mg, 
0.500 mmol) for 48 h. Purification by flash column chromatography [9:1 (hexane:EtOAc), 1% 
Et3N] gave dihydroisoquinoline 255 as a colourless liquid (120 mg, 71%);.
1H NMR (300 MHz, 
CDCl3) δ 7.31 (dd, J = 8.7, 5.4 Hz, 1H), 7.20 (dd, J = 9.2, 2.7 Hz, 1H), 7.10 (td, J = 8.5, 2.7 Hz, 
1H), 6.84 (s, 1H), 4.84 (br. s, 1H), 4.76 (br. s, 1H), 4.59 – 4.46 (m, 2H), 4.26 – 4.17 (m, 2H), 
3.19 (s, 2H), 3.06 (s, 3H), 1.74 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 162.0 (d, JC-F = 247.0 Hz, 
C), 143.1 (C), 132.9 (d, JC-F = 6.9 Hz, C), 128.1 (d, JC-F = 3.2 Hz, C), 124.8 (d, JC-F = 7.8 Hz, CH), 
123.1 (CH), 116.8 (d, JC-F = 21.7 Hz, CH), 115.5 (C), 112.7 (CH2), 112.2 (C), 110.7 (d, JC-F = 23.9 
Hz, CH), 66.7 (2 × CH2), 43.3 (CH3), 38.6 (CH2), 22.4 (CH3); IR vma×/cm
-1 3675, 2988, 2901, 
1650, 1500, 1343, 1261, 1159, 1057, 950, 826, 763, 649, 517; HRMS (ES-TOF): m/z: calcd for 








Prepared according to GP12 using freshly prepared bromoalkyne 2-(2-(bromoethynyl)-6-
fluorophenyl)-1,3-dioxolane (GP7, 210 mg, 0.775 mmol) and sulfonamide 236 (170 mg, 
0.658 mmol) for 48 h. Purification by flash column chromatography [9:1 (hexane:EtOAc), 1% 
Et3N] gave dihydroisoquinoline 261 as a yellow solid (200 mg, 70%);.mp: 105-108 °C; 
1H 
NMR (300 MHz, CDCl3) δ 8.24 (d, J = 8.9 Hz, 2H), 7.92 (d, J = 8.9 Hz, 2H), 7.32 (td, J = 8.1, 5.2 
Hz, 1H), 7.13 (s, 1H), 7.07 (d, J = 7.8 Hz, 1H), 6.92 (ddd, J = 11.8, 8.2, 0.7 Hz, 1H), 6.05 – 5.85 
(m, 1H), 5.17 (app. t, J = 1.5 Hz, 1H), 5.13 (dd, J = 7.0, 1.5 Hz, 1H), 4.63 – 4.48 (m, 2H), 4.37 – 
4.23 (m, 2H), 3.27 (dd, J = 6.1, 1.1 Hz, 2H); 13C NMR (101 MHz, CDCl3) δ 159.5 (d, JC-F = 252.8 
Hz, C), 150.1 (C), 147.7 (C), 135.2 (CH), 133.4 (C), 130.9 (d, JC-F = 9.9 Hz, CH), 127.8 (2 × CH), 
124.3 (2 × CH), 123.4 (CH), 119.2 (d, JC-F = 9.1 Hz, C), 118.6 (d, JC-F = 3.5 Hz, CH), 117.5 (CH2), 
116.1 (d, JC-F = 3.4 Hz, C)), 115.4 (d, JC-F = 23.5 Hz, CH), 113.2 (C), 67.1 (CH2), 67.1 (CH2), 34.5 
(CH2); IR vma×/cm
-1 3114, 2915, 1650, 1531, 1359, 1263, 1171, 1023, 845, 743, 629, 564; 






Prepared according to GP12 using freshly prepared bromoalkyne 2-(2-(bromoethynyl)-6-
fluorophenyl)-1,3-dioxolane (GP7, 1.00 g, 3.69 mmol) and sulfonamide 213 (0.98 g, 3.41 
mmol) for 48 h. Purification by flash column chromatography [9:1 (hexane:EtOAc), 1% Et3N] 
gave dihydroisoquinoline 262 as a white foam (1.21 g, 74%);. 1H NMR (300 MHz, CDCl3) δ 
7.65 (d, J = 8.4 Hz, 2H), 7.35 – 7.27 (m, 2H), 7.25 – 7.19 (m, 5H), 7.16 (s, 1H), 7.14 – 7.10 (m, 
1H), 6.92 (d, J = 7.8 Hz, 1H), 6.83 (dd, J = 12.0, 8.1 Hz, 1H), 6.22 (ddd, J = 16.8, 10.2, 6.3 Hz, 
1H), 5.28 (app. dt, J = 10.2, 1.4 Hz, 1H), 4.92 (app. dt, J = 17.1, 1.3 Hz, 1H), 4.74 (d, J = 6.3 Hz, 
1H), 4.66 – 4.56 (m, 2H), 4.40 – 4.27 (m, 2H), 2.37 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 159.7 
(d, JC-F = 252.1 Hz, C), 143.8 (C), 141.1 (C), 139.1 (d, JC-F = 4.1 Hz, CH)), 133.4 (C), 130.3 (d, JC-F 
= 9.9 Hz, CH), 129.6 (2 × CH), 128.7 (2 × CH), 128.7 (2 × CH), 126.9 (CH), 126.7 (2 × CH), 126.1 
(CH), 119.7 (d, JC-F = 9.1 Hz, C), 118.6 (d, JC-F = 3.4 Hz, CH)), 117.7 (CH2), 116.3 (C) 116.2 (C), 
114.6 (d, JC-F = 23.8 Hz, CH), 113.4 (C), 67.4 (CH2), 67.4 (CH2), 49.2 (CH), 21.7 (CH3); IR 
vma×/cm
-1 2971, 1639, 1476, 1340, 1243, 1168, 1101, 1042, 1027, 853, 699, 674, 576; HRMS 





Prepared according to GP12 using freshly prepared bromoalkyne 2-(2-(bromoethynyl)-5-
methoxyphenyl)-1,3-dioxolane (GP7, 220 mg, 0.778 mmol) and sulfonamide 168 (150 mg, 
0.710 mmol) for 48 h. Purification by flash column chromatography [85:15 (hexane:EtOAc), 




NMR (300 MHz, CDCl3) δ 7.40 – 7.28 (m, 5H), 7.21 (d, J = 8.7 Hz, 1H), 7.10 (d, J = 2.7 Hz, 1H), 
6.90 (dd, J = 8.7, 2.7 Hz, 1H), 6.86 (s, 1H), 6.27 (ddd, J = 17.0, 10.2, 6.6 Hz, 1H), 5.30 (app. dt, 
J = 10.2, 1.4 Hz, 1H), 5.00 (app. dt, J = 17.1, 1.4 Hz, 1H), 4.83 (d, J = 6.4 Hz, 1H), 4.69 – 4.54 
(m, 2H), 4.34 – 4.24 (m, 2H), 3.87 (s, 3H), 3.14 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 159.0 (C), 
141.3 (C), 139.2 (CH), 132.7 (C), 128.7 (2 × CH), 128.7 (2 × CH), 126.8 (CH), 124.7 (CH), 124.6 
(C), 122.6 (CH), 119.7 (C), 117.5 (CH2), 115.1 (CH), 112.5 (C), 108.9 (CH), 67.0 (CH2), 66.2 
(CH2), 55.6 (CH3), 49.2 (CH), 43.3 (CH3); IR vma×/cm
-1 3675, 2988, 2901,1407, 1394, 1337, 
1154, 1066, 953, 523; HRMS (ES-TOF): m/z: calcd for C22H24NO5S: 414.1375, found: 414.1373 




Prepared according to GP12 using freshly prepared bromoalkyne 2-(2-(bromoethynyl)-5-
methoxyphenyl)-1,3-dioxolane (GP7, 190 mg, 0.671 mmol) and sulfonamide 172 (89.5 mg, 
0.600 mmol) for 48 h. Purification by flash column chromatography [85:15 (hexane:EtOAc), 
1% Et3N] gave dihydroisoquinoline 270 as a viscous colourless liquid (120 mg, 57%, a 
mixture of E/Z isomers in 0.5:1 ratio); 1H NMR (300 MHz, CDCl3) δ 7.32 – 7.27 (m, 1H), 7.07 – 
7.03 (m, 1H), 7.01 – 6.95 (m, 1H), 6.74 – 6.69 (m, 1H), 5.66 – 5.47 (m, 2H), 4.58 – 4.46 (m, 
2H), 4.26 – 4.12 (m, 2H), 3.85 (s, 3H), 3.27 – 3.14 (m, 2H), 3.02 (s, 3H), 1.76 – 1.63 (m, 3H); 
13C NMR (101 MHz, CDCl3) δ 159.2 (C, minor), 159.2 (C, major),  132.5 (C, minor), 132.4 (C, 
major), 128.1 (CH, major), 127.6 (CH, major), 127.5 (CH, minor),  126.2 (CH, minor), 125.1 (C, 
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minor), 125.0 (C, major), 124.2 (CH, major), 123.9 (CH, minor), 120.7 (CH, major), 120.5 (CH, 
minor), 117.7 (C, major), 117.5 (C, minor), 115.3 (CH, major and minor), 112.5 (C, major and 
minor), 109.2 (CH, minor), 109.1 (CH, major), 66.5 (2 × CH2, major and minor), 55.6 (CH3, 
major and minor), 43.0 (CH3, major and minor), 33.1 (CH2, major), 27.6 (CH2, minor), 18.1 
(CH3, major), 13.1 (CH3, minor); IR vma×/cm
-1 3675, 2988, 2901, 1614, 1499, 1332, 1294, 
1216, 1144, 1029, 966, 948, 818, 648, 521; HRMS (ES-TOF): m/z: calcd for C17H22NO5S: 
352.1219, found: 352.1217 [M + H]+. 
4-(2-Bromoallyl)-1-methoxy-2-(methylsulfonyl)-1-phenyl-1,2-dihydroisoquinoline (273) 
 
Prepared according to GP12 using freshly prepared bromoalkyne 1-(bromoethynyl)-2-
(methoxy(phenyl)methyl)benzene (GP7, 160 mg, 0.531 mmol) and sulfonamide 173 (110 
mg, 0.513 mmol) for 48 h. Purification by flash column chromatography [9:1 
(hexane:EtOAc), 1% Et3N] gave dihydroisoquinoline 273 as a yellow liquid (100 mg, 45%); 
1H 
NMR (300 MHz, CDCl3) δ 7.54 – 7.49 (m, 2H), 7.37 – 7.28 (m, 3H), 7.25 – 7.17 (m, 2H), 7.12 
(dd, J = 7.9, 1.4 Hz, 1H), 7.08 (s, 1H), 6.96 (dd, J = 7.9, 1.0 Hz, 1H), 5.74 (d, J = 1.7 Hz, 1H), 
5.59 (d, J = 1.7 Hz, 1H), 3.60 (s, 2H), 3.20 (s, 3H), 2.52 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 
144.8 (C), 134.0 (C), 132.2 (C), 130.3 (C), 129.3 (CH), 128.7 (CH), 128.2 (CH), 127.8 (2 × CH), 
127.6 (2 × CH), 127.4 (CH), 126.4 (CH), 121.2 (CH), 118.5 (CH2), 108.5 (C), 93.7 (C), 51.1 (CH3), 
42.6 (CH2), 42.3 (CH3); IR vma×/cm
-1 3059, 1630, 1386, 1167, 1038, 765, 700, 523; HRMS (ES-






Prepared according to GP12 using freshly prepared bromoalkyne 2-(bromoethynyl)-3-(1,3-
dioxolan-2-yl)pyridine (GP7, 220 mg, 0.866 mmol) and sulfonamide 175 (110 mg, 0.814 
mmol) for 24 h. Purification by flash column chromatography [8:2 (hexane:EtOAc), 1% Et3N] 
gave dihydroisoquinoline 281 as a brown solid (100 mg, 40%);. mp: 88-90 °C; 1H NMR (300 
MHz, CDCl3) δ 8.67 (dd, J = 4.8, 1.7 Hz, 1H), 7.75 (dd, J = 7.9, 1.7 Hz, 1H), 7.29 – 7.22 (m, 1H), 
7.10 (s, 1H), 6.05 (ddt, J = 16.5, 10.1, 6.4 Hz, 1H), 5.20 – 5.06 (m, 2H), 4.64 – 4.49 (m, 2H), 
4.29 – 4.14 (m, 2H), 3.44 (ddd, J = 6.4, 2.6, 1.3 Hz, 2H), 3.09 (s, 3H); 13C NMR (101 MHz, 
CDCl3) δ 150.5 (CH), 149.5 (C), 135.9 (CH), 131.6 (CH), 126.5 (C), 126.3 (CH), 121.8 (CH), 
118.0 (C), 116.7 (CH2), 113.2 (C), 66.9 (2 × CH2), 43.6 (CH3), 32.4 (CH2); IR vma×/cm
-1 3675, 
2989, 2901, 1640, 1587, 1459, 1337, 1259, 1157, 1057, 963, 948, 760, 521; HRMS (ES-TOF): 





Prepared according to GP12 using freshly prepared bromoalkyne 2-(3-
(bromoethynyl)thiophen-2-yl)-1,3-dioxolane (GP7, 200 mg, 0.772 mmol) and sulfonamide 
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236 (170 mg, 0.658 mmol) for 24 h. Purification by flash column chromatography [90:10 
(hexane:EtOAc), 1% Et3N] gave dihydroisoquinoline 290 as a yellow solid (100 mg, 36%);. 
mp: 138-140 °C; 1H NMR (300 MHz, CDCl3) δ 8.22 (d, J = 8.9 Hz, 2H), 8.16 (d, J = 5.3 Hz, 1H), 
8.07 (d, J = 8.9 Hz, 2H), 7.87 (s, 1H), 7.59 (d, J = 5.3 Hz, 1H), 5.94 (ddt, J = 16.5, 10.1, 6.3 Hz, 
1H), 5.28 – 5.09 (m, 2H), 5.07 – 4.96 (m, 2H), 4.20 – 4.07 (m, 2H), 3.66 (d, J = 5.7 Hz, 2H); 13C 
NMR (101 MHz, CDCl3) δ 155.9 (C), 151.3 (C), 150.9 (C), 148.7 (C), 139.7 (CH), 133.5 (CH), 
129.3 (CH), 127.5 (2 × CH), 124.5 (C), 123.7 (2 × CH), 123.4 (CH), 119.2 (C), 119.0 (CH2), 75.1 
(CH2), 61.0 (CH2), 34.6 (CH2); IR vma×/cm
-1 3392, 2973, 2901, 1667, 1603, 1320, 1348, 1232, 
1178, 1121, 1031, 853, 740, 637, 551; HRMS (ES-TOF): m/z: calcd for C18H17N2O6S2: 
421.0528, found: 421.0530 [M + H]+. 
4-Allyl-2-tosylisoquinolin-1(2H)-one (292a) 
 
Prepared according to GP12 using ynamide 291 (66.0 mg, 0.150 mmol), stirring at 100 oC for 
24 h. Purification by flash column chromatography [8:2 (hexane:EtOAc), 1% Et3N] gave 
isoquinoline (alongside diketone 292b) 292a as a brown solid (25.0 mg, 49%); mp: 163-165 
°C; 1H NMR (300 MHz, CDCl3) δ 8.31 (d, J = 7.9 Hz, 1H), 8.02 (d, J = 8.3 Hz, 2H), 7.77 (s, 1H), 
7.72 – 7.58 (m, 2H), 7.50 – 7.41 (m, 1H), 7.35 (d, J = 8.2 Hz, 2H), 6.02 (ddt, J = 16.6, 10.5, 6.1 
Hz, 1H), 5.26 – 5.11 (m, 2H), 3.47 (d, J = 5.9 Hz, 2H), 2.42 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 
160.5 (CO), 145.9 (C), 136.7 (C), 135.1 (CH), 134.6 (C), 133.9 (CH), 129.7 (2 × CH), 129.6 (2 × 
CH), 129.0 (CH), 127.7 (CH), 126.7 (C), 123.8 (CH), 123.2 (CH), 117.8 (CH2), 115.8 (C) 34.1 
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(CH2), 21.9 (CH3); IR vma×/cm
-1 2921, 1677,1594, 1353, 1241, 1162,771 676, 543; HRMS (ES-




Prepared according to GP12 using ynamide 291 (66.0 mg, 0.150 mmol), stirring at 100 oC for 
24 h. Purification by flash column chromatography [8:2 (hexane:EtOAc), 1% Et3N] gave 
diketone 292b as a white soild solid (21.4 mg, 40%); mp: 100 – 112 °C; 1H NMR (400 MHz, 
CDCl3) δ 9.86 (s, 1H), 7.94 (d, J = 8.4 Hz, 2H), 7.76 (dd, J = 7.3, 1.7 Hz, 1H), 7.56 – 7.46 (m, 
2H), 7.35 (d, J = 8.0 Hz, 2H), 7.22 – 7.18 (m, 1H), 5.93 (ddt, J = 17.1, 10.3, 5.7 Hz, 1H), 5.32 
(dd, J = 17.2, 1.2 Hz, 1H), 5.24 (dd, J = 10.3, 1.2 Hz, 1H), 4.52 (app. dt, J = 5.7, 1.4 Hz, 2H), 
4.34 (s, 2H), 2.44 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 193.3 (CHO), 170.7 (CO), 144.9 (C), 
136.7 (C), 135.6 (CH), 135.2 (C), 134.3 (C), 133.9 (CH), 133.0 (CH), 132.8 (CH), 129.8 (2 × CH), 
128.2 (2 × CH), 128.1 (CH), 118.5 (CH2), 49.1 (CH2), 42.0 (CH2), 21.8 (CH3); IR vma×/cm
-1 1698, 
1347, 1169, 1086, 758, 665, 537; HRMS (ES-TOF): m/z: calcd for C19H19NO4SNa: 380.0932, 





Prepared according to GP12 using ynamide 293(119 mg, 0.3 mmol), stirring at 100 oC for 20 
h. Purification by flash column chromatography [9:1 (hexane:EtOAc), 1% Et3N] gave 
dihydroisoquinoline 294 as a brown liquid (67.0 mg, 56%); 1H NMR (300 MHz, CDCl3) δ 7.54 
(d, J = 8.4 Hz, 2H), 7.36 – 7.27 (m, 3H), 7.26 – 7.16 (m, 1H), 7.08 (d, J = 8.0 Hz, 2H), 7.02 (s, 
1H), 5.99 (ddt, J = 17.0, 10.1, 6.1 Hz, 1H), 5.20 – 5.08 (m, 2H), 5.03 – 4.89 (m, 1H), 4.60 (dd, J 
= 7.2, 6.3 Hz, 1H), 3.66 (app. t, J = 7.2 Hz, 1H), 3.30 (ddd, J = 6.0, 2.6, 1.4 Hz, 2H), 2.29 (s, 3H), 
1.35 (d, J = 6.2 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 143.4 (C), 139.2 (C), 135.9 (CH), 131.5 
(C), 131.1 (C), 129.3 (2 × CH), 129.3 (2 × CH) 127.4 (CH), 126.8 (CH), 124.2 (CH), 123.8 (CH), 
122.4 (CH), 118.1 (C), 117.1 (CH2), 112.7 (C), 73.6 (CH3), 72.9 (CH2), 34.2 (CH2), 21.7 (CH), 
18.4 (CH3); IR vma×/cm
-1 2978, 1640, 1450, 1347, 1266, 1168, 982, 671, 581, 544; ; HRMS (ES-




Prepared according to GP13 using ynamide 351 (51.0 mg, 0.150 mmol), heating at 80 °C for 
1 hour. Purification by flash column chromatography [9:1 (hexane:EtOAc)] gave the 
dienamide 362 as a white solid (46.9 mg, 92%); mp: 114-116 °C; 1H NMR (300 MHz, CDCl3) δ 
7.69 (d, J = 8.3 Hz, 2H), 7.34 – 7.25 (m, 4H), 7.14 (d, J = 8.0 Hz, 2H), 5.49 – 5.44 (m, 3H), 3.95 
(t, J = 8.3 Hz, 2H), 2.43 (s, 3H), 2.36 (s, 3H), 2.12 (td, J = 8.3, 2.8 Hz, 2H); 13C NMR (101 MHz, 
CDCl3) δ 144.9 (C), 143.7 (C), 142.2 (C), 137.7 (C), 136.3 (C), 134.9 (C), 129.5 (2 × CH), 129.0 
(2 × CH), 128.0 (2 × CH), 127.2 (2 × CH), 119.7 (CH), 115.9 (CH2), 51.4 (CH2), 28.2 (CH2), 21.7 
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(CH3), 21.4 (CH3); IR vma×/cm
-1 2959, 1513, 1351, 1162, 1085,984, 820, 666, 582, 546; HRMS 




Prepared according to GP13 using ynamide 352 (71.1 mg, 0.200 mmol), heating at 80 °C for 
1 hour. Purification by flash column chromatography [9:1 (hexane:EtOAc)] gave the 
dienamide 363 as a white solid (59.0 mg, 83%); mp:94-96 °C; 1H NMR (300 MHz, CDCl3) δ 
7.69 (d, J = 8.3 Hz, 2H), 7.34 (d, J = 8.8 Hz, 2H), 7.31 – 7.25 (m, 2H), 6.86 (d, J = 8.8 Hz, 2H), 
5.48 (t, J = 2.8 Hz, 1H), 5.43 (d, J = 1.4 Hz, 1H), 5.40 (d, J = 1.4 Hz, 1H), 3.95 (t, J = 8.3 Hz, 2H), 
3.82 (s, 3H), 2.43 (s, 3H), 2.12 (td, J = 8.3, 2.8 Hz, 2H); 13C NMR (101 MHz, CDCl3) δ 159.3 (C), 
144.8 (C), 143.6 (C), 141.7 (C), 134.8 (C), 131.6 (C),129.4 (2 × CH) 128.3 (2 × CH), 127.9 (2 × 
CH), 119.5 (CH), 115.0 (CH2), 113.5 (2 × CH), 55.3 (CH3), 51.2 (CH2), 28.0 (CH2), 21.6 (CH3); IR 
vma×/cm
-1 3392, 2930, 1720, 1609, 1509, 1354, 1277, 1245, 1166, 1020, 711, 667, 580, 548; 




Prepared according to GP13 using ynamide 353 (80.9 mg, 0.200 mmol), heating at 80 °C for 
1 hour. Purification by flash column chromatography [8:2 (hexane:EtOAc)] gave the 
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dienamide 364 as a brown foam (68.0 mg, 84%); 1H NMR (300 MHz, CDCl3) δ 7.59 (d, J = 8.3 
Hz, 2H), 7.37 (d, J = 8.5 Hz, 2H), 7.24 – 7.17 (m, 4H), 5.48 – 5.38 (m, 3H), 3.87 (t, J = 8.3 Hz, 
2H), 2.36 (s, 3H), 2.08 (td, J = 8.3, 2.9 Hz, 2H); 13C NMR (101 MHz, CDCl3) δ 144.2 (C), 143.9 
(C), 141.6 (C), 138.0 (C), 134.7 (C), 131.4 (2 × CH), 129.6 (2 × CH), 128.9 (2 × CH), 127.9 (2 × 
CH), 122.0 (C), 120.1 (CH), 116.8 (CH2), 51.3 (CH2), 28.2 (CH2), 21.7 (CH3); IR vma×/cm
-1 2959, 
2833, 1687, 1487, 1347, 1250, 1163, 1085, 898, 844, 655; HRMS (ES-TOF): m/z: calcd for 




Prepared according to GP13 using ynamide 354 (103 mg, 0.300 mmol), heating at 80 °C for 1 
hour. Purification by flash column chromatography [9:1 (hexane:EtOAc)] gave the dienamide 
365 as a white solid (71.1 mg, 69%); mp:107-109 °C; 1H NMR (300 MHz, CDCl3) δ 7.68 (d, J = 
8.3 Hz, 2H), 7.37 (dd, J = 8.8, 5.4 Hz, 2H), 7.28 (d, J = 8.2 Hz, 2H), 7.01 (t, J = 8.7 Hz, 2H), 5.50 
(t, J = 2.8 Hz, 1H), 5.47 (d, J = 1.1 Hz, 1H), 5.44 (d, J = 1.1 Hz, 1H), 3.94 (t, J = 8.3 Hz, 2H), 2.43 
(s, 3H), 2.13 (td, J = 8.3, 2.8 Hz, 2H); 13C NMR (101 MHz, CDCl3) δ 162.7 (d, JC-F = 246.6 Hz, C), 
144.5 (C), 143.9 (C), 141.6 (C), 135.2 (d, JC-F = 3.7 Hz, C), 134.8 (C), 129.6 (2 × CH), 128.9 (d, JC-
F = 7.9 Hz, 2 × CH)), 128.0 9 (2 × CH), 129.0 (CH), 116.3 (CH2), 115.1 (d, JC-F = 21.5 Hz, 2 × CH)), 
51.3 (CH2), 28.2 (CH2), 21.7 (CH3); IR vma×/cm
-1 2972, 1599, 1507, 1350, 1218, 1162, 1085, 
844, 688, 666, 576, 545; HRMS (ES-TOF): m/z: calcd for C19H19NO2SF: 344.1121, found: 
344.1119 [M + H]+. 
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Methyl 4-(1-(1-tosyl-4,5-dihydro-1H-pyrrol-2-yl)vinyl)benzoate (366) 
 
Prepared according to GP13 using ynamide 355 (76.7 mg, 0.200 mmol), heating at 80 °C for 
4 hours. Purification by flash column chromatography [8:2 (hexane:EtOAc)] gave the 
dienamide 366 as a white solid (53.7 mg, 70%); mp: 91-93 °C; 1H NMR (300 MHz, CDCl3) δ 
8.00 (d, J = 8.4 Hz, 2H), 7.67 (d, J = 8.2 Hz, 2H), 7.47 (d, J = 8.4 Hz, 2H), 7.32 – 7.23 (m, 2H), 
5.58 (s, 2H), 5.52 (t, J = 2.8 Hz, 1H), 4.00 – 3.90 (m, 5H), 2.43 (s, 3H), 2.17 (td, J = 8.4, 2.8 Hz, 
2H); 13C NMR (101 MHz, CDCl3) δ 167.1 (CO), 144.0 (C), 143.9 (C), 143.6 (C), 141.8 (C), 134.7 
(C), 129.6 (2 × CH), 129.6 (2 × CH), 129.5 (C), 127.9 (2 × CH), 127.2 (2 × CH), 120.2 (CH), 118.0 
(CH2), 52.2 (CH3), 51.2 (CH2), 28.2 (CH2), 21.7 (CH3); IR vma×/cm
-1 2955, 1719, 1608, 1428, 
1339, 1278, 1160, 1016, 710, 656; HRMS (ES-TOF): m/z: calcd for C21H21NO4SNa: 406.1089, 
found: 406.1091 [M + Na]+. 
5-(1-(Thiophen-2-yl)vinyl)-1-tosyl-2,3-dihydro-1H-pyrrole (368) 
 
Prepared according to GP13 using ynamide 357 (66.3 mg, 0.200 mmol), heating at 80 °C for 
1 hour. Purification by flash column chromatography [90:10 (hexane:EtOAc)] gave the 
dienamide 368 as a dark liquid (40.4 mg, 61%); 1H NMR (300 MHz, CDCl3) δ 7.72 (d, J = 8.2 
Hz, 2H), 7.29 (d, J = 8.2 Hz, 2H), 7.21 (d, J = 4.9 Hz, 1H), 7.14 (d, J = 3.6 Hz, 1H), 6.98 (dd, J = 
4.9, 3.6 Hz, 1H), 5.60 (s, 1H), 5.55 (t, J = 2.8 Hz, 1H), 5.42 (s, 1H), 3.98 (t, J = 8.3 Hz, 2H), 2.44 
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(s, 3H), 2.08 (td, J = 8.3, 2.8 Hz, 2H); 13C NMR (101 MHz, CDCl3) δ 144.1 (C), 143.9 (C), 142.5 
(C), 135.5 (C), 134.6 (C), 129.6 (2 × CH), 128.1 (2 × CH), 127.3 (CH), 125.7 (CH), 124.9 (CH), 
119.8 (CH), 115.7 (CH2), 51.5 (CH2), 28.1 (CH2), 21.7 (CH3); IR vma×/cm
-1 2958, 1597, 1384, 
1160, 1088, 908, 813, 663, 588, 544; HRMS (EI-TOF): m/z: calcd for C17H17NO2S2: 331.0701, 
found: 331.0702 [M]+. 
5-(1-(Naphthalen-1-yl)vinyl)-1-tosyl-2,3-dihydro-1H-pyrrole (369) 
 
Prepared according to GP13 using ynamide 360 (75.1 mg, 0.200 mmol), heating at 80 °C for 
1 hour. Purification by flash column chromatography [8:2 (hexane:EtOAc)] gave the 
dienamide 369 (90% purity) as a brown foam (60.1 mg, 80%); 1H NMR (300 MHz, CDCl3) δ 
7.85 – 7.77 (m, 4H), 7.68 (d, J = 8.2 Hz, 2H), 7.55 (dd, J = 8.7, 1.5 Hz, 1H), 7.48 – 7.43 (m, 2H), 
7.23 (d, J = 8.0 Hz, 2H), 5.64 (d, J = 1.2 Hz, 1H), 5.61 (d, J = 1.2 Hz, 1H), 5.54 (t, J = 2.8 Hz, 1H), 
4.02 (t, J = 8.3 Hz, 2H), 2.40 (s, 3H), 2.21 (td, J = 8.3, 2.8 Hz, 2H); 13C NMR (101 MHz, CDCl3) δ 
144.7 (C), 143.7 (C), 142.3 (C), 136.5 (C), 135.0 (C), 133.4 (C), 133.2 (C), 129.5 (2 × CH), 128.4 
(CH), 128.0 (2 × CH), 127.8 (CH), 127.7 (CH), 126.3 (CH), 126.1 (CH), 126.0 (CH), 125.5 (CH), 
119.8 (CH), 117.2 (CH2), 51.4 (CH2), 28.3 (CH2), 21.7 (CH3); IR vma×/cm
-1 3055, 2851, 1596, 
1347, 1160, 1087, 1021, 815, 669; HRMS (ES-TOF): m/z: calcd for C23H22NO2S: 376.1371, 






Prepared according to GP13 using ynamide 358 (111 mg, 0.300 mmol), heating at 80 °C for 2 
hours. Purification by flash column chromatography [8:2 (hexane:EtOAc)] gave the 
dienamide 370 as a white solid (94.4 mg, 85%); mp: 138-140 °C; 1H NMR (300 MHz, CDCl3) δ 
7.69 (d, J = 8.3 Hz, 2H), 7.31 – 7.26 (m, 2H), 6.95 – 6.86 (m, 2H), 6.77 (d, J = 7.9 Hz, 1H), 5.96 
(s, 2H), 5.48 (t, J = 2.8 Hz, 1H), 5.41 (d, J = 1.3 Hz, 1H), 5.40 (d, J = 1.3 Hz, 1H), 3.95 (t, J = 8.3 
Hz, 2H), 2.43 (s, 3H), 2.13 (td, J = 8.3, 2.8 Hz, 2H); 13C NMR (101 MHz, CDCl3) δ 147.6 (C), 
147.5 (C), 144.7 (C), 143.8 (C), 142.0 (C), 134.8 (C), 133.3 (C), 129.5 (2 × CH), 128.0 (2 × CH), 
121.0 (CH), 119.8 (CH), 115.5 (CH2), 108.1 (CH), 107.8 (CH), 101.2 (CH2), 51.3 (CH2), 28.1 
(CH2), 21.7 (CH3); ); IR vma×/cm
-1 2960, 1596, 1489, 1441, 1347, 1228, 1157, 1034, 900, 816, 




Prepared according to GP13 using ynamide 356 (78.7 mg, 0.200 mmol), heating at 80 °C for 
1 hour. Purification by flash column chromatography [9:1 (hexane:EtOAc)] gave the 
dienamide 371 as a colourless liquid (67.7 mg, 86%); 1H NMR (300 MHz, CDCl3) δ 7.65 (d, J = 
8.2 Hz, 2H), 7.58 (d, J = 8.3 Hz, 2H), 7.50 (d, J = 8.2 Hz, 2H), 7.30 – 7.25 (m, 2H), 5.61 – 5.51 
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(m, 3H), 3.95 (t, J = 8.4 Hz, 2H), 2.43 (s, 3H), 2.18 (td, J = 8.4, 2.8 Hz, 2H); 13C NMR (101 MHz, 
CDCl3) δ 144.0 (C), 144.0 (C), 142.6 (C), 141.7 (C), 134.7 (C), 129.8 (q, JC-F = 31.8 Hz, C)), 129.6 
(2 × CH), 127.9 (2 × CH), 127.5 (2 × CH), 125.3 (q, JC-F = 3.7 Hz, 2  × CH)), 123.0 (q, JC-F = 264.1 
Hz, C)), 120.3 (CH), 118.0 (CH2), 51.2 (CH2), 28.2 (CH2), 21.7 (CH3). IR vma×/cm
-1.2960, 1720, 
1597, 1322, 1162, 1112, 1064, 657, 547, 532; HRMS (EI-TOF): m/z: calcd for C20H18NO2SF3: 
393.1010, found: 393.1008 [M]+. 
5-(1-Phenylvinyl)-1-tosyl-2,3-dihydro-1H-pyrrole (372) 
 
Prepared according to GP13 using ynamide 361 (65.1 mg, 0.200 mmol), heating at 80 °C for 
1 hour. Purification by flash column chromatography [8:2 (hexane:EtOAc)] gave the 
dienamide 372 as a brown solid (61.8 mg, 94%); mp: 113-115 °C; 1H NMR (300 MHz, CDCl3) δ 
7.64 (d, J = 8.3 Hz, 2H), 7.39 – 7.34 (m, 2H), 7.32 – 7.26 (m, 2H), 7.25 – 7.20 (m, 3H), 5.46 (br. 
s, 2H), 5.44 (t, J = 2.8 Hz, 1H), 3.91 (t, J = 8.3 Hz, 2H), 2.38 (s, 3H), 2.08 (td, J = 8.3, 2.8 Hz, 
2H); 13C NMR (101 MHz, CDCl3) δ 144.7 (C), 143.8 (C), 142.4 (C), 139.1 (C), 134.8 (C), 129.5 (2 
× CH), 128.2 (2 × CH), 128.0 (2 × CH), 127.9 (CH), 127.3 (2 × CH), 119.9 (CH), 116.6 (CH2), 51.4 
(CH2), 28.2 (CH2), 21.7 (CH3); IR vma×/cm
-1 3089, 2850, 1597, 1348, 1163, 1088, 977, 895, 776, 






Prepared according to GP14 using ynamide 376 (71.5 mg, 0.200 mmol), heating at 80 °C for 
22 hours. chromatography [8:2 (hexane:EtOAc)] gave the dienamide 377 as a red viscous 
liquid (53.6 mg, 75%); 1H NMR (300 MHz, CDCl3) δ 7.62 – 7.53 (m, 4H), 7.39 – 7.30 (m, 3H), 
7.20 (d, J = 8.0 Hz, 2H), 5.94 (s, 1H), 5.75 (t, J = 3.0 Hz, 1H), 5.49 (s, 1H), 3.77 (t, J = 7.9 Hz, 
2H), 2.40 (s, 3H), 1.73 (td, J = 7.9, 3.0 Hz, 2H); 13C NMR (101 MHz, CDCl3) δ 143.9 (C), 143.5 
(C), 136.2 (C), 134.0 (C), 133.7 (C), 133.0 (2 × CH), 129.5 (2 × CH), 129.2 (2 × CH), 128.2 (2 × 
CH), 127.9 (CH), 122.3 (CH), 121.0 (CH2), 52.2 (CH2), 28.3 (CH2), 21.7 (CH3); IR vma×/cm
-1 3056, 
2984, 1597, 1439, 1343, 1158, 1086, 910, 666; HRMS (ES-TOF): m/z: calcd for C19H20NO2S2: 




Prepared according to modified GP14 using ynamide 376 (71.5 mg, 0.200 mmol), and 4-
phenyl-1,2,3-triazole-3,5-dione 378 (38.5 mg, 0.220 mmol), heating at 80 °C for 24 hours. 
Purification by flash column chromatography [80:20 (hexane:EtOAc)] gave the dione 379 as 
a white solid (54.6 mg, 51%) over two steps; mp: 108-110 °C; 1H NMR (300 MHz, CDCl3) δ 
7.78 (d, J = 8.1 Hz, 2H), 7.56 – 7.30 (m, 12H), 4.39 (dd, J = 15.9, 2.6 Hz, 1H), 3.88 – 3.77 (m, 
2H), 3.67 (td, J = 10.6, 7.6 Hz, 2H), 2.78 – 2.64 (m, 1H), 2.46 (s, 3H), 2.12 – 1.95 (m, 1H); 13C 
NMR (101 MHz, CDCl3) δ 153.9 (CO), 151.6 (CO), 145.0 (C), 135.2 (C), 134.2 (C), 133.0 (2 × 
CH), 131.7 (C), 130.9 (C), 130.2 (2 × CH), 129.6 (2 × CH), 129.4 (2 × CH), 128.7 (CH), 128.6 
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(CH), 128.1 (2 × CH), 125.5 (2 × CH), 117.8 (C), 57.0 (CH), 48.6 (CH2), 46.5 (CH2), 27.9 (CH2), 
21.8 (CH3); IR vma×/cm
-1 2920, 1780, 1718, 1502, 1413, 1355, 1166, 750, 674; HRMS (ES-TOF): 




Prepared according to GP13 using ynamide 416 (40.1 mg, 0.0999 mmol), heating at 80 °C for 
1 hour. Purification by flash column chromatography [9:1 (hexane:EtOAc)] gave the 
dienamide 421 as a brown solid (32.1 mg, 80%); mp:83-85 °C; 1H NMR (400 MHz, CDCl3) δ 
7.72 (d, J = 8.3 Hz, 2H), 7.43 (d, J = 7.2 Hz, 2H), 7.39 – 7.34 (m, 2H), 7.33 – 7.27 (m, 8H), 5.60 
(br. s, 1H), 5.49 (d, J = 1.3 Hz, 1H), 5.42 (dd, J = 3.6, 2.1 Hz, 1H), 5.34 (dd, J = 9.4, 2.3 Hz, 1H), 
2.69 – 2.58 (m, 1H), 2.49 – 2.41 (m, 4H); 13C NMR (101 MHz, CDCl3) δ 144.1 (C), 143.9 (C), 
142.5 (C), 142.4 (C), 139.3 (C), 135.1 (C), 129.6 (2 × CH), 128.6 (2 × CH), 128.1 (2 × CH), 128.0 
(2 × CH), 127.9 (CH), 127.7 (2 × CH), 127.6 (CH), 126.3 (2 × CH), 118.5 (CH), 117.3 (CH2), 64.8 
(CH), 36.3 (CH2), 21.8 (CH3); IR vma×/cm
-1 3029, 1645, 1597, 1494, 1351, 1163, 1089, 988, 







Prepared according to GP13 using ynamide 418 (83.1 mg, 0.200 mmol), heating at 80 °C for 
1 hour. Purification by flash column chromatography [8:2 (hexane:EtOAc)] gave the 
dienamide 422 as a brown solid (64.8 mg, 78%); mp:97-99 °C; 1H NMR (400 MHz, CDCl3) δ 
7.72 (d, J = 8.3 Hz, 2H), 7.35 – 7.26 (m, 9H), 7.17 (d, J = 7.9 Hz, 2H), 5.60 (br. s, 1H), 5.49 (d, J 
= 1.3 Hz, 1H), 5.42 (dd, J = 3.5, 2.2 Hz, 1H), 5.30 (dd, J = 9.3, 2.1 Hz, 1H), 2.67 – 2.56 (m, 1H), 
2.45 (s, 3H), 2.42 – 2.39 (m, 1H), 2.36 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 144.0 (C), 143.8 
(C), 142.5 (C), 139.5 (C), 139.3 (C), 137.3 (C), 135.2 (C), 129.6 (2 × CH), 129.3 (2 × CH), 128.1 
(2 × CH), 128.0 (2 × CH), 127.9 (CH), 127.7 (2 × CH), 126.3 (2 × CH), 118.5 (CH), 117.2 (CH2), 
64.7 (CH), 36.4 (CH2), 21.8 (CH3), 21.2 (CH3); IR vma×/cm
-1 3026, 1644, 1514, 1445, 1352, 
1291, 1163, 1088, 988, 775, 679,; HRMS (ES-TOF): m/z: calcd for C26H25NO2SNaBr: 438.1504, 
found: 438.1507 [M + Na]+. 
2-(2-Bromophenyl)-5-(1-phenylvinyl)-1-tosyl-2,3-dihydro-1H-pyrrole (423) 
 
Prepared according to GP13 using ynamide 417 (96.1 mg, 0.200 mmol), heating at 80 °C for 
1 hour. Purification by flash column chromatography [8:2 (hexane:EtOAc)] gave the 
dienamide 423 as a white solid (72.1 mg, 75%); mp:119-121 °C; 1H NMR (400 MHz, CDCl3) δ 
7.78 (d, J = 8.3 Hz, 2H), 7.61 – 7.53 (m, 2H), 7.49 – 7.44 (m, 2H), 7.41 – 7.28 (m, 6H), 7.17 – 
7.11 (m, 1H), 5.71 (br. s,  1H), 5.56 – 5.50 (m, 2H), 5.25 (dd, J = 3.4, 2.2 Hz, 1H), 2.90 – 2.79 
(m, 1H), 2.47 (s, 3H), 2.24 – 2.09 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 144.4 (C), 144.2 (C), 
142.5 (C), 142.5 (C), 139.8 (C), 134.4 (C), 132.9 (CH), 129.8 (CH), 128.9 (CH), 128.3 (3 × CH), 
128.1 (CH), 128.0 (2 × CH), 127.7 (CH), 121.6 (C), 118.2 (CH2), 117.5 (CH), 64.8 (CH), 37.7 
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(CH2), 21.81 (CH3); IR vma×/cm
-12975, 2231, 1595, 1463, 1359, 1267, 1169, 984, 744, 653; 





Following the general procedure GP14 using ynamide 291 (44.0 mg, 0.100 mmol) for 2 
hours. Purification by flash column chromatography [8:2 (hexane:EtOAc)] gave the polycycle 
434 as a white solid (30.3 mg, 69%); mp: 192-194 °C; 1H NMR (300 MHz, CDCl3) δ 7.71 (d, J = 
8.2 Hz, 2H), 7.48 (dd, J = 5.7,2.9 Hz, 1H), 7.32 (d, J = 8.0 Hz, 2H), 7.24 – 7.19 (m, 2H), 6.72 
(dd, J = 5.7,2.9 Hz, 1H), 4.39 (s, 1H), 4.09 (dd, J = 11.7, 4.1 Hz, 1H), 3.68 (d, J = 11.7 Hz, 1H), 
2.44 (s, 3H), 1.58 (d, J = 4.3 Hz, 4H), 1.54 (s, 3H), 1.48 (s, 3H), 1.31 (s, 3H), 0.99 – 0.92 (m, 1H) 
, -0.57 (dd, J = 6.3, 4.8 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 143.9 (C), 143.8 (C), 139.5 (C), 
137.0 (C), 130.1 (2 × CH), 129.5 (CH), 127.5 (2 × CH), 127.1 (CH), 124.0 (CH), 119.9 (CH), 
113.1 (C), 84.8 (C), 84.4 (C), 75.1 (CH), 54.4 (CH2), 37.1 (C), 26.6 (CH), 26.1 (CH3), 26.0 (CH3), 
25.9 (CH3), 25.3 (CH3), 21.7 (CH3), 10.2 (CH2); IR vma×/cm
-1 2984, 2948, 1370, 1239, 1157, 
1134, 1102, 756, 666; HRMS (ES-TOF): m/z: calcd for C25H29NO4SNa: 462.1715, found: 








Following the general procedure GP14 using ynamide 433 (53.6 mg, 0.100 mmol) for 4 
hours. Purification by flash column chromatography [8:2 (hexane:EtOAc)] gave the polycycle 
435 as a white solid (39.1 mg, 73%, dr, 1:3.5); mp: 82-84 °C; 1H NMR (400 MHz, CDCl3) δ 7.83 
– 7.82 (m, 1H, minor), 7.80 (d, J = 8.3 Hz, 2H, major), 7.73 – 7.70 (m, 1H, minor), 7.64 – 7.60 
(m, 2H, major), 7.54 – 7.51 (m, 2H, minor), 7.40 – 7.28 (m, 11H, major and 11H, minor), 7.25 
– 7.21 (m, 2H, major and 2H, minor), 6.81 (ddd, J = 7.3, 4.1, 1.6 Hz, 1H, major and 1H, 
minor), 5.48 (d, J = 8.9 Hz, 1H, minor), 5.20 (d, J = 8.7 Hz, 1H, major), 5.14 (d, J = 8.7 Hz, 1H, 
major), 4.92 (d, J = 8.9 Hz, 1H, minor), 4.72 (s, 1H, major), 4.67 (s, 1H, minor), 4.15 (dd, J = 
11.4, 4.3 Hz, 1H, minor), 4.06 (dd, J = 11.5, 4.3 Hz, 1H, major), 3.82 (d, J = 11.4 Hz, 1H, 
minor), 3.69 (d, J = 11.5 Hz, 1H, major), 2.46 (s, 3H, major), 2.44 (s, 3H, minor), 1.50 – 1.46 
(m, 1H, minor), 1.46 – 1.41 (m, 1H, major), 1.28 (d, J = 5.0 Hz, 1H, minor), 1.24 (dd, J = 8.2, 
6.4 Hz, 1H, major), -0.13 (app. t, J = 5.6 Hz, 1H, minor), -0.17 (app. t, J = 5.6 Hz, 1H, major); 
13C NMR (101 MHz, CDCl3) δ 143.8 (C, major and minor), 142.8 (C, major), 142.6 (C, minor), 
140.1 (C, major), 139.9 (C, minor), 136.6 (C, major), 136.4 (C, minor), 136.1 (C, major ), 135.5 
(C, minor), 135.1 (C major and minor), 130.4 (CH, minor), 130.3 (CH major), 130.1 (2 × CH, 
major and minor), 130.0 (2 × CH, major and minor), 128.8 (CH minor), 128.6 (CH major), 
128.5 (2 × CH, major), 128.3 (2 × CH, minor), 128.1 (2 × CH, minor), 127.9 (2 × CH major), 
127.5 (2 × CH, major and minor), 127.3 (2 × CH, major and minor), 126.5 (CH, major and 
minor), 123.9 (CH, minor), 123.8 (CH major), 119.7 (CH, minor), 119.5 (CH, major), 113.6 (CH 
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major and minor), 113.0 (C, major and minor), 88.2 (CH, major), 85.9 (CH, minor), 85.7 (CH 
major), 85.4 (CH, minor), 74.4 (CH, minor), 74.3 (CH, major), 54.5 (CH2, minor), 54.2 (CH2, 
major), 37.7 (C, major and minor), 26.7 (CH3, major), 26.4 (CH3, minor), 21.7 (CH, major and 
minor), 11.8 (CH2, minor), 11.5 (CH2, major); IR vma×/cm
-1 2899, 1598, 1454, 1343, 1217, 
1161, 1023, 998, 758, 599, 546; HRMS (ES-TOF): m/z: calcd for C33H29NO4SNa: 558.1715, 
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